UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
(Mark one)
☒ | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended SeptemberJune 30, 20172023
OR
☐ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from ______ to ______.
Commission File Number: 001-35141
RENNOVA HEALTH, INC.
(Exact name of registrant as specified in its charter)
Delaware | 68-0370244 | |
(State or other jurisdiction of incorporation or organization) | (IRS Employer Identification No.) | |
400 Suite 800 West Palm Beach, FL | 33401 | |
(Address of principal executive offices) | (Zip Code) |
(561)855-1626
(Registrant’s telephone number, including area code)
Securities registered under Section 12(b) of the Act:
Title of Each Class | Trading Symbol(s) | Name of each exchange on which registered | ||
None | None | None |
Securities registered pursuant to Section 12(g) of the Act:
Common Stock, $0.0001 Par Value
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes [X] ☒ No [ ]☐
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes [X] ☒ No [ ]☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer”,filer,” “accelerated filer”,filer,” “smaller reporting company”,company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act: (Check one)
Large accelerated filer | Accelerated filer |
Non-accelerated filer | Smaller reporting company |
Emerging growth company | ☐ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes [ ] ☐ No [X] ☒
As of November 17, 2017,August 8, 2023, the registrant had 5,639,669 shares of its Common Stock, $0.01$0.0001 par value, outstanding.
RENNOVA HEALTH, INC. AND SUBSIDIARIES
FORM 10-Q
SeptemberJune 30, 20172023
TABLE OF CONTENTS
2 |
RENNOVA HEALTH, INC.
PART I-FINANCIALI - FINANCIAL INFORMATION
Item 1. Financial Statements.
CONDENSED CONSOLIDATED BALANCE SHEETS
June 30, | December 31, | |||||||||||||||
September 30, 2017 | December 31, 2016 | 2023 | 2022 | |||||||||||||
(unaudited) | (unaudited) | |||||||||||||||
ASSETS | ||||||||||||||||
Current assets: | ||||||||||||||||
Cash | $ | 41,019 | $ | 75,017 | $ | 725,517 | $ | 499,470 | ||||||||
Accounts receivable, net | 401,026 | 1,199,899 | 2,881,150 | 3,110,969 | ||||||||||||
Note receivable / receivable from related party | 2,334,251 | 1,457,253 | ||||||||||||||
Inventory | 235,365 | 242,645 | ||||||||||||||
Prepaid expenses and other current assets | 146,713 | 149,385 | 383,526 | 215,365 | ||||||||||||
Inventory | 73,732 | - | ||||||||||||||
Income tax refunds receivable | 1,458,438 | 1,458,438 | 837,460 | 837,460 | ||||||||||||
Current assets of AMSG classified as held for sale | 68,775 | 337,900 | ||||||||||||||
Total current assets | 2,189,703 | 3,220,639 | 7,397,269 | 6,363,162 | ||||||||||||
Property and equipment, net | 3,090,047 | 3,043,590 | 4,277,790 | 4,194,299 | ||||||||||||
Intangible asset | 259,443 | 259,443 | ||||||||||||||
Investment | 9,016,072 | 9,016,072 | ||||||||||||||
Deposits | 157,461 | 141,402 | 164,413 | 165,530 | ||||||||||||
Non-current assets of AMSG classified as held for sale | 928,722 | 76,762 | ||||||||||||||
Right-of-use assets | 440,310 | 574,256 | ||||||||||||||
Total assets | $ | 6,365,933 | $ | 6,482,393 | $ | 21,555,297 | $ | 20,572,762 | ||||||||
LIABILITIES AND STOCKHOLDERS' DEFICIT | ||||||||||||||||
LIABILITIES AND STOCKHOLDERS’ DEFICIT | ||||||||||||||||
Current liabilities: | ||||||||||||||||
Accounts payable (includes related parties of $0.3 and $0.2 milion, respectively) | $ | 4,296,213 | $ | 2,928,524 | ||||||||||||
Accounts payable (includes related party amounts of $23,155 and $47,636, respectively) | $ | 13,008,981 | $ | 11,514,322 | ||||||||||||
Accrued expenses | 5,010,298 | 2,882,029 | 19,319,575 | 19,563,808 | ||||||||||||
Income taxes payable | 490,436 | 942,433 | 1,865,425 | 1,348,425 | ||||||||||||
Current portion of notes payable | 7,299,088 | 9,011,247 | 1,318,315 | 2,917,390 | ||||||||||||
Current portion of notes payable, related party | 223,500 | 328,500 | ||||||||||||||
Current portion of capital lease obligations | 1,491,666 | 1,796,053 | ||||||||||||||
Current liabilities of AMSG classified as held for sale | 1,368,612 | 1,675,981 | ||||||||||||||
Current portion of loan payable, related party | 2,253,000 | 2,995,000 | ||||||||||||||
Current portion of debentures | 8,222,240 | 8,622,240 | ||||||||||||||
Current portion of right-of-use operating lease obligations | 168,761 | 215,063 | ||||||||||||||
Current portion of finance lease obligation | 220,461 | 220,461 | ||||||||||||||
Derivative liability | 455,336 | 455,336 | ||||||||||||||
Current liabilities of discontinued operations | 1,464,209 | 1,456,112 | ||||||||||||||
Total current liabilities | 20,179,813 | 19,564,767 | 48,296,303 | 49,308,157 | ||||||||||||
Other liabilities: | ||||||||||||||||
Debentures | 4,239,005 | - | ||||||||||||||
Capital lease obligations, net of current portion | 735,538 | 1,774,121 | ||||||||||||||
Derivative liabilities | - | 2,803 | ||||||||||||||
Non-current liabilities of AMSG classified as held for sale | - | 26,598 | ||||||||||||||
Right-of-use operating lease obligations, net of current portion | 271,549 | 359,193 | ||||||||||||||
Total liabilities | 25,154,356 | 21,368,289 | 48,567,852 | 49,667,350 | ||||||||||||
Commitments and contingencies | - | - | ||||||||||||||
Stockholders' deficit: | ||||||||||||||||
Series G preferred stock, $0.01 par value, 14,000 shares authorized, 215 shares issued and outstanding | $ | 2 | 2 | |||||||||||||
Series H preferred stock, $0.01 par value, 14,202 shares authorized, 60 and 10,019 shares issued and outstanding | - | 100 | ||||||||||||||
Series F preferred stock, $0.01 par value, 1,750,000 shares authorized, 1,750,000 and 0 shares issued and outstanding | 17,500 | - | ||||||||||||||
Common stock, $0.01 par value, 500,000,000 shares authorized, 1,354,171 and 186,692 shares issued and outstanding | 13,542 | 1,867 | ||||||||||||||
Stockholders’ deficit: | ||||||||||||||||
Series H preferred stock, $ | par value, $ stated value per share, shares authorized, shares issued and outstanding- | - | ||||||||||||||
Series L preferred stock, $ | par value, $ stated value per share, shares authorized, shares issued and outstanding2,500 | 2,500 | ||||||||||||||
Series M preferred stock, $ | par value, $ stated value per share, shares authorized, shares issued and outstanding208 | 208 | ||||||||||||||
Series N preferred stock, $ | par value, $ stated value per share, shares authorized, and shares issued and outstanding, respectively29 | 29 | ||||||||||||||
Series O preferred stock, $ | par value, $ stated value per share, shares authorized, and shares issued and outstanding, respectively86 | 87 | ||||||||||||||
Series P preferred stock, $ | par value, $ stated value per share, shares authorized, shares issued and outstanding102 | 102 | ||||||||||||||
Preferred stock value | ||||||||||||||||
Common stock, $ | par value, shares authorized, and shares issued and outstanding, respectively2,993,432 | 2,908,432 | ||||||||||||||
Additional paid-in-capital | 126,335,119 | 45,752,999 | 1,671,486,835 | 1,671,571,834 | ||||||||||||
Accumulated deficit | (145,154,586 | ) | (60,640,864 | ) | (1,701,494,387 | ) | (1,703,577,780 | ) | ||||||||
Total stockholders' deficit | (18,788,423 | ) | (14,885,896 | ) | ||||||||||||
Total liabilities and stockholders' deficit | $ | 6,365,933 | $ | 6,482,393 | ||||||||||||
Total Rennova stockholders’ deficit | (27,011,195 | ) | (29,094,588 | ) | ||||||||||||
Noncontrolling interest | (1,360 | ) | - | |||||||||||||
Total stockholders’ deficit | (27,012,555 | ) | (29,094,588 | ) | ||||||||||||
Total liabilities and stockholders’ deficit | $ | 21,555,297 | $ | 20,572,762 |
The accompanying notes are an integral part of these condensed consolidated financial statements.
3 |
RENNOVA HEALTH, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(unaudited)
Three Months Ended | Nine Months Ended | |||||||||||||||
September 30, | September 30, | |||||||||||||||
2017 | 2016 | 2017 | 2016 | |||||||||||||
Net revenues | $ | 1,414,211 | $ | 41,362 | $ | 3,312,476 | $ | 4,067,562 | ||||||||
Operating expenses: | ||||||||||||||||
Direct costs of revenue | 309,347 | 305,157 | 849,632 | 1,128,060 | ||||||||||||
General and administrative | 5,169,478 | 6,497,718 | 12,978,349 | 17,142,263 | ||||||||||||
Sales and marketing expenses | 170,028 | 415,976 | 620,560 | 1,441,322 | ||||||||||||
Bad debt | 477,249 | 3,666,707 | 1,051,590 | 3,667,992 | ||||||||||||
Depreciation and amortization | 451,597 | 680,579 | 1,508,042 | 2,037,910 | ||||||||||||
Total operating expenses | 6,577,699 | 11,566,137 | 17,008,173 | 25,417,547 | ||||||||||||
Loss from continuing operations before other income (expense) and income taxes | (5,163,488 | ) | (11,524,775 | ) | (13,695,697 | ) | (21,349,985 | ) | ||||||||
Other income (expense): | ||||||||||||||||
Other income | 40,455 | 127,008 | 91,212 | 227,020 | ||||||||||||
Change in fair value of derivative instruments | - | 1,827,112 | (42,702,815 | ) | 6,553,772 | |||||||||||
Gain (loss) on extinguishment of debt | - | - | 42,702,815 | - | ||||||||||||
Loss on legal settlement | - | - | - | (17,654 | ) | |||||||||||
Interest expense | (5,331,681 | ) | (1,651,629 | ) | (16,510,525 | ) | (4,700,664 | ) | ||||||||
Total other income (expense), net | (5,291,226 | ) | 302,491 | (16,419,313 | ) | 2,062,474 | ||||||||||
Net loss from continuing operations before income taxes | (10,454,714 | ) | (11,222,284 | ) | (30,115,010 | ) | (19,287,511 | ) | ||||||||
Provision for income taxes | 372 | - | 3,622 | - | ||||||||||||
Net loss from continuing operations | (10,455,086 | ) | (11,222,284 | ) | (30,118,632 | ) | (19,287,511 | ) | ||||||||
Net loss from discontinued operations | (370,151 | ) | (787,155 | ) | (1,053,471 | ) | (2,828,030 | ) | ||||||||
Net loss | (10,825,237 | ) | (12,009,439 | ) | (31,172,103 | ) | (22,115,541 | ) | ||||||||
Deemed dividend from trigger of down round provision feature | (2,280,280 | ) | - | (53,341,619 | ) | - | ||||||||||
Net loss to common shareholders | $ | (13,105,157 | ) | $ | (12,009,439 | ) | $ | (84,513,722 | ) | $ | (22,115,541 | ) | ||||
Net loss per common share: | ||||||||||||||||
Basic and diluted: continuing operations | $ | (10.59 | ) | $ | (122.24 | ) | $ | (122.12 | ) | $ | (368.16 | ) | ||||
Basic and diluted: discontinued operations | (0.31 | ) | (8.57 | ) | (1.54 | ) | (53.98 | ) | ||||||||
Total Basic and diluted | $ | (10.90 | ) | $ | (130.81 | ) | $ | (123.66 | ) | $ | (422.14 | ) | ||||
Weighted average number of common shares outstanding during the period: | ||||||||||||||||
Basic and diluted | 1,202,299 | 91,808 | 683,411 | 52,389 |
2023 | 2022 | 2023 | 2022 | |||||||||||||
Three Months Ended | Six Months Ended | |||||||||||||||
June 30, | June 30, | |||||||||||||||
2023 | 2022 | 2023 | 2022 | |||||||||||||
Net revenues | $ | 6,389,219 | $ | 3,606,236 | $ | 11,305,115 | $ | 4,750,756 | ||||||||
Operating expenses: | ||||||||||||||||
Direct costs of revenues | 1,834,107 | 1,571,673 | 3,687,153 | 2,946,316 | ||||||||||||
General and administrative expenses | 2,358,758 | 1,880,167 | 4,575,428 | 3,452,503 | ||||||||||||
Depreciation and amortization | 99,357 | 117,216 | 193,492 | 234,040 | ||||||||||||
Total operating expenses | 4,292,222 | 3,569,056 | 8,456,073 | 6,632,859 | ||||||||||||
Income (loss) from continuing operations before other income (expense), income taxes and net loss attributable to noncontrolling interest | 2,096,997 | 37,180 | 2,849,042 | (1,882,103 | ) | |||||||||||
Other income (expense): | ||||||||||||||||
Other income (expense), net | 212,368 | (316,369 | ) | 255,114 | (42,281 | ) | ||||||||||
Gain from forgiveness of debt | 200,000 | 334,819 | 200,000 | 334,819 | ||||||||||||
(Loss) gain from legal settlements, net | (276,313 | ) | (76,218 | ) | 286,719 | (76,218 | ) | |||||||||
Interest expense | (431,484 | ) | (479,253 | ) | (983,747 | ) | (1,100,190 | ) | ||||||||
Total other income (expense), net | (295,429 | ) | (537,021 | ) | (241,914 | ) | (883,870 | ) | ||||||||
Income (loss) from continuing operations before income taxes, including noncontrolling interest | 1,801,568 | (499,841 | ) | 2,607,128 | (2,765,973 | ) | ||||||||||
Provision for income taxes | (517,000 | ) | - | (517,000 | ) | - | ||||||||||
Net income (loss) from continuing operations, including noncontrolling interest | 1,284,568 | (499,841 | ) | 2,090,128 | (2,765,973 | ) | ||||||||||
Net loss from discontinued operations | (8,097 | ) | (3,945 | ) | (8,097 | ) | (5,379 | ) | ||||||||
Net income (loss), including noncontrolling interest | 1,276,471 | (503,786 | ) | 2,082,031 | (2,771,352 | ) | ||||||||||
Net loss attributable to noncontrolling interest | 1,362 | - | 1,362 | - | ||||||||||||
Net income (loss) attributable to Rennova | 1,277,833 | (503,786 | ) | 2,083,393 | (2,771,352 | ) | ||||||||||
Deemed dividends | - | (194,951,624 | ) | - | (330,876,369 | ) | ||||||||||
Net income (loss) available to common stockholders | $ | 1,277,833 | $ | (195,455,410 | ) | $ | 2,083,393 | $ | (333,647,721 | ) | ||||||
Net income (loss) available to common stockholders per share - basic: | ||||||||||||||||
Continuing operations | $ | 0.00 | $ | (0.11 | ) | $ | 0.00 | $ | (0.39 | ) | ||||||
Discontinued operations | (0.00 | ) | (0.00 | ) | (0.00 | ) | (0.00 | ) | ||||||||
Total basic | $ | 0.00 | $ | (0.11 | ) | $ | 0.00 | $ | (0.39 | ) | ||||||
Net income (loss) available to common stockholders per share - diluted: | ||||||||||||||||
Continuing operations | $ | 0.00 | $ | (0.11 | ) | $ | 0.00 | $ | (0.39 | ) | ||||||
Discontinued operations | (0.00 | ) | (0.00 | ) | (0.00 | ) | (0.00 | ) | ||||||||
Total diluted | $ | 0.00 | $ | (0.11 | ) | $ | 0.00 | $ | (0.39 | ) | ||||||
Weighted average number of shares of common stock outstanding during the period: | ||||||||||||||||
Basic | 29,934,322,257 | 1,702,149,425 | 29,845,095,738 | 858,169,865 | ||||||||||||
Diluted | 482,079,733,368 | 1,702,149,425 | 488,414,836,833 | 858,169,865 |
The accompanying notes are an integral part of these condensed consolidated financial statements.
4 |
RENNOVA HEALTH, INC.
CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS’ DEFICIT
FOR THE NINE MONTHS ENDED SEPTEMBERFor Each of the Quarters in the Six-Month Period Ended June 30, 20172023
(unaudited)
Preferred Stock | Additional | Total | ||||||||||||||||||||||||||||||||||||||||||||||||||
Series G | Series H | Series F | Total | Common Stock | paid-in | Accumulated | Stockholders' | |||||||||||||||||||||||||||||||||||||||||||||
Shares | Amount | Shares | Amount | Shares | Amount | Shares | Amount | Shares | Amount | capital | Deficit | Deficit | ||||||||||||||||||||||||||||||||||||||||
Balance at December 31, 2016 | 215 | $ | 2 | 10,019 | $ | 100 | - | $ | - | 10,234 | $ | 102 | 186,692 | $ | 1,867 | $ | 45,752,999 | $ | (60,640,864 | ) | $ | (14,885,896 | ) | |||||||||||||||||||||||||||||
Conversion of preferred stock into common stock | - | - | (7,785 | ) | (78 | ) | - | - | (7,785 | ) | $ | (78 | ) | 370,446 | 3,704 | (3,627 | ) | - | - | |||||||||||||||||||||||||||||||||
Preferred stock issued for business acquisition | - | - | - | - | 1,750,000 | 17,500 | 1,750,000 | $ | 17,500 | - | - | 156,597 | - | 174,097 | ||||||||||||||||||||||||||||||||||||||
Common stock issued in exchange for warrants | - | - | - | - | - | - | - | - | 2,056 | 21 | 57,848 | - | 57,869 | |||||||||||||||||||||||||||||||||||||||
Shares issued in settlement of notes payable and warrants | - | - | - | - | - | - | - | - | 26,667 | 267 | 439,733 | - | 440,000 | |||||||||||||||||||||||||||||||||||||||
Exchange of preferred stock for convertible debentures | - | - | (2,174 | ) | (22 | ) | - | - | (2,174 | ) | (22 | ) | - | - | (2,173,978 | ) | - | (2,174,000 | ) | |||||||||||||||||||||||||||||||||
Conversion of debentures into common stock | - | - | - | - | - | - | - | - | 548,932 | 5,489 | 4,058,672 | - | 4,064,161 | |||||||||||||||||||||||||||||||||||||||
Rounding up of common shares in connection with reverse stock split | - | - | - | - | - | - | - | - | 526 | 5 | (5 | ) | - | - | ||||||||||||||||||||||||||||||||||||||
Common stock granted to employees | - | - | - | - | - | - | - | - | 185 | 2 | (2 | ) | - | - | ||||||||||||||||||||||||||||||||||||||
Discount on convertible debentures | - | - | - | - | - | - | - | - | - | - | 252,143 | - | 252,143 | |||||||||||||||||||||||||||||||||||||||
Warrants and benefical conversion features related to the issuance of convertible notes | - | - | - | - | - | - | - | - | - | - | 24,177,258 | - | 24,177,258 | |||||||||||||||||||||||||||||||||||||||
Stock-based compensation | - | - | - | - | - | - | - | - | - | - | 34,081 | 34,081 | ||||||||||||||||||||||||||||||||||||||||
Deemed dividend from trigger of down round provision feature | - | - | - | - | - | - | - | - | - | - | 53,341,619 | (53,341,619 | ) | - | ||||||||||||||||||||||||||||||||||||||
Restricted stock issued to employees | - | - | - | - | - | - | - | - | 181,933 | 1,819 | 81,145 | - | 82,964 | |||||||||||||||||||||||||||||||||||||||
Common stock issued for services and severance | - | - | - | - | - | - | - | - | 41,667 | 417 | 160,586 | - | 161,003 | |||||||||||||||||||||||||||||||||||||||
Shares returned to treasury | - | - | - | - | - | - | - | - | (4,933 | ) | (49 | ) | 49 | - | ||||||||||||||||||||||||||||||||||||||
Net loss | - | - | - | - | - | - | - | - | - | - | - | (31,172,103 | ) | (31,172,103 | ) | |||||||||||||||||||||||||||||||||||||
Balance at September 30, 2017 | 215 | $ | 2 | 60 | $ | 0 | 1,750,000 | $ | 17,500 | 1,750,275 | $ | 17,502 | 1,354,171 | $ | 13,542 | $ | 126,335,119 | $ | (145,154,586 | ) | $ | (18,788,423 | ) |
Shares | Amount | Shares | Amount | capital | Deficit | Deficit | Interest | Deficit | ||||||||||||||||||||||||||||
Additional | Rennova | Total | ||||||||||||||||||||||||||||||||||
Preferred Stock | Common Stock | paid-in | Accumulated | Stockholders’ | Noncontrolling | Stockholders’ | ||||||||||||||||||||||||||||||
Shares | Amount | Shares | Amount | capital | Deficit | Deficit | Interest | Deficit | ||||||||||||||||||||||||||||
Balance at December 31, 2022 | 292,600 | �� | $ | 2,926 | 29,084,322,257 | $ | 2,908,432 | $ | 1,671,571,834 | $ | (1,703,577,780 | ) | $ | (29,094,588 | ) | $ | - | $ | (29,094,588 | ) | ||||||||||||||||
Conversion of Series N Preferred Stock into common stock | (36 | ) | - | 400,000,000 | 40,000 | (40,000 | ) | - | - | - | ||||||||||||||||||||||||||
Conversion of Series O Preferred Stock into common stock | (40 | ) | (1 | ) | 450,000,000 | 45,000 | (44,999 | ) | - | - | - | |||||||||||||||||||||||||
Net income | - | 805,560 | 805,560 | - | 805,560 | |||||||||||||||||||||||||||||||
Balance at March 31, 2023 | 292,524 | 2,925 | 29,934,322,257 | 2,993,432 | 1,671,486,835 | (1,702,772,220 | ) | (28,289,028 | ) | - | (28,289,028 | ) | ||||||||||||||||||||||||
Sale of noncontrolling interest | 2 | 2 | ||||||||||||||||||||||||||||||||||
Net income | - | - | - | - | - | 1,277,833 | 1,277,833 | (1,362 | ) | 1,276,471 | ||||||||||||||||||||||||||
Balance at June 30, 2023 | 292,524 | $ | 2,925 | 29,934,322,257 | $ | 2,993,432 | $ | 1,671,486,835 | $ | (1,701,494,387 | ) | $ | (27,011,195 | ) | $ | (1,360 | ) | $ | (27,012,555 | ) |
The accompanying notes are an integral part of these condensed consolidated financial statements.
5 |
RENNOVA HEALTH, INC.
CONDENSED CONSOLIDATED STATEMENTSSTATEMENT OF CASH FLOWSCHANGES IN STOCKHOLDERS’ DEFICIT
(unaudited)For Each of the Quarters in the Six-Month Period Ended June 30, 2022
Nine Months Ended September 30, | ||||||||
2017 | 2016 | |||||||
Cash flows used in operating activities: | ||||||||
Net loss from continuing operations | $ | (30,118,632 | ) | $ | (19,287,511 | ) | ||
Adjustments to reconcile net loss to net cash used in operations: | ||||||||
Depreciation and amortization | 1,508,042 | 2,037,910 | ||||||
Non-cash gain on derivative instruments | - | (6,653,774 | ) | |||||
Stock issued for services | 161,003 | 9,310 | ||||||
Stock-based compensation | 34,081 | 884,165 | ||||||
Bad debt expense | 1,051,590 | 3,667,992 | ||||||
Non-cash interest expense | 8,441,043 | - | ||||||
Amortization of debt discount | 6,228,352 | 2,474,497 | ||||||
Non-cash settlement of debt | (50,000 | ) | - | |||||
Loss (gain) on extinguishment of debt | (42,702,815 | ) | (100,000 | ) | ||||
Change in fair value of derivative instrument | 42,702,815 | - | ||||||
Loss from discontinued operations | (1,053,471 | ) | (2,828,030 | ) | ||||
Changes in operating assets and liabilities: | ||||||||
Accounts receivable | (252,717 | ) | 1,878,086 | |||||
Inventory | (73,732 | ) | - | |||||
Prepaid expenses and other current assets | 2,672 | 236,612 | ||||||
Security deposits | (16,059 | ) | 3,040 | |||||
Accounts payable | 1,367,689 | (1,679,960 | ) | |||||
Accrued expenses | 2,081,876 | 331,797 | ||||||
Income tax assets and liabilities | (451,997 | ) | 2,202,206 | |||||
Net cash used in operating activities of continuing operations | (11,140,260 | ) | (16,823,660 | ) | ||||
Net cash used in discontinued operations | (643,181 | ) | (216,614 | ) | ||||
Net cash used in operating activities | (11,783,441 | ) | (17,040,274 | ) | ||||
Cash flows provided by (used in) investing activities: | ||||||||
Purchase of property and equipment | (1,554,499 | ) | (15,998 | ) | ||||
Net cash used in investing activities of continuing operations | (1,554,499 | ) | (15,998 | ) | ||||
Net cash provided by investing activites of discontinued operations | 1,936 | 79,271 | ||||||
Net cash provided by (used in) investing activities | (1,552,563 | ) | 63,273 | |||||
Cash flows provided by financing activities: | ||||||||
Proceeds from the issuance of common stock and warrants, net of offering cost | - | 7,521,036 | ||||||
Proceeds from issuance of related party notes payable and advances | 3,805,000 | 8,285,000 | ||||||
Proceeds from issuance of notes payable and debentures | 15,742,500 | 5,394,500 | ||||||
Payments on related party notes payable and advances | (3,860,000 | ) | (6,000,000 | ) | ||||
Payments on notes payable | (1,042,524 | ) | (5,715,000 | ) | ||||
Payments on capital lease obligations | (1,342,970 | ) | (791,365 | ) | ||||
Net cash provided by financing activities of continuing operations | 13,302,006 | 8,694,171 | ||||||
Net cash used in financing activities of discontinued operations | - | (36,056 | ) | |||||
Net cash provided by financing activities | 13,302,006 | 8,658,115 | ||||||
Net (decrease) in cash | (33,998 | ) | (8,318,886 | ) | ||||
Cash at beginning of period | 75,017 | 8,833,230 | ||||||
Cash at end of period | $ | 41,019 | $ | 514,344 |
(unaudited)
Shares | Amount | Shares | Amount | capital | Deficit | Deficit | ||||||||||||||||||||||
Preferred Stock | Common Stock | Additional paid-in- | Accumulated | Total Stockholders’ | ||||||||||||||||||||||||
Shares | Amount | Shares | Amount | capital | Deficit | Deficit | ||||||||||||||||||||||
Balance at December 31, 2021 | 2,045,201 | $ | 20,451 | 4,244,700 | $ | 424 | $ | 1,342,085,957 | $ | (1,369,408,356 | ) | $ | (27,301,524 | ) | ||||||||||||||
Balance | 2,045,201 | $ | 20,451 | 4,244,700 | $ | 424 | $ | 1,342,085,957 | $ | (1,369,408,356 | ) | $ | (27,301,524 | ) | ||||||||||||||
Conversions of Series N Preferred Stock into common stock | (593 | ) | (6 | ) | 12,932,500 | 1,293 | (1,287 | ) | - | - | ||||||||||||||||||
Issuances of Series P Preferred Stock | 1,100 | 11 | - | - | 999,989 | - | 1,000,000 | |||||||||||||||||||||
Deemed dividends from issuances of Series P Preferred Stock | - | - | - | - | 222,222 | (222,222 | ) | - | ||||||||||||||||||||
Payment of cash in lieu of fractional shares | - | - | (10 | ) | - | (9 | ) | - | (9 | ) | ||||||||||||||||||
Deemed dividends from triggers of down round provisions | - | - | - | - | 135,702,523 | (135,702,523 | ) | - | ||||||||||||||||||||
Net loss | - | - | - | - | - | (2,267,566 | ) | (2,267,566 | ) | |||||||||||||||||||
Net income (loss) | - | - | - | - | - | (2,267,566 | ) | (2,267,566 | ) | |||||||||||||||||||
Balance at March 31, 2022 | 2,045,708 | $ | 20,456 | 17,177,190 | $ | 1,717 | $ | 1,479,009,395 | $ | (1,507,600,667 | ) | $ | (28,569,099 | ) | ||||||||||||||
Balance | 2,045,708 | $ | 20,456 | 17,177,190 | $ | 1,717 | $ | 1,479,009,395 | $ | (1,507,600,667 | ) | $ | (28,569,099 | ) | ||||||||||||||
Conversions of Series N Preferred Stock into common stock | (1,240 | ) | (12 | ) | 2,627,145,066 | 262,715 | (262,703 | ) | - | - | ||||||||||||||||||
Conversions of Series O Preferred Stock into common stock | (179 | ) | (2 | ) | 1,581,000,000 | 158,100 | (158,098 | ) | - | - | ||||||||||||||||||
Issuance of Series P Preferred Stock | 550 | 6 | - | - | 499,994 | - | 500,000 | |||||||||||||||||||||
Deemed dividends from issuance of Series P Preferred Stock | - | - | - | - | 111,111 | (111,111 | ) | - | ||||||||||||||||||||
Deemed dividends from triggers of down round provisions | - | - | - | - | 194,840,513 | (194,840,513 | ) | - | ||||||||||||||||||||
Net loss | - | - | - | - | - | (503,786 | ) | (503,786 | ) | |||||||||||||||||||
Net income (loss) | - | - | - | - | - | (503,786 | ) | (503,786 | ) | |||||||||||||||||||
Balance at June 30, 2022 | 2,044,838 | $ | 20,448 | 4,225,322,256 | $ | 422,532 | $ | 1,674,040,212 | $ | (1,703,056,077 | ) | $ | (28,572,885 | ) | ||||||||||||||
Balance | 2,044,838 | $ | 20,448 | 4,225,322,256 | $ | 422,532 | $ | 1,674,040,212 | $ | (1,703,056,077 | ) | $ | (28,572,885 | ) |
The accompanying notes are an integral part of these condensed consolidated financial statements.
6 |
RENNOVA HEALTH, INC.
Notes to Condensed Consolidated Financial StatementsCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(unaudited)
(unaudited)
2023 | 2022 | |||||||
Six Months Ended June 30, | ||||||||
2023 | 2022 | |||||||
Cash flows from operating activities: | ||||||||
Net income (loss) from continuing operations, including noncontrolling interest | $ | 2,090,128 | $ | (2,765,973 | ) | |||
Adjustments to reconcile net income (loss) to net cash used in operations: | ||||||||
Depreciation and amortization | 193,492 | 234,040 | ||||||
Loss on disposition of property and equipment | - | 858 | ||||||
Net (gain) loss from legal settlements | (286,719 | ) | 76,218 | |||||
Gain on forgiveness of debt | (200,000 | ) | (334,819 | ) | ||||
Loss from discontinued operations | (8,097 | ) | (5,379 | ) | ||||
Changes in operating assets and liabilities: | ||||||||
Accounts receivable | 229,819 | 186,131 | ||||||
Inventory | 7,280 | 36,890 | ||||||
Prepaid expenses and other current assets | (168,159 | ) | 21,304 | |||||
Security deposits | 1,117 | (10,000 | ) | |||||
Change in right-of-use assets | 133,946 | 117,871 | ||||||
Accounts payable | 1,494,659 | 484,458 | ||||||
Accrued expenses | (531,720 | ) | 867,828 | |||||
Income taxes payable | 517,000 | - | ||||||
Change in right-of-use operating lease obligations | (133,946 | ) | (117,871 | ) | ||||
Net cash provided by (used in) operating activities of continuing operations | 3,338,800 | (1,208,444 | ) | |||||
Net cash provided by (used in) operating activities of discontinued operations | 8,097 | (1,714 | ) | |||||
Net cash provided by (used in) operating activities | 3,346,897 | (1,210,158 | ) | |||||
Cash flows from investing activities: | ||||||||
Receivable from related party | (876,998 | ) | (428,943 | ) | ||||
Purchases of property and equipment | (276,983 | ) | (33,940 | ) | ||||
Net cash used in investing activities of continuing operations | (1,153,981 | ) | (462,883 | ) | ||||
Cash flows from financing activities: | ||||||||
Proceeds from issuance of related party loan payable | 580,000 | 750,000 | ||||||
Payments of related party loan payable | (1,322,000 | ) | - | |||||
Payments of debentures | (400,000 | ) | - | |||||
Payments of notes payable | (824,869 | ) | (1,171,603 | ) | ||||
Receivables paid under accounts receivable sales agreements | - | (317,647 | ) | |||||
Proceeds from issuances of preferred stock | - | 1,500,000 | ||||||
Proceeds from HHS Provider Relief Funds | - | 314,651 | ||||||
Cash paid for fractional shares in connection with reverse stock split | - | (9 | ) | |||||
Net cash (used in) provided by financing activities of continuing operations | (1,966,869 | ) | 1,075,392 | |||||
Net change in cash | 226,047 | (597,649 | ) | |||||
Cash at beginning of period | 499,470 | 724,524 | ||||||
Cash at end of period | $ | 725,517 | $ | 126,875 |
The accompanying notes are an integral part of these condensed consolidated financial statements.
7 |
RENNOVA HEALTH, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
For the Three and Six Months Ended June 30, 2023 and 2022
(unaudited)
Note 1 – Organization and BasisSummary of PresentationSignificant Accounting Policies
Description of Business
Rennova Health, Inc. (“Rennova”), together with its subsidiaries, (thethe “Company”, “we”, “us”, “its” or “our”), is a vertically integrated provider of healthcare related products andhealth care services. The Company owns one operating hospital in Oneida, Tennessee, a hospital located in Jamestown, Tennessee that it plans to reopen, and operate and an operating rural health clinic in Kentucky. In addition, the Company owns a subsidiary pursuing opportunities in the behavioral health sector and, on August 14, 2023, commenced operations of an alcohol and drug treatment facility on the campus of its hospital in Oneida, Tennessee. The Company’s principal linesoperations consist of business are (i) clinicalonly one segment.
Scott County Community Hospital (d/b/a Big South Fork Medical Center)
On January 13, 2017, we acquired certain assets related to Scott County Community Hospital, based in Oneida, Tennessee (the “Oneida Assets”). The Oneida Assets include a 52,000-square foot hospital building and 6,300-square foot professional building on approximately 4.3 acres. Scott County Community Hospital has 25 beds, a 24/7 emergency department and a laboratory operations; (ii) supportive software solutionsthat provides a range of diagnostic services. Scott County Community Hospital closed in July 2016 in connection with the bankruptcy filing of its parent company, Pioneer Health Services, Inc. We acquired the Oneida Assets out of bankruptcy for a purchase price of $1.0 million. The hospital, which has since been renamed Big South Fork Medical Center, became operational on August 8, 2017. The hospital became certified as a Critical Access Hospital (rural) hospital in December 2021, retroactive to healthcare providers including ElectronicJune 30, 2021.
CarePlus Clinic
On March 5, 2019, we acquired certain assets related to an outpatient clinic located in Williamsburg, Kentucky. The clinic and its associated assets, which were acquired from CarePlus Rural Health RecordsClinic, LLC, offers compassionate care in a modern, patient-friendly facility. The CarePlus Clinic is located 32 miles northwest of our Big South Fork Medical Center.
Myrtle Recovery Centers, Inc.
In the second quarter of 2022, the Company formed a subsidiary, Myrtle Recovery Centers, Inc. (“EHR”Myrtle”), to pursue opportunities in the behavioral health sector, initially in our core, rural markets. We intend to focus on leveraging our existing physical locations and corporate and regional infrastructure to offer behavioral health services, including substance abuse treatment. Services will be provided on either an inpatient, residential basis or an outpatient basis.
On August 10, 2023, Myrtle was granted a license under the rules of the Department of Mental Health and Substance Abuse Services of Tennessee to operate an alcohol and drug treatment facility in Oneida Tennessee. The facility, which is located at Rennova’s Big South Fork Medical Billing ServicesCenter campus, commenced operations and Laboratory Information Services;began accepting patients on August 14, 2023. The facility offers alcohol and (iii)drug residential detoxification and residential rehabilitation treatment services for up to 30 patients. Myrtle intends to offer outpatient opioid treatment services at its Oneida facility in the recent additionfuture.
On April 11, 2023, Myrtle sold shares of its common stock equivalent to a rural critical access hospital.1.961% ownership stake in the subsidiary for de minimis value to an unaffiliated individual licensed as a physician in Tennessee. The shares have certain transfer restrictions, including the right of the subsidiary to transfer the shares to another physician licensed in Tennessee for de minimis value. The shares were sold to the individual for Tennessee healthcare regulatory reasons.
Jamestown Regional Medical Center
On June 1, 2018, we acquired from Community Health Systems, Inc. certain assets related to an acute care hospital located in Jamestown, Tennessee, referred to as Jamestown Regional Medical Center, for a purchase price of $0.7 million. The hospital is an 85-bed facility of approximately 90,000-square feet on over eight acres of land, which offered a 24-hour emergency department with two trauma bays and seven private exam rooms, inpatient and outpatient medical services and a progressive care unit which provided telemetry services. The acquisition also included a separate physician practice known as Mountain View Physician Practice, Inc.
The Company suspended operations at the hospital and physician practice in June 2019, as a result of the termination of the hospital’s Medicare agreement and other factors. The Company is evaluating whether to reopen the facility as an acute care hospital or as another type of healthcare facility. Jamestown is located 38 miles west of Big South Fork Medical Center.
8 |
Basis of Presentation
The accompanying unaudited condensed consolidated financial statements were prepared using generally accepted accounting principles for interim financial information and the instructions to Form 10-Q and Regulation S-X. Accordingly, these financial statements do not include all information or notes required by generally accepted accounting principles for annual financial statements and should be read in conjunction with the 2016 auditedconsolidated financial statements includedas filed in the Company’s Annual Report on Form 10-K filed withfor the U.S. Securities and Exchange Commission (the “SEC”) on April 10, 2017. Theseyear ended December 31, 2022. In the opinion of management, the unaudited condensed consolidated interim financial statements included herein contain all adjustments necessary to present fairly the Company’s consolidated financial position as of June 30, 2023, and the results of its operations and changes in stockholders’ deficit for the three and six months ended June 30, 2023 and 2022 and its cash flows for the six months ended June 30, 2023 and 2022. Such adjustments are of a normal recurring nature. The results of operations for the three and six months ended June 30, 2023 may not be indicative of results for the year ending December 31, 2023.
Principles of Consolidation
The unaudited condensed consolidated financial statements, which have been prepared in accordance with the instructions to Form 10-Q and Article 8 of Regulation S-X of the SEC, and therefore omit or condense certain footnotes and other information normally included in consolidated interim financial statements prepared in accordance with U.S.accounting principles generally accepted accounting principlesin the United States of America (“U.S. GAAP”)., include the accounts of Rennova and its wholly-owned and majority-owned subsidiaries. All material intercompany balancestransactions and transactionsbalances have been eliminated in consolidation. In the opinionconsolidation.
Comprehensive Income (Loss)
During the three and six months ended June 30, 2023 and 2022, comprehensive income (loss) was equal to the net income (loss) amounts presented in the unaudited condensed consolidated statements of operations.
Use of Estimates
The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent liabilities at the date of the Company’s management, the unaudited interim condensed consolidated financial statements, contain all adjustments (consisting onlyand the reported amounts of normal recurring accruals) considered necessary fornet revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates and assumptions include the estimates of fair presentationvalues of assets acquired and liabilities assumed in business combinations, contractual allowances and bad debt reserves, the financial positionrecoverability of long-lived assets, the valuation allowance relating to the Company’s deferred tax assets, the valuations of investments, equity and derivative instruments, deemed dividends, litigation and related reserves, among others. Actual results could differ from those estimates and would impact future results of operations and cash flows for the interim periods reported herein. The results of operations presented are not necessarily indicative of the results to be expected for any other interim period or for the entire year.flows.
During the three and nine months ended September 30, 2017 and 2016, comprehensive loss was equal to the net loss amounts presented in the accompanying condensed consolidated statements of operations. In addition, certainReclassifications
Certain prior year balancesamounts have been reclassified to conform to the current year presentation.
ReclassificationCash and Cash Equivalents
The Company considers all highly liquid temporary cash investments with an original maturity of three months or less to be cash equivalents.
Revenue Recognition
We recognize revenue in accordance with Accounting Standard Codification (“ASC”), “Revenue from Contracts with Customers (Topic 606),” including subsequently issued updates. Under the accounting guidance, our revenues are presented net of estimated contractual allowances and estimated implicit price concessions. We also do not present “allowances for doubtful accounts” on our balance sheets.
9 |
Our revenues relate to contracts with patients in which our performance obligations are to provide health care services to the patients. Revenues are recorded during the period our obligations to provide health care services are satisfied. Our performance obligations for inpatient services are generally satisfied over periods averaging approximately three days, and revenues are recognized based on charges incurred. Our performance obligations for outpatient services, including emergency room-related services, are generally satisfied over a period of less than one day. The contractual relationships with patients, in most cases, also involve a third-party payer (Medicare, Medicaid, managed care health plans and commercial insurance companies, including plans offered through the health insurance exchanges) and the transaction prices for the services provided are dependent upon the terms provided by (Medicare and Medicaid) or negotiated with (managed care health plans and commercial insurance companies) the third-party payers. The payment arrangements with third-party payers for the services we provide to the related patients typically specify payments at amounts less than our standard charges. Medicare, because of the Big South Fork Medical Center’s designation as a Critical Access Hospital, generally pays for inpatient and outpatient services at rates related to the hospital’s costs. Services provided to patients having Medicaid coverage are generally paid at prospectively determined rates per discharge, per identified service or per covered member. Agreements with commercial insurance carriers, managed care and preferred provider organizations generally provide for payments based upon predetermined rates per diagnosis, per diem rates or discounted fee-for-service rates. Management continually reviews the contractual estimation process to consider and incorporate updates to laws and regulations and the frequent changes in managed care contractual terms resulting from contract renegotiations and renewals. Our net revenues are based upon the estimated amounts we expect to be entitled to receive from patients and third-party payers. Estimates of contractual allowances under managed care and commercial insurance plans are based upon the payment terms specified in the related contractual agreements. Revenues related to uninsured patients and uninsured copayment and deductible amounts for patients who have health care coverage may have discounts applied (uninsured discounts and contractual discounts). We also record estimated implicit price concessions (based primarily on historical collection experience) related to uninsured accounts to record self-pay revenues at the estimated amounts we expect to collect.
Laws and regulations governing the Medicare and Medicaid programs are complex and subject to interpretation. Estimated reimbursement amounts are adjusted in subsequent periods as cost reports are prepared and filed and as final settlements are determined (in relation to certain government programs, primarily Medicare, this is generally referred to as the “cost report” filing and settlement process). As of June 30, 2023, $1.0 million of Medicare cost report settlement reserves were recorded as liabilities on the condensed balance sheet, as more fully discussed in Note 5.
The collection of outstanding receivables for Medicare, Medicaid, managed care payers, other third-party payers and patients is our primary source of operating cash and is critical to our operating performance. The primary collection risks relate to uninsured patient accounts, including patient accounts for which the primary insurance carrier has paid the amounts covered by the applicable agreement, but patient responsibility amounts (deductibles and copayments) remain outstanding. Implicit price concessions relate primarily to amounts due directly from patients. Estimated implicit price concessions are recorded for all uninsured accounts, regardless of the aging of those accounts. Accounts are written off when all reasonable internal and external collection efforts have been performed. The estimates for implicit price concessions are based upon management’s assessment of historical write offs and expected net collections, business and economic conditions, trends in federal, state and private employer health care coverage and other collection indicators. Management relies on the results of detailed reviews of historical write-offs and collections at facilities that represent a majority of our revenues and accounts receivable (the “hindsight analysis”) as a primary source of information in estimating the collectability of our accounts receivable.
Contractual Allowances and Doubtful Accounts Policy
Accounts receivable are reported at realizable value, net of estimated contractual allowances and estimated implicit price concessions (also referred to as doubtful accounts), which are estimated and recorded in the period the related revenue is recorded. The Company has reclassified certain amountsa standardized approach to estimating and reviewing the collectability of its receivables based on a number of factors, including the period they have been outstanding. Historical collection and payer reimbursement experience is an integral part of the estimation process related to contractual allowances and doubtful accounts. In addition, the Company regularly assesses the state of its billing operations in order to identify issues which may impact the 2016 condensed consolidated financial statementsreceivables or reserve estimates. Receivables deemed to be consistent withuncollectible are charged against the 2017 presentation. These principally relateallowance for doubtful accounts at the time such receivables are written-off. Recoveries of receivables previously written-off are recorded as credits to classificationthe allowance for doubtful accounts. Revisions to the allowances for doubtful accounts are recorded as an adjustment to revenues.
During the three months ended June 30, 2023 and 2022, estimated contractual allowances of certain revenues, cost$8.5 million and $5.1 million, respectively, and estimated implicit price concessions of $1.4 million and $2.7 million, respectively, have been recorded as reductions to our revenues and accounts receivable balances to enable us to record our revenues and accounts receivable at the estimated amounts we expect to collect. As required by Topic 606, after estimated implicit price concessions and contractual and related segment data, as well as balance sheet classificationsallowance adjustments to assetsrevenues of $9.9 million and liabilities held for sale. Reclassifications relating to the discontinued operations of AMSG are described further in Note 14. The reclassifications had no impact on operations or cash flows$7.8 million, respectively, for the three and nine months ended SeptemberJune 30, 2016.2023 and 2022, we reported net revenues of $6.4 million and $3.6 million, respectively.
Reverse Stock Splits
On February 7, 2017,During the Company’s Boardsix months ended June 30, 2023 and 2022, estimated contractual allowances of Directors approved an amendment$19.6 million and $13.2 million, respectively, and estimated implicit price concessions of $2.4 million and $4.1 million, respectively, have been recorded as reductions to our revenues and accounts receivable balances to enable us to record our revenues and accounts receivable at the Company’s Certificate of Incorporationestimated amounts we expect to effect a 1-for-30 reverse stock split of the Company’s shares of common stock effective on February 22, 2017 and on September 21, 2017, the Company’s Board of Directors approved an amendment to the Company’s Certificate of Incorporation to effect a 1-for-15 reverse stock split effective October 5, 2017 (the “Reverse Stock Splits”). The stockholders of the Company had approved these amendments to the Company’s Certificate of Incorporation on December 22, 2016collect. As required by Topic 606, for the February 7, 2017 reverse stock splitsix months ended June 30, 2023 and on September 20, 20172022, after estimated implicit price concessions and contractual and related allowance adjustments to revenues of $22.0 million and $17.3 million, respectively, we reported net revenues of $11.3 million and $4.8 million, respectively.
We continue to review the provisions for the October 5, 2017 reverse stock split. In both cases, the Company’s stockholders had granted authorization to the Board of Directors to determine in its discretion the specific ratio, subject to limitations,implicit price concessions and the timing of the reverse splits within certain specified effective dates.contractual allowances. See Note 4 – Accounts Receivable.
As a result of the Reverse Stock Splits, every 30 shares of the Company’s then outstanding common stock was combined and automatically converted into one share of the Company’s common stock, par value $0.01 per share, on February 7, 2017 and every 15 shares of the Company’s then outstanding common stock was combined and automatically converted into one share of the Company’s common stock, par value $0.01 per share, on October 5, 2017. In addition, the conversions and exercise prices of all of the Company’s outstanding preferred stock, common stock purchase warrants, stock options, restricted stock, equity incentive plans and convertible notes payable were proportionately adjusted at the 1:30 reverse split ratio and again at the 1:15 reverse split ratio in accordance with the terms of such instruments. In addition, proportionate voting rights and other rights of common stockholders were not affected by the Reverse Stock Splits, other than as a result of the rounding up of fractional shares in the February reverse split and the payment of cash in lieu of fractional shares in the October reverse split, as no fractional shares were issued in connection with the Reverse Stock Splits.
The par value and other terms of the common stock were not affected by the Reverse Stock Splits. The authorized capital of the Company of 500,000,000 shares of common stock and 5,000,000 shares of preferred stock were also unaffected by the Reverse Stock Splits.
All share, per share and capital stock amounts for all periods presented have been restated to give effect to the Reverse Stock Splits.
RENNOVA HEALTH, INC.Impairment or Disposal of Long-Lived Assets
Notes
We account for the impairment or disposal of long-lived assets according to Condensed Consolidated Financial Statements
(unaudited)
Adoption of ASU 2017-11
In July 2017, the Financial Accounting Standards Board (“FASB”(the “FASB”) issuedASC Topic 360, Property, Plant and Equipment (“ASC 360”). ASC 360 clarifies the accounting for the impairment of long-lived assets and for long-lived assets to be disposed of, including the disposal of business segments and major lines of business. Long-lived assets are reviewed when facts and circumstances indicate that the carrying value of the asset may not be recoverable. When necessary, impaired assets are written down to estimated fair value based on the best information available. Estimated fair value is generally either based on appraised value or measured by discounting estimated future cash flows. Considerable management judgment is necessary to estimate discounted future cash flows. Accordingly, actual results could vary significantly from such estimates. The Company did not record an asset impairment charge during the three and six months ended June 30, 2023 and 2022.
Leases in Accordance with ASU No. 2016-02
We account for leases in accordance with Accounting Standards Update (“ASU”) No. 2016-02, Leases (Topic 842), which requires leases with durations greater than 12 months to be recognized on the balance sheet. Upon adoption in 2019, we elected the package of transition provisions available which allowed us to carryforward our historical assessments of (1) whether contracts are or contain leases, (2) lease classification and (3) initial direct costs. We lease property and equipment under finance and operating leases. For operating leases with terms greater than 12 months, we record the related right-of-use assets and right-of-use obligations at the present value of lease payments over the term. For finance leases, we record the present value of the lease payments as finance lease obligations. We do not separate lease and non-lease components of contracts. Our finance and operating leases are more fully discussed in Note 8.
Fair Value Measurements
In accordance with ASC 820, “Fair Value Measurements and Disclosures,” the Company applies fair value accounting for all financial assets and liabilities and non-financial assets and liabilities that are recognized or disclosed at fair value in the financial statements on a recurring basis. Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities which are required to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact and the market-based risk measurements or assumptions that market participants would use in pricing the asset or liability, such as risks inherent in valuation techniques, transfer restrictions and credit risk. Fair value is estimated by applying the following hierarchy, which prioritizes the inputs used to measure fair value into three levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement:
● | Level 1 applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities that we have the ability to access at the measurement date. | |
● | Level 2 applies to assets or liabilities for which there are inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly, such as quoted prices for similar assets or liabilities in active markets; or quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets). | |
● | Level 3 applies to assets or liabilities for which fair value is derived from valuation techniques in which one or more significant inputs are unobservable, including our own assumptions. |
On June 30, 2023 and December 31, 2022, we applied the Level 3 fair value hierarchy in determining the fair value of InnovaQor, Inc.’s Series B-1 Non-Voting Convertible Preferred Stock (the “InnovaQor Series B-1 Preferred Stock”), which is reflected on our unaudited condensed consolidated balance sheets as an investment. Also, on June 30, 2023 and December 31, 2022, we applied the Level 3 fair value hierarchy in determining the fair value of a derivative liability for an embedded conversion option of an outstanding convertible debenture. Our determination of fair value is more fully discussed in Note 9.
11 |
Derivative Financial Instruments and Fair Value, Including ASU 2017-11 and ASU 2021-04
In July 2017, the FASB issued ASU 2017-11, “Earnings Per Share (Topic 260) Distinguishing Liabilities from Equity (Topic 480) Derivatives and Hedging (Topic 815).” The amendments in Part I of this Update change the classification analysis of certain equity-linked financial instruments (or embedded features) with down round features. When determining whether certain financial instruments should be classified as liabilities or equity instruments, a down round feature no longer precludes equity classification when assessing whether the instrument is indexed to an entity’s own stock. The amendments also clarify existing disclosure requirements for equity-classified instruments. As a result, a freestanding equity-linked financial instrument (or embedded conversion option) no longer would be accounted for as a derivative liability at fair value as a result of the existence of a down round feature. For freestanding equity classified financial instruments, the amendments require entities that present earnings (loss) per share (EPS) in accordance with Topic 260 to recognize the effect of the down round feature when it is triggered. That effect is treated as a dividend and as a reduction of income available to common shareholdersstockholders in basic and diluted EPS. Convertible instruments with embedded conversion options that have down round features are now subject to the specialized guidance for contingent beneficial conversion features (in Subtopic 470-20, Debt—Debt with Conversion and Other Options), including related EPS guidance (in Topic 260). The amendments in Part II of this Update recharacterize
In May 2021, the indefinite deferral of certain provisions of Topic 480 that now are presented as pending content in the Codification, to a scope exception. Those amendments do not have an accounting effect.
Under current GAAP, an equity-linked financial instrument with a down round feature that otherwise is not required to be classified as a liability under the guidance in Topic 480 is evaluated under the guidance in Topic 815, DerivativesFASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt—Modifications and Hedging, to determine whether it meets the definition of a derivative. If it meets that definition, the instrument (or embedded feature) is evaluated to determine whether it is indexed to an entity’s own stock as part of the analysis of whether it qualifies for a scope exception from derivative accounting. Generally, for warrantsExtinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and conversion options embedded in financial instruments that are deemed to have a debt host (assuming the underlying shares are readily convertible to cash or the contract provides for net settlement such that the embedded conversion option meets the definition of a derivative), the existence of a down round feature results in an instrument not being considered indexed to an entity’s own stock. This results in a reporting entity being required to classify the freestanding financial instrument or the bifurcated conversion option as a liability, which the entity must measure at fair value initially and at each subsequent reporting date.
The amendments in this Update revise the guidance for instruments with down round features in Subtopic 815-40, Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40), Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options. The FASB issued this update to clarify and reduce diversity in an issuer’s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. The guidance clarifies whether an issuer should account for a modification or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange as (1) an adjustment to equity (that is, deemed dividends) and, if so, the related earnings per share (EPS) effects, if any, or (2) an expense and, if so, the manner and pattern of recognition. We adopted this new accounting guidance on January 1, 2022. Under the new guidance, the FASB decided not to include convertible debt instruments in the guidance because ASU No 2016-01, Financial Instruments – Overall (Subtopic 825-10) requires that an entity capture the impact of changes in down round provision features of convertible debt within the fair value of the instruments. During the three and six months ended June 30, 2023 and 2022, there were no changes in the fair values of the Company’s convertible debentures with down round provision features as these debentures issued in 2018 have floors of $ per share and were not in-the-money during these periods. Debentures are more fully discussed in Note 6.
There were no triggers of down round provisions to warrants during the three and six months ended June 30, 2023. The incremental value of modification to warrants as a result of triggers of the down round provisions of $194.7 million and $330.5 million were recorded as deemed dividends in the three and six months ended June 30, 2022, respectively. See Note 9 for an additional discussion of derivative financial instruments and deemed dividends.
In addition, we recorded deemed dividends of approximately $0.2 million and $0.3 million during the three and six months ended June 30, 2022, respectively, as a result of the issuances of shares of our Series P Convertible Redeemable Preferred Stock (the “Series P Preferred Stock”), which is more fully discussed in Note 10.
Income Taxes
Income taxes are accounted for under the liability method of accounting for income taxes. Under the liability method, future tax liabilities and assets are recognized for the estimated future tax consequences attributable to differences between the amounts reported in the financial statement carrying amounts of assets and liabilities and their respective tax bases. Future tax assets and liabilities are measured using enacted or substantially enacted income tax rates expected to apply when the asset is realized or the liability settled. The effect of a change in income tax rates on future income tax liabilities and assets is recognized in income in the period that the change occurs. Future income tax assets are recognized to the extent that they are considered in determining whether an equity-linked financial instrument qualifiesmore likely than not to be realized. When projected future taxable income is insufficient to provide for the realization of deferred tax assets, the Company recognizes a scope exception from derivative accounting. An entity stillvaluation allowance.
In accordance with U.S. GAAP, the Company is required to determine whether instrumentsa tax position of the Company is more likely than not to be sustained upon examination by the applicable taxing authority, including resolution of any related appeals or litigation processes, based on the technical merits of the position. The tax benefit to be recognized is measured as the largest amount of benefit that is greater than fifty percent likely of being realized upon ultimate settlement. Derecognition of a tax benefit previously recognized could result in the Company recording a tax liability (or reducing a tax asset) that would be classified in equity under the guidance in Subtopic 815-40 in determining whether they qualify for that scope exception. If they do qualify, freestanding instruments with down round features are no longer classified as liabilitiesreduce net assets. The Company did not have an unrecognized tax benefit at June 30, 2023 and embedded conversion options with down round features are no longer bifurcated.December 31, 2022.
12 |
For entities that present EPS
The Company reports earnings (loss) per share in accordance with ASC Topic 260, “Earnings Per Share,” which establishes standards for computing and whenpresenting earnings (loss) per share. Basic earnings (loss) per share of common stock is calculated by dividing net earnings (loss) available to common stockholders by the down round featureweighted-average shares of common stock outstanding during the period, without consideration of common stock equivalents. Diluted earnings (loss) per share is included in an equity-classified freestanding financial instrument,calculated by adjusting the valueweighted-average shares of common stock outstanding for the dilutive effect of common stock equivalents, including preferred stock, convertible debt, stock options and warrants outstanding for the period, with options and warrants determined using the treasury stock method. For purposes of the diluted earnings (loss) per share calculation, common stock equivalents are excluded from the calculation when their effect would be anti-dilutive. See Note 3 for the computation of earnings (loss) per share for the three and six months ended June 30, 2023 and 2022.
Reverse Stock Split
On March 15, 2022, the Company effected a 1-for-10,000 reverse stock split (the “Reverse Stock Split”). As a result of the down round feature is treated as a dividend when it is triggered and as a numerator adjustment in the basic EPS calculation. This reflects the occurrence of an economic transfer of value to the holderReverse Stock Split, every shares of the instrument, while alleviating the complexityCompany’s common stock then outstanding was combined and income statement volatility associated with fair value measurement on an ongoing basis. Convertible instruments are unaffected by the Topic 260 amendments in this Update.
Those amendments in Part 1 of this Update are a cost savings relative to current GAAP. This is because, assuming the required criteria for equity classification in Subtopic 815-40 are met, an entity that issued such an instrument no longer measures the instrument at fair value at each reporting period (in the case of warrants) or separately accounts for a bifurcated derivative (in the case of convertible instruments) on the basisautomatically converted into one share of the existenceCompany’s common stock on March 15, 2022. The conversion and exercise prices of a down round feature. For convertible instruments with embedded conversion options that have down round features, applying specialized guidance such as the model for contingent beneficial conversion features rather than bifurcating an embedded derivative also reduces cost and complexity. Under that specialized guidance, the issuer recognizes the intrinsic valueall of the feature only whenCompany’s outstanding convertible preferred stock, common stock purchase warrants, stock options and convertible debentures were proportionately adjusted at the feature becomes beneficial instead of bifurcating the conversion option and measuring it at fair value each reporting period.
The amendments in Part II of this Update replace the indefinite deferral of certain guidance in Topic 480 with a scope exception. This has the benefit of improving the readability of the Codification and reducing the complexity associated with navigating the guidance in Topic 480.
For public business entities, the amendments in Part I of this Update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. For all other entities, the amendments in Part I of this Update are effective for fiscal years beginning after December 15, 2019, and interim periods within fiscal years beginning after December 15, 2020. Early adoption is permitted for all entities, including adoption in an interim period. If an entity early adopts the amendments in an interim period, any adjustments should be reflected as of the beginning of the fiscal year that includes that interim period. The amendments in Part 1 of this Update should be applied in either of the following ways: 1. Retrospectively to outstanding financial instruments with a down round feature by means of a cumulative-effect adjustment to the statement of financial position as of the beginning of the first fiscal year and interim period(s) in which the pending content that links to this paragraph is effective; or 2. Retrospectively to outstanding financial instruments with a down round feature for each prior reporting period presentedapplicable reverse split ratio in accordance with the guidance on accounting changesterms of such instruments. The par value and other terms of the common stock were not affected by the Reverse Stock Split. All share, per share and capital stock amounts and common stock equivalents presented herein have been restated where appropriate to give effect to the Reverse Stock Split.
Amendment to Certificate of Incorporation
Effective November 5, 2021, the Company filed an Amendment to its Certificate of Incorporation, as amended, with the Secretary of State of the State of Delaware to provide that the number of authorized shares of the Company’s common stock or preferred stock may be increased or decreased (but not below the number of shares then outstanding) by the affirmative vote of the holders of a majority in paragraphs 250-10-45-5 through 45-10.voting power of the stock of the Company entitled to vote generally in the election of directors, irrespective of the provisions of Section 242(b)(2) of the General Corporation Law of the State of Delaware (or any successor provision thereto), voting together as a single class, without a separate vote of the holders of the class or classes the number of authorized shares of which are being increased or decreased unless a vote by any holders of one or more series of preferred stock is required by the express terms of any series of preferred stock pursuant to the terms thereof.
RENNOVA HEALTH, INC.Note 2 – Liquidity and Financial Condition
Notes to Condensed Consolidated Financial Statements
(unaudited)Going Concern
The amendments in Part II of this Update do not require any transition guidance because those amendments do not have an accounting effect.
The Company has determined that this amendment had a material impact on its condensed consolidated financial statements and has early adopted this accounting standard update. The cumulative effect of the adoption of ASU 2017-11 resulted in the reclassification of the derivative liability recorded of $56 million and the reversal of $41 million of interest expense recorded in the Company’s first fiscal quarter of 2017. The remaining $16 million was offsetresponsibility to additional paid in capital (discount on convertible debenture). Additionally, the Company recognized a deemed dividend from the trigger of the down round provision feature of $53.3 million. A $51 million deemed dividend was recorded retrospectively as of the beginning of the issuance of the March 2017 debentures where the initial derivative liability was recorded. A $2.3 million deemed dividend adjustment was recorded in the three months ended September 30, 2017 as a result of the down round provision feature.
Going Concern
The Company’s condensed consolidated financial statements are prepared using U.S. GAAP applicable to a going concern that contemplates the realization of assets and liquidation of liabilities in the normal course of business. The Company has accumulated significant losses and has negative cash flows from operations, and at September 30, 2017 had a working capital deficit and stockholders’ deficit of $18.0 million and $18.8 million, respectively, whichevaluate whether conditions and/or events raise substantial doubt about its ability to meet its future financial obligations as they become due within one year after the date that the financial statements are issued. As required by ASC, Presentation of Financial Statements-Going Concern (Subtopic 205-40) (“ASC 205-40”), this evaluation shall initially not take into consideration the potential mitigating effects of plans that have not been fully implemented as of the date the financial statements are issued. Management has assessed the Company’s ability to continue as a going concern. In addition,concern in accordance with the Company’s cash positionrequirements of ASC 205-40.
At June 30, 2023, the Company had a working capital deficit and a stockholders’ deficit of $40.9 million and $27.0 million, respectively. While the Company incurred net income of $2.1 million for the six months ended June 30, 2023, it incurred a net loss of $3.3 million for the year ended December 31, 2022 and as of the date of this report, its cash is critically deficient criticaland payments are not being madefor its operations in the ordinary course are not being made. The prior year loss and other related factors, including past due accounts payable and payroll taxes, as well as payment defaults under the terms of businessoutstanding notes payable and certain indebtedness in the amount of $6.0 million matured on March 31, 2017, which the Company does not have the financial resources to satisfy (see Note 5), all of whichdebentures, raise substantial doubt about the Company’s ability to continue as a going concern.concern for 12 months from the filing date of this report.
The Company continues to consider efficiencies and is currently using one laboratory for the majority of its toxicology diagnostics thereby reducing the number of employees and associated operating expenses, in order to reduce costs. In addition,Company’s unaudited condensed consolidated financial statements are prepared assuming the Company received approximately $15.7 million in cash fromcan continue as a going concern, which contemplates continuity of operations through realization of assets, and the issuancessettling of debentures and warrantsliabilities in the first nine monthsnormal course of 2017 (see Note 6), $3.8 million from related partiesbusiness. The Company’s current financial condition may make it difficult to attract and an additional $4.0 million of proceeds on October 30, 2017 from the issuance of convertible preferred stock (see Note 15). In July 2017, the Company announced that it plansmaintain adequate expertise in its management team to spin offsuccessfully operate its Advanced Molecular Services Group (“AMSG”) as an independent publicly traded company by way of a tax-free distribution to its shareholders. Completion of the spinoff of AMSG is expected to occur during the first quarter of 2018, and is subject to numerous conditions, including effectiveness of a Registration Statement on Form 10 to be filed with the Securities and Exchange Commission and consents, including under various funding agreements previously entered into by the Company. The intent of the spinoff of AMSG is to create two public companies, each of which can focus on its own strengths and operational plans. In accordance with ASC 205-20 and having met the criteria for “held for sale”, the Company has reflected amounts relating to AMSG as a disposal group classified as held for sale and included as part of discontinued operations. AMSG is no longer included in the segment reporting following the reclassification to discontinued operations. The discontinued operations of AMSG are described further in Note 14. The Company also announced that the Big South Fork Medical Center received CMS regional office licensure approval and opened its doors on August 8, 2017. The hospital provided services to over 1,854 patients and recognized approximately $0.6 million of revenues during the three months ended September 30, 2017. The Company may amend its current revenue recognition policy and percentage for the hospital when payments are received to support amended revenue recognition methodologies. Therefore, the Company expects that the opening of the hospital will continue to provide additional revenue and cash flow sources.healthcare facilities.
There can be no assurance that the Company will be able to achieve its business plan, raise any additional capital or secure the additional financing necessary to implement its current operating plan. The ability of the Company to continue as a going concern is dependent upon its ability to significantly reduceraise adequate capital to fund its operations and repay its outstanding debt and other past due obligations, fully align its operating costs, increase its net revenues, and eventually regainmaintain profitable operations. The accompanyingunaudited condensed consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.
13 |
Recent EventsHHS Provider Relief Funds
Common Stock ListingThe Company received HHS Provider Relief Funds, which were provided to eligible healthcare providers out of the $100 billion Public Health and Social Services Emergency Fund provided for in the Coronavirus Aid, Relief and Economic Security Act (the “CARES Act”). The funds were allocated to eligible healthcare providers for expenses and lost revenue attributable to the COVID-19 pandemic. As of June 30, 2023, our facilities have received approximately $13.6 million in relief funds. The fund payments are grants, not loans, and HHS will not require repayment, but the funds must be used only for grant approved purposes. Based on an analysis of the compliance and reporting requirements of the Provider Relief Funds and the impact of the pandemic on our operating results through June 30, 2023, we have recognized a net of $13.0 million of these funds as income of which $0.6 million, $4.4 million and $8.0 million were recognized as income during the years ended December 31, 2022, 2021 and 2020, respectively. Accordingly, approximately $0.6 million of relief funds received as of June 30, 2023 are included on our balance sheets in accrued expenses – see Note 5.
Effective October 25, 2017,As of June 30, 2023, the Company’s common stock (RNVA)estimate of the amount for which it is reasonably assured of meeting the underlying terms and warrantsconditions of the grants was based on, among other things, the various notices issued by HHS on September 19, 2020, October 22, 2020, and January 15, 2021 and the Company’s results of operations during the three and six months ended June 30, 2023 and the years ended December 31, 2022, 2021 and 2020. The Company believes that it was appropriate to purchase common stock (RNVAW) were no longer listedrecognize a net of $13.0 million of the HHS Provider Relief Funds as income in various periods, as discussed in the paragraph above. Accordingly, the $13.0 million is not recognized as a liability at June 30, 2023. Additional guidance or new and amended interpretations of existing guidance on the Nasdaq Stock Market but began trading onterms and conditions of such payments may result in changes in the OTCQB instead,Company’s estimate of amounts for which the terms and conditions are reasonably assured of being met, and any such changes may be material. Additionally, any such changes may result in derecognition of amounts of income previously recognized, which may be material. If we are unable to attest to or comply with current or future terms and conditions, and there is no assurance we will be able to do so, our ability to retain some or all of the funds received may be impacted.
The Company has been served with a qui tam complaint with regards to the use of monies received from HHS Provider Relief Funds, as more fully discussed in Note 15.12.
Schedule of Earnings Per Share
2023 | 2022 | 2023 | 2022 | |||||||||||||
Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
2023 | 2022 | 2023 | 2022 | |||||||||||||
Numerator | ||||||||||||||||
Net income (loss) from continuing operations | $ | 1,285,930 | $ | (499,841 | ) | $ | 2,091,490 | $ | (2,765,973 | ) | ||||||
Deemed dividends | - | (194,951,624 | ) | - | (330,876,369 | ) | ||||||||||
Net income (loss) available to common stockholders, continuing operations | 1,285,930 | (195,451,465 | ) | 2,091,490 | (333,642,342 | ) | ||||||||||
Net loss from discontinued operations | (8,097 | ) | (3,945 | ) | (8,097 | ) | (5,379 | ) | ||||||||
Net income (loss) available to common stockholders | $ | 1,277,833 | $ | (195,455,410 | ) | $ | 2,083,393 | $ | (333,647,721 | ) | ||||||
Denominator | ||||||||||||||||
Weighted average number of shares of common stock outstanding during the period - basic | 29,934,322,257 | 1,702,149,425 | 29,845,095,738 | 858,169,865 | ||||||||||||
Warrants | - | - | 6,335,103,465 | - | ||||||||||||
Preferred stock | 452,145,411,111 | - | 452,234,637,630 | - | ||||||||||||
Weighted average number of shares of common stock outstanding during the period - diluted | 482,079,733,368 | 1,702,149,425 | 488,414,836,833 | 858,169,865 | ||||||||||||
Net earnings (loss) available to common stockholders per share - basic: | ||||||||||||||||
Continuing operations | $ | 0.00 | $ | (0.11 | ) | $ | 0.00 | $ | (0.39 | ) | ||||||
Discontinued operations | (0.00 | ) | (0.00 | ) | (0.00 | ) | (0.00 | ) | ||||||||
Total basic | $ | 0.00 | $ | (0.11 | ) | $ | 0.00 | $ | (0.39 | ) | ||||||
Net earnings (loss) available to common stockholders per share - diluted: | ||||||||||||||||
Continuing operations | $ | 0.00 | $ | (0.11 | ) | $ | 0.00 | $ | (0.39 | ) | ||||||
Discontinued operations | (0.00 | ) | (0.00 | ) | (0.00 | ) | (0.00 | ) | ||||||||
Total diluted | $ | 0.00 | $ | (0.11 | ) | $ | 0.00 | $ | (0.39 | ) |
Notes to Condensed Consolidated Financial Statements
(unaudited)For the three months ended June 30, 2023 and 2022, the following potential common stock equivalents were excluded from the calculation of diluted earnings (loss) per share as their effect was anti-dilutive:
Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share
2023 | 2022 | |||||||
Three Months Ended June 30, | ||||||||
2023 | 2022 | |||||||
Common stock warrants | 511,333,351,089 | 511,333,351,097 | ||||||
Convertible preferred stock | - | 477,576,633,334 | ||||||
Convertible debentures | 28,777,833,333 | 28,777,833,333 | ||||||
Stock options | 26 | 26 | ||||||
Anti-dilutive shares | 540,111,184,448 | 1,017,687,817,790 |
For the six months ended June 30, 2023 and 2022, the following potential common stock equivalents were excluded from the calculation of diluted earnings (loss) per share as their effect was anti-dilutive:
Financing Agreements
2023 | 2022 | |||||||
Six Months Ended June 30, | ||||||||
2023 | 2022 | |||||||
Common stock warrants | 504,998,247,624 | 511,333,351,097 | ||||||
Convertible preferred stock | - | 477,576,633,334 | ||||||
Convertible debentures | 28,777,833,333 | 28,777,833,333 | ||||||
Stock options | 26 | 26 | ||||||
Anti-dilutive shares | 533,776,080,983 | 1,017,687,817,790 |
On October 30, 2017,The terms of certain of the warrants, convertible preferred stock and convertible debentures issued by the Company issued its Series I-1 Convertible Preferred Stock,provide for reductions in the per share exercise prices of the warrants and modified the anti-dilution provisionsper share conversion prices of certain outstandingthe debentures and preferred stock (if applicable and subject to floors in certain cases) in the event that the Company issues common stock or common stock equivalents (as that term is defined in the agreements) at an effective exercise/conversion price that is less than the then exercise/conversion prices of the outstanding warrants, preferred stock or debentures, as the case may be. In addition, many of these securities contain exercise or conversion prices that were issuedvary based upon the price of the Company’s common stock on the date of exercise/conversion (see Notes 6, 9 and 10). These provisions have resulted in March 2017,significant dilution of the Company’s common stock.
As a result of the Voting Agreement and Irrevocable Proxy (the “Voting Agreement”) discussed in Note 10 and the November 5, 2021 Amendment to the Company’s Certificate of Incorporation, as amended, to provide that the number of authorized shares of the Company’s common stock or preferred stock may be increased or decreased (but not below the number of shares then outstanding) by the affirmative vote of the holders of a majority in voting power of the stock of the Company, which is more fully discussed in Note 15.1, as of the date of filing this report, the Company believes that it has the ability to ensure that it has and or can obtain sufficient authorized shares of its common stock to cover all outstanding rights to acquire potentially dilutive common shares.
As a result of these down round provisions, the potential common stock and common stock equivalents totaled 1.0 trillion at August 8, 2023. See Note 10 for a discussion of the number of shares of the Company’s authorized common and preferred stock.
15 |
Note 24 – Accounts Receivable
Accounts receivable at SeptemberJune 30, 20172023 (unaudited) and December 31, 20162022 consisted of the following:
September 30, 2017 | December 31, 2016 | |||||||
Accounts receivable - laboratory services | $ | 4,118,407 | $ | 12,715,835 | ||||
Accounts receivable - hospital | 2,982,771 | - | ||||||
Accounts receivable - all others | 528,196 | 499,508 | ||||||
Total accounts receivable | 7,629,374 | 13,215,343 | ||||||
Less: | ||||||||
Allowance for discounts | (3,583,014 | ) | (11,664,490 | ) | ||||
Allowance for discounts - hospital | (2,368,565 | ) | - | |||||
Allowance for bad debts | (1,276,769 | ) | (350,954 | ) | ||||
Accounts receivable, net | $ | 401,026 | $ | 1,199,899 |
Note 3 – Property and Equipment
Property and equipment at September 30, 2017 (unaudited) and December 31, 2016 consistedSchedule of the following:Accounts Receivable
September 30, 2017 | December 31, 2016 | |||||||
Medical equipment | $ | 713,799 | $ | 696,195 | ||||
Building | 1,359,484 | - | ||||||
Equipment | 461,912 | 461,912 | ||||||
Equipment under capital leases | 4,497,025 | 4,497,025 | ||||||
Furniture | 408,101 | 377,630 | ||||||
Leasehold improvements | 1,333,385 | 1,329,387 | ||||||
Vehicles | 196,534 | 196,534 | ||||||
Computer equipment | 587,742 | 564,742 | ||||||
Software | 1,859,289 | 1,739,348 | ||||||
11,417,271 | 9,862,773 | |||||||
Less accumulated depreciation | (8,327,224 | ) | (6,819,183 | ) | ||||
Property and equipment, net | $ | 3,090,047 | $ | 3,043,590 |
On January 13, 2017, the Company completed an asset purchase agreement to acquire certain assets related to Scott County Community Hospital, based in Oneida, Tennessee (the “Hospital Assets”). The Hospital Assets include a 52,000 square foot hospital building and 6,300 square foot professional building on approximately 4.3 acres. Scott County Community Hospital, which has since been renamed as Big South Fork Medical Center, is classified as a Critical Access Hospital (rural). The Company acquired the Hospital Assets out of bankruptcy for a purchase price of $1.0 million, and the purchase price has been recorded as property and equipment in the Company’s condensed consolidated balance sheet. The Company opened the hospital on August 8, 2017.
Depreciation expense on property and equipment was $0.5 million and $0.7 million for the three months ended September 30, 2017 and 2016, and $1.5 million and $2.0 million for the nine months ended September 30, 2017 and 2016, respectively. Management periodically reviews the valuation of long-lived assets, including property and equipment, for potential impairment. Management did not recognize any impairment of these assets during the nine months ended September 30, 2017 and 2016.
RENNOVA HEALTH, INC.
Notes to Condensed Consolidated Financial Statements
(unaudited)
June 30, | December 31, | |||||||
2023 | 2022 | |||||||
Accounts receivable | $ | 12,268,792 | $ | 13,046,646 | ||||
Less: | ||||||||
Allowance for contractual obligations | (8,190,137 | ) | (8,529,904 | ) | ||||
Allowance for doubtful accounts | (1,197,505 | ) | (1,405,773 | ) | ||||
Accounts receivable, net | $ | 2,881,150 | $ | 3,110,969 |
Note 4 – Accrued Expenses
Note 5 – Accrued Expenses
Accrued expenses at SeptemberJune 30, 20172023 (unaudited) and December 31, 20162022 consisted of the following:
September 30, 2017 | December 31, 2016 | |||||||
Commisions payable | $ | 29,860 | $ | 44,788 | ||||
Accrued payroll and related liabilities | 1,755,131 | 493,521 | ||||||
Accrued interest | 2,211,588 | 1,471,191 | ||||||
Other accrued expenses | 1,013,719 | 872,529 | ||||||
Total accrued expenses | $ | 5,010,298 | $ | 2,882,029 |
Schedule of Accrued Expenses
June 30, | December 31, | |||||||
2023 | 2022 | |||||||
Accrued payroll and related liabilities | $ | 8,327,011 | $ | 8,533,710 | ||||
HHS Provider Relief Funds | 552,099 | 552,099 | ||||||
Accrued interest | 6,308,052 | 5,736,096 | ||||||
Accrued legal expenses and settlements | 498,000 | 534,550 | ||||||
Medicare cost report settlement reserves | 990,062 | 2,101,837 | ||||||
Other accrued expenses | 2,644,351 | 2,105,516 | ||||||
Accrued expenses | $ | 19,319,575 | $ | 19,563,808 |
Accrued payroll and related liabilities included approximately $7.3million and $7.0 million, respectively, for accrued past due payroll taxes and associated penalties and interest as of June 30, 2023 and December 31, 2022, respectively.
As of December 31, 2022, the Company had Medicare cost reports settlement reserves of $2.1 million. During the six months ended June 30, 2023, the Company reduced its reserve amount by $1.1 million due to payments (recoupments) and various final and estimated cost report settlements leaving Medicare cost report settlement reserves of $1.0 million at June 30, 2023.
Note 56 – Notes PayableDebt
The Company and its subsidiaries are party to a number of loans with affiliates and unrelated parties. At SeptemberJune 30, 20172023 (unaudited) and December 31, 2016, notes payable2022, debt consisted of the following:
Schedule of Debt
June 30, 2023 | December 31, 2022 | |||||||
Notes payable- third parties | $ | 1,318,315 | $ | 2,917,390 | ||||
Loan payable – related party | 2,253,000 | 2,995,000 | ||||||
Debentures | 8,222,240 | 8,622,240 | ||||||
Total debt | 11,793,555 | 14,534,630 | ||||||
Less current portion of debt | (11,793,555 | ) | (14,534,630 | ) | ||||
Total debt, net of current portion | $ | - | $ | - |
16 |
At June 30, 2023 (unaudited) and December 31, 2022, notes payable with third parties consisted of the following:
Notes Payable – Third Parties
Schedule of Notes Payable Third Parties
September 30, 2017 | December 31, 2016 | |||||||
Loan payable under prepaid forward purchase contract | $ | 5,000,000 | $ | 5,000,000 | ||||
Loan payable to TCA Global Master Fund, LP ("TCA") in the original principal amount of $3 million at 16% interest (the "TCA Debenture"). Principal and interest payments due in various installments through December 31, 2017. | 1,957,476 | 3,000,000 | ||||||
Notes payable to CommerceNet and Jay Tenenbaum in the original principal amount of $500,000, bearing interest at 6% per annum (the "Tegal Notes"). Prinicpal and interest payments are due annually from July 12, 2015 through July 12, 2017 | 341,612 | 341,612 | ||||||
Other convertible notes payable | - | 440,000 | ||||||
Unamortized discount on other convertible notes | - | (179,889 | ) | |||||
Derivative liability associated with the TCA Debenture, at fair value | - | 409,524 | ||||||
7,299,088 | 9,011,247 | |||||||
Less current portion | (7,299,088 | ) | (9,011,247 | ) | ||||
Notes payable - third parties, net of current portion | $ | - | $ | - |
June 30, 2023 | December 31, 2022 | |||||||
Notes payable to CommerceNet and Jay Tenenbaum in the original principal amount of $500,000 (the “Tegal Notes”). | $ | 291,557 | $ | 291,557 | ||||
Note payable to Anthony O’Killough dated September 27, 2019 in the original principal amount of $1.9 million. Issued net of $0.4 million of debt discount and financing fees. | - | 1,137,380 | ||||||
Notes payable to Western Healthcare, LLC dated August 10, 2021, in the aggregate principal amount of $2.4 million, bearing interest at 18% per annum, payable in monthly installments aggregating $0.2 million, due August 30, 2022. | 1,026,758 | 1,488,453 | ||||||
Note payable | 1,318,315 | 2,917,390 | ||||||
Less current portion | (1,318,315 | ) | (2,917,390 | ) | ||||
Notes payable - third parties, net of current portion | $ | - | $ | - |
On March 31,December 7, 2016, the Company entered into an agreement to pledge certainholders of its accounts receivable as collateralthe Tegal Notes filed suit against a prepaid forward purchase contract whereby the Company seeking payment for the amounts due under the notes and accrued interest. On April 23, 2018, the holders of the Tegal Notes received considerationa judgment against the Company in the amount of $5.0 million. The receivables had an estimated collectable value of $8.7 million which had been adjusted down to approximately $1.5 million on the Company’s balance sheet as of December 31, 2016 and $0 as of September 30, 2017. In exchange for the consideration received, the counterparty received the right to: (i) a 20% per annum investment return from$384,384 plus post-judgment interest. On June 1, 2023, the Company onand the consideration, withholders of the Tegal Notes agreed to settle all amounts owed pursuant to the judgment for a minimum repayment termtotal of $462,500 comprised of an initial payment of $200,000 followed by six months and minimum return of $0.5 million, (ii) all payments recovered from the accounts receivable up to $5.25 million, if paid in full within six months, or $5.5 million, if not paid in full within six months, and (iii) 20% of allmonthly payments of the accounts receivable in excess of amounts received in (i) and (ii)$43,750. On March 31, 2017, to the extent that the counterparty has not been paid $6.0 million, the Company was required to pay the difference, plus 30% interest per annum on the total balance. To date, theThe Company has not recovered anymade all required payments againstto date, including the accounts receivable. Asinitial payment of September 30, 2017, the Company has accrued $1.9 million for the counterparty’s required investment return, which is reflected in accrued expenses in the accompanying condensed consolidated balance sheet, and $6.9 million was due to the counterparty on September 30, 2017. The Company does not have the financial resources to repay this obligation.
The Company did not make the required monthly principal and interest payments due under the TCA Debenture for the period from October 2016 through March 2017. On February 2, 2017, the Company made a payment to TCA in the amount of $0.4 million$200,000, which was applied to accrued interest.
On September 27, 2019, the Company issued a promissory note payable to Anthony O’Killough in the principal amount of $1.9 million with payments due in November and unpaid interestDecember 2019. These payments were not made. In February 2020, Mr. O’Killough sued the Company and fees, including defaultChristopher Diamantis, as guarantor and in May 2020, the Company, Mr. Diamantis, as guarantor, and Mr. O’Killough entered into a Stipulation providing for payment of a total of $2.2 million (which included accrued “penalty” interest as of that date) in installments through November 1, 2020. The Company made payments totaling $450,000 in 2020. On January 18, 2022, Mr. Diamantis paid $750,000 and the dateremaining balance was due 120 days thereafter. Mr. O’Killough agreed to forebear from any further enforcement action until then. On various dates during the remainder of payment. On March 21, 2017,2022, Mr. Diamantis made additional payments to Mr. O’Killough totaling $300,000 and the Company made agave Mr. Diamantis $350,000 for further payment to TCAMr. O’Killough. The Company is obligated to repay Mr. Diamantis for the payments, plus interest, that he made to Mr. O’Killough. As a result of these payments, the past due balance owed to Mr. O’Killough was $1.1 million on December 31, 2022. During the six months ended June 30, 2023, the parties entered into a final settlement wherein the Company and Mr. Diamantis settled the obligation in the amount of $0.75 million, of which approximately $0.1 million was applied to accrued and unpaid interest and fees in accordance with the termsfull for $580,000. As a result of the TCA Debenture. Alsosettlement, the Company recorded a $0.6 million gain on March 21, 2017,legal settlement during the six months ended June 30, 2023.
On August 10, 2021, the Company entered into a letter agreementtwo notes payable with TCA, which (i) waived any payment defaults through March 21, 2017; (ii) provided for the $0.75 million payment discussed above; (iii) set forth a revised repayment schedule whereby the remaining principal plus interest aggregating to approximately $2.6 million was to be repaid in various monthly installments from April of 2017 through September of 2017; and (iv) provided for payment of an additional service fee in the amount of $150,000, which was due on June 27, 2017, the day after effective date of the registration statement filed by the Company; which amount is reflected in accrued expenses in the accompanying condensed consolidated balance sheet at September 30, 2017. In addition, TCA entered into an intercreditor agreement with the purchasers of the convertible debentures (see Note 6) which sets forth rights, preferences and priorities with respect to the security interests in the Company’s assets. On September 19, 2017, the Company entered into a new agreement with TCA, which extended the repayment schedule through to December 31, 2017. The Company is current with its payments.
RENNOVA HEALTH, INC.
Notes to Condensed Consolidated Financial Statements
(unaudited)
On September 15, 2016, the Company entered into an agreement with two investors whereby the Company sold to the investors convertible notesWestern Healthcare, LLC in the aggregate principal amount of $0.4$2.4 million. The notes were issued under the terms of a settlement agreement related to agreements that the Company had previously entered into for medical staffing services. The notes bear interest at a rate of 18% per annum and payments consisting of principal and interest were due no later than August 30, 2022. The Company paid $0.2 million (the “September 2016 Notes”)to the note holders upon issuance of the notes. On May 12, 2023, the Company and Western Healthcare, LLC agreed to reduce the aggregate principal amount of the notes by $400,000 in exchange for a cash payment of $200,000. As a result of the reduction of the principal balance in excess of the amount paid, during the three and six months ended June 30, 2023, the Company recorded a gain on forgiveness of debt of $0.2 million. The September 2016 Notes were convertible into sharesCompany has not made all of the monthly installments due under the notes and the notes are past due.
17 |
Loan Payable – Related Party
At June 30, 2023 (unaudited) and December 31, 2022, loan payable - related party consisted of the following:
Schedule of Loan Payable Related Parties
June 30, 2023 | December 31, 2022 | |||||||
Loan payable to Christopher Diamantis | $ | 2,253,000 | $ | 2,995,000 | ||||
Less current portion of loan payable, related party | (2,253,000 | ) | (2,995,000 | ) | ||||
Total loan payable, related party, net of current portion | $ | - | $ | - |
Mr. Diamantis was a member of the Company’s common stock at a conversion priceBoard of $112.50 per share. In conjunction withDirectors until his resignation on February 26, 2020. During the salesix months ended June 30, 2023 and 2022, Mr. Diamantis loaned the Company $580,000 and $750,000, respectively, which the Company used to pay amounts owed under the note payable to Mr. O’Killough. These payments and the note payable to Mr. O’Killough are more fully discussed above under the heading Notes Payable –Third Parties. During the six months ended June 30, 2023, the Company made payments on the principal amount of the September 2016 Notes,loans from Mr. Diamantis of $1.3 million. No principal payments were made on loans from Mr. Diamantis during the Company issued warrants to purchase an aggregate of 4,444 shares ofsix months ended June 30, 2022.
During the Company’s common stock at an exercise price of $180.00 per share. Based onthree months ended June 30, 2023 and 2022, the allocation of the net proceeds from the September 2016 Notes to the fair value of the warrants, and the resulting beneficial conversion features, the Company recognized a discount for the entire face value of the September 2016 Notes, which was accreted through the notes’ maturity date of March 15, 2017. On March 13, 2017, the September 2016 Notes, along with the accompanying warrants, were exchanged for 26,667 shares of the Company’s common stock.
The Company did not makeincur interest expense on the principal payments underloans from Mr. Diamantis. During the Tegal Notes that were due on July 12, 2016. On November 3, 2016,six months ended June 30, 2023 and 2022, the Company received a default notice fromincurred interest expense on the holders of the Tegal Notes demanding immediate repayment of the outstanding principal and accrued interest aggregating to $0.4 million. On December 7, 2016 the Company received a breach of contract complaint with a request for entry of a default judgment (see Note 11). To date, the Company has yet to repay this amount.
Notes Payable – Related Parties
September 30, 2017 | December 31, 2016 | |||||||
Loan payable to Alcimede LLC, bearing interest at 6% per annum, with all principal and interest due on February 2, 2018 | $ | 168,500 | $ | 218,500 | ||||
Other advances from related parties | 55,000 | 110,000 | ||||||
223,500 | 328,500 | |||||||
Less current portion | (223,500 | ) | (328,500 | ) | ||||
Total notes payable - related parties, net of current portion | $ | - | $ | - |
On February 3, 2015, the Company borrowed $3.0 million from Alcimede LLC (“Alcimede”). Seamus Lagan, the Company’s President and Chief Executive Officer, is the sole manager of Alcimede. The note has an interest rate of 6% and was originally due on February 2, 2016. Alcimede later agreed to extend the maturity date of the loan to August 2, 2017. On June 29, 2015, Alcimede exercised options granted in October 2012 to purchase 66,667 shares of the Company’s common stock at an exercise price of $37.50 per share, and the loan outstanding was reduced in satisfaction of the aggregate exercise price of $2.5 million. In August of 2016, $0.3 million was repaid by the Company through the issuance of shares of common stock. In March of 2017, the Company and Mr. Lagan agreed that a payment made to Alcimede in the amount of $50,000 would be deducted from the outstanding balance of the note. On August 2, 2017, the Company and Alcimede agreed to further extend the maturity date of the loan to February 2, 2018.
The remaining balance due on this loan as of September 30, 2017 was $0.2 million, including accrued interest.
During the nine months ended September 30, 2017, the Company repaid $0.1 million that was outstanding to a former principal stockholder, and borrowed an additional $75,000 from this same stockholder of which $50,000 has been repaid and $3.6 millionloans from Mr. Diamantis of $58,000 and $0.1 million, respectively.
No accrued interest was owed to Mr. Diamantis at June 30, 2023 and December 31, 2022. Interest accrues on loans from Mr. Diamantis at a directorrate of 10% of the Company, which has been fully repaid (see Note 7).amount loaned.
RENNOVA HEALTH, INC.Debentures
Notes to Condensed Consolidated Financial Statements
(unaudited)
Note 6 – Debentures
The carrying amount of all outstanding debentures with institutional investors as of SeptemberJune 30, 20172023 (unaudited) is as follows:
September 30, 2017 | ||||
Debentures | $ | 20,962,234 | ||
Discount on Debentures | (16,398,666 | ) | ||
Deferred financing fees | (324,563 | ) | ||
4,239,005 | ||||
Less current portion | - | |||
Debentures | $ | 4,239,005 |
There were no debentures outstanding as ofand December 31, 2016.2022 was as follows:
Schedule of Debentures
February Offering
June 30, 2023 | December 31, 2022 | |||||||
March 2017 Debenture | $ | 2,580,240 | $ | 2,580,240 | ||||
2018 Debentures | 5,642,000 | 5,642,000 | ||||||
October 2022 Debentures | - | 400,000 | ||||||
Debentures, Gross | 8,222,240 | 8,622,240 | ||||||
Less current portion | (8,222,240 | ) | (8,622,240 | ) | ||||
Debentures, net of current portion | $ | - | $ | - |
March 2017 Debenture
On February 2,
In March 2017, the Company issued $1.6 million aggregate principal amount of Original Issue Discount Convertible Debenturesa debenture due three months from the date of issuance (the “February Debentures”) and warrants to purchase an aggregate of 6,667 shares of common stock, which can be exercised at any time after August 17, 2017 at an exercise price of $38.70 per share (the “February Warrants”), to an accredited investor for a purchase price of $1.5 million. Onin March 21, 2017, the February Debentures were exchanged for $2.5 million of exchange debentures as more fully discussed below.
March Offerings
On March 21, 2017, the Company issued $10.85 million aggregate principal amount of Senior Secured Original Issue Discount Convertible Debentures due March 21, 2019 (the “Convertible Debentures”“March 2017 Debenture”). The Company received net proceeds from this transaction in the approximate amount with a principal balance of $8.4$2.6 million at June 30, 2023 and December 31, 2022, including a 30% late-payment penalty of $0.6 million. The Company used $3.8 millionMarch 2017 Debenture is past due by its original terms. The March 2017 Debenture bears default interest at the rate of the net proceeds to repay the 2017 Diamantis Note (see Note 7)18% per annum and $0.75 million of the net proceeds to make the partial repaymentis secured by a first priority lien on the TCA Debenture (see Note 5). The remainder of the net proceeds were used for general corporate purposes. In conjunction with the issuance of the Convertible Debentures, the holder of the February Debentures exchanged these debentures for $2.5 million of new debentures (the “Exchange Debentures” and, collectively with the Convertible Debentures, the “March Debentures”) on the same terms as, and pari passu with, the Convertible Debentures and warrants. The Company recorded non-cash interest expense in the amount of $0.4 million as a result of this exchange. Additionally, the holders of an aggregate of $2.2 million stated valueall of the Company’s Series H Convertible Preferred Stock (the “Series H Preferred Stock”) exchanged such preferred stock into $2.7assets. The Company incurred default interest expense on this past due debenture of $0.1 million principal amountand $0.1 million, respectively, during the three months ended June 30, 2023 and 2022 and $0.2 million and $0.2 million, respectively, during the six months ended June 30, 2023 and 2022. As of Exchange Debentures and warrants. The March Debentures contain a 24% original issue discount, have no regularly scheduledJune 30, 2023, accrued default interest payments except in the event of a default and have a maturity date of March 21, 2019.
In connection withon the March Debentures2017 Debenture totaled $2.0 million.
On June 30, 2023, the Company issued warrants to purchase an aggregate of 9,166,616 shares of the Company’s common stock to several accredited investors. The warrants were issued to the investors in three tranches, Series A Warrants, Series B Warrants and Series C Warrants (collectively, the “March Warrants”). The Series A Warrants are exercisable for 3,214,911 shares of the Company’s common stock. They are immediately exercisable and have a term of exercise equal to five years. The Series B Warrants are exercisable for 2,736,794 shares of the Company’s common stock and are exercisable for a period of 18 months commencing immediately. The Series C Warrants are exercisable for 3,214,911 shares of the Company’s common stock and have a term of five years provided such warrants shall only vest if, when and to the extent that the holders exercise the Series B Warrants. At September 30,March 2017 the Series A, Series B and Series C Warrants each have an exercise price of $5.85 per share, which reflects an adjustment pursuant to their terms. The Series A, Series B and Series C Warrants are subject to “full ratchet” and other customary anti-dilution protections.
The March Debentures areDebenture is convertible into shares of the Company’s common stock, at a conversion price, which has been adjusted pursuant to theits terms, of the March Debentures to $5.85$0.00009 per share asor billion shares of September 30, 2017, due to prices at which the Company has subsequently issued shares ofCompany’s common stock. The Convertible Debentures began to amortize monthly commencing on the 90th day following the closing date. The Exchange Debentures began to amortize monthly on the closing date. On each monthly amortization date, the Company may elect to repay 5% of the original principal amount of the March Debentures in cash or, in lieu thereof, the conversion price of such debentures will thereafter be 85% of the volume weighted average price at the time of conversion. In the event the Company does not elect to pay such amortization amounts in cash, each investor, in their sole discretion, may increase the conversion amount subject to the alternative conversion price by up to four times the amortization amount. The March Debentures contain customary affirmative and negative covenants. The conversion prices areis subject to reset in the event of offerings or other issuances of common stock, or rights to purchase common stock, at a price below the then conversion price, as well as other customary anti-dilution protections as more fully described in the debentures.protections.
The March Debentures are secured by all of the Company’s assets and are guaranteed by substantially all of the Company’s subsidiaries. Between March 22, 2017 and September 30, 2017, holders of the March Debentures converted an aggregate of $4.1 million of these debentures into 548,932 shares of common stock.
RENNOVA HEALTH, INC.
Notes to Condensed Consolidated Financial Statements
(unaudited)
The exercise prices of the March WarrantsDebenture was issued in connection with the March Debentures are subject to reset in the event of offerings or other issuances of common stock, or rights to purchase common stock, at a price below the then exercise price, as well as other customary anti-dilution protections. As a result of these provisions, both the March Debentures and the March Warrants were deemed to be not indexed to the Company’s common stock, and the Company recognized derivative liabilities for the embedded conversion feature of the March Debentures and the March Warrants in the original amount of $15.3 million and $41.3 million, respectively. The Company recognized a discount for 100% of the principal value of the March Debentures and non-cash interest expense in the amount of $43.7 million in connection with the recognition of these derivative liabilities. As a result of the adoption of ASU 2017-11 in the second quarter of 2017, the interest expense and derivative liability originally recognized were adjusted and extinguished during the three months ended June 30, 2017. See Note 1 for the adoption of ASU 2017-11 for the retrospective adjustments made to the Company’s condensed consolidated financial statements with respect to the derivative liabilities associated with these debentures and warrants.
June Offerings
In June 2017, the Company issued debentures due three months from the date of issuance in two issuances (collectively, the “June Debentures”) and warrants to purchase an aggregate of 100,000 shares of common stock (33,333 warrants in the June 2, 2017 transaction and 66,667 in the June 22, 2017 transaction), which can be exercised at any time after nine months at an exercise price of $5.85 per share for the June 2, 2017 warrants and $5.70 per share for the June 22, 2017 warrants (collectively the “June(the “March Warrants”), to accredited investors for a purchase price of $1,902,700 and proceeds to the Company of $1.5 million. The Company recorded a discount on the debentures of $107,700 which has been fully amortized.As more fully discussed below, on July 17, 2017, the June Debentures were exchanged.
July Offerings
On July 17, 2017, the Company closed an offering of $4,136,862 aggregate principal amount of Original Issue Discount Debentures due October 17, 2017 (the “July Debentures”) and warrants to purchase an aggregate of 141,333 shares of common stock (the “July Warrants”) for consideration of $2,000,000 in cash and the exchange of the full $1,902,700 aggregate principal amount of the June Debentures. Under the Purchase Agreement, the Company was required to hold a stockholders’ meeting to obtain stockholder approval for at least a 1-for-8 reverse split of the Company’s common stock on or before September 20, 2017. Accordingly, the Company’s stockholders approved a reverse stock split on September 20, 2017 and the Company effected a 1-for-15 reverse stock split of its common stock on October 5, 2017, as further discussed in Note 1. The July Debentures were guaranteed by substantially all of the subsidiaries of the Company pursuant to a Subsidiary Guarantee in favor of the holders of the July Debentures. As more fully discussed below, on September 19, 2017, the July Debentures were exchanged for $6.4 million of exchange debentures.
The July Warrants are exercisable into shares of the Company’s common stock at any time fromuntil March 21, 2024. During the three and after six months from the closing date at an exercise price of $5.63 per common share (subject to adjustment). The July Warrants will terminate five years after they become exercisable.
September Offerings
On September 19, 2017,ended June 30, 2022, the Company closed an offeringrecorded $194.8 million and $330.5 million of $2,604,000 principal amount of Senior Secured Original Issue Discount Convertible Debentures due September 19, 2019 (the “New Debentures”) and three series of warrants to purchase an aggregate of 6,935,517 shares of the Company’s common stock (the “Series A Warrants,” the “Series B Warrants,” and the “Series C Warrants,” and collectively, the “September Warrants”). The offering was pursuant to the terms of a Securities Purchase Agreement, dated as of August 31, 2017 (the “Purchase Agreement”), between the Company and certain existing institutional investors of the Company. The Company received proceeds of $2,100,000 from the offering.
Also on September 19, 2017, the Company closed exchanges by which the holders of the Company’s July Debentures exchanged $4,136,862 principal amount of such debentures for $6,412,136 principal amount of new debentures on the same items as, and pari passu with, the New Debentures (the “September Exchange Debentures” and, together with the New Debentures, the “September Debentures”). The Company recorded non-cash interest expense in the amount of $1.0 milliondeemed dividends, respectively, as a result of this exchange. All issuance amountsthe down round provisions of March Warrants. No deemed dividends were recorded in the three and six months ended June 30, 2023 as there was no change in the exercise prices of the March Warrants during the periods. Deemed dividends and outstanding warrants are more fully discussed in Notes 1, 9 and 10.
18 |
2018 Debentures
During 2018, the Company closed various offerings of debentures (the “2018 Debentures”) with principal balances aggregating $14.5 million, including late-payment penalties, due in September Debentures reflect a 24% original issue discount.
The September Debentures contain customary affirmative and negative covenants.2019. The conversion price is subject to “full ratchet” and other customary anti-dilution protectionsterms of the 2018 Debentures are the same as those of the March 2017 Debenture, as more fully described inabove, with the debentures. The Septemberexception of the conversion price, which was $0.052 per share at June 30, 2023 and is subject to a floor of $0.052 per share. At June 30, 2023 and December 31, 2022, the outstanding principal balance of the 2018 Debentures, may be converted at any timeincluding 30% late-payment penalties of $1.3 million, was $5.6 million and the debentures were convertible into million shares of the Company’s common stock. The September Debentures begin to amortize monthly commencing on October 1, 2017. For the first three amortization dates, the amortization amount is $100,000. Thereafter, on each monthly amortization date, the Company may elect to repay 5% of the original principal amount of September Debentures in cash or, in lieu thereof, the conversion price of such September Debentures shall thereafter be 85% of the volume weighted average pricedebentures bear default interest at the timerate of conversion. In the event the Company does not elect to pay such amortization amounts in cash, each investor, in their sole discretion, may increase the conversion amount subject to the alternative conversion price by up to four times the amortization amount.
RENNOVA HEALTH, INC.
Notes to Condensed Consolidated Financial Statements
(unaudited)
The Series A Warrants are exercisable for an aggregate of 2,311,829 shares of the Company’s common stock. They are immediately exercisable18% per annum and have a term of exercise equal to five years. The Series B Warrants are exercisable for an aggregate of 2,311,859 shares of the Company’s common stock and are exercisable for a period of 18 months commencing immediately. The Series C Warrants are exercisable for an aggregate of 2,311,829 shares of the Company’s common stock, and have a term of five years provided such Series C Warrants shall only vest if, when and to the extent that the holders exercise the Series B Warrants. The September Warrants each have an exercise price of $3.90. All of the September Warrants are subject to “full ratchet” and other customary anti-dilution protections.
The Company’s obligations under the September Debentures are secured by a security interest infirst priority lien on all of the Company’s assets. The Company incurred default interest expense on these past due debentures of $0.3 million and its subsidiaries’ assets, pursuant to$0.3 million, respectively, during the termsthree months ended June 30, 2023 and 2022 and $0.5 million and $0.5 million, respectively, during the six months ended June 30, 2023 and 2022. As of June 30, 2023, accrued default interest on the 2018 Debentures totaled $3.8 million.
See Notes 3 and 10 for a discussion of the Security Agreement, dateddilutive effect of the outstanding convertible debentures and warrants as of March 20, 2017.June 30, 2023.
During the nine months ended September 30, 2017,October 2022 Debentures
On October 12, 2022, the Company realized approximately $15.7 millionissued non-convertible, non-interest bearing debentures to institutional investors in the amount of $550,000, including $50,000 of original issue discounts, for net proceeds fromof $500,000. These debentures were due by their initial terms on February 12, 2023 and were secured by a portion of the issuancesCompany’s investment in InnovaQor Series B-1 Preferred Stock. On December 15, 2022, the Company and the institutional investors agreed to revise the repayment terms of these debentures as follows: (i) payment of $150,000 on December 15, 2022; and warrants. At September 30, 2017,(ii) monthly payments of $100,000 due by the unamortized discounts12th day of January, February, March and April 2023. The debentures were $16.4 million. These discounts represent original issue discounts, the relative fair value of the warrants issued with the debentures and the relative fair value of the beneficial conversion features of the debentures. During the three and nine months ended September 30, 2017, the Company recorded approximately $4.8 million and approximately $14.7 million of non-cash interest and amortization of debt discount expense primarilyfully repaid in connection with the debentures and warrants.April 2023.
See Note 9 for summarized information related to warrants issued and the activity during the nine months ended September 30, 2017.
Note 7 – Related Party Transactions
In addition to the transactions discussed in Note 5,Notes 6 and 10, the Company had the following related party transactionsactivity during the ninethree and six months ended SeptemberJune 30, 20172023 and 2016:2022:
Alcimede Limited
Pursuant to a consulting agreement, Alcimede Limited billed $0.1 million and $0.1 million for services for the three months ended June 30, 2023 and 2022, respectively, and $0.2 million and $0.2 million for the six months ended June 30, 2023 and 2022, respectively. Seamus Lagan, the Company’s President and Chief Executive Officer, is the Managing Director of Alcimede Limited.
InnovaQor, Inc.
In Januaryaddition to the investment in InnovaQor’s Series B-1 Preferred Stock (see Notes 1 and February of 2017,9), at June 30, 2023 and December 31, 2022, the Company received advances aggregating $3.6 millionhad a note receivable / related party receivable resulting from Christopher Diamantis, a director of the Company. The advances, along with $0.5 million of previously accrued but unpaid interest, were due on demand, bearing interest at 10% per annum. The Company used theworking capital advances to pay the purchase price for the Hospital AssetsInnovaQor, Inc. (“InnovaQor”) of approximately $2.3 million and for general corporate purposes. On March 7, 2017,$1.5 million, respectively. From January 1, 2023 to June 30, 2023, the Company issuedadvanced $0.9 million to InnovaQor to finance its working capital requirements. The balance at June 30, 2023 and December 31, 2022 includes amounts due under a note receivable as discussed below.
As of July 1, 2022, the Company had an outstanding related party receivable from InnovaQor of $803,416. InnovaQor signed a promissory note, dated July 1, 2022, in favor of the Company that provided that InnovaQor repay the Company $883,757 on December 31, 2022 (inclusive of 10% original issue discount). Effective December 31, 2022, the Company and InnovaQor agreed to Mr. Diamantisrestructure the promissory note receivable in favor of the Company in the amount of $3.8 $883,757 and additional monies owed in the amount of $441,018 for a new promissory note receivable with a principal amount of $1,457,253 (inclusive of a 10% original issue discount, or $132,478) and an original maturity date of June 30, 2023 except that InnovaQor will pay 25% of any capital it receives from new capital secured prior to the maturity date. The note receivable, in the event of default, bears interest at 18% per annum. During the year ended December 31, 2022, the Company recognized original issue discounts totaling $0.2 million as interest income. On August 9, 2023, certain modifications were made to the note receivable, as more fully discussed in Note 15.
During the three months ended June 30, 2023 and 2022, the Company contracted with InnovaQor to provide it with ongoing health information technology-related services totaling approximately $0.1 million and $50,000, respectively, and during the six months ended June 30, 2023 and 2022, the Company contracted with InnovaQor to provide such services totaling approximately $0.2 million and $0.1 million, respectively. In addition, InnovaQor currently subleases office space from the Company at a cost of approximately $10,200 per month for rent and utilities.
19 |
The terms of the foregoing activities, and those discussed in Notes 6 and 10, are not necessarily indicative of those that would have been agreed to with unrelated parties for similar transactions.
Note 8 – Finance and Operating Lease Obligations
We lease property and equipment under finance and operating leases. For operating leases with terms greater than 12 months, we record the related right-of-use assets and right-of-use obligations at the present value of lease payments over the term. We do not separate lease and non-lease components of contracts.
Generally, we use our most recent agreed-upon borrowing interest rate at lease commencement as our interest rate, as most of our operating leases do not provide a readily determinable implicit interest rate.
The following table presents our lease-related assets and liabilities at June 30, 2023 (unaudited) and December 31, 2022:
Schedule of Lease-related Assets and Liabilities
Balance Sheet Classification | June 30, 2023 | December 31, 2022 | ||||||||
Assets: | ||||||||||
Operating leases | Right-of-use operating lease assets | $ | 440,310 | $ | 574,256 | |||||
Finance lease | Property and equipment, net | - | - | |||||||
Total lease assets | $ | 440,310 | $ | 574,256 | ||||||
Liabilities: | ||||||||||
Current: | ||||||||||
Operating leases | Right-of-use operating lease obligations | $ | 168,761 | $ | 215,063 | |||||
Finance lease | Finance lease obligation | 220,461 | 220,461 | |||||||
Long-term | Right-of-use operating lease obligations | 271,549 | 359,193 | |||||||
Total lease liabilities | $ | 660,771 | $ | 794,717 | ||||||
Weighted-average remaining term: | ||||||||||
Operating leases | 2.33 years | 2.59 years | ||||||||
Finance lease (1) | N/a | N/a | ||||||||
Weighted-average discount rate: | ||||||||||
Operating leases | 13.0 | % | 13.0 | % | ||||||
Finance lease | 4.9 | % | 4.9 | % |
20 |
The following table presents certain information related to lease expense for finance and operating leases for the three and six months ended June 30, 2023 and 2022 (unaudited):
Schedule of Lease Expense
Three Months Ended June 30, 2023 | Three Months Ended June 30, 2022 | Six Months Ended June 30, 2023 | Six Months Ended June 30, 2022 | |||||||||||||
Finance lease expense: | ||||||||||||||||
Depreciation/amortization of leased assets | $ | - | $ | - | $ | - | $ | - | ||||||||
Interest on lease liabilities | - | - | - | - | ||||||||||||
Operating leases: | ||||||||||||||||
Short-term lease expense (2) | 82,347 | 97,681 | 174,915 | 165,039 | ||||||||||||
Short-term lease expense (2) | 82,347 | 97,681 | 174,915 | 165,039 | ||||||||||||
Total lease expense | $ | 82,347 | $ | 97,681 | $ | 174,915 | $ | 165,039 |
Other Information
The following table presents supplemental cash flow information for the six months ended June 30, 2023 and 2022 (unaudited):
Schedule of Lease Supplemental Cash Flow Information
Six Months June 30, 2023 | Six Months June 30, 2022 | |||||||
Cash paid for amounts included in the measurement of lease liabilities: | ||||||||
Operating cash flows for operating leases | $ | 175,460 | $ | 162,539 | ||||
Operating cash flows for finance lease | $ | - | $ | - | ||||
Financing cash flows for finance lease payments | $ | - | $ | - |
(1) | As of June 30, 2023 and December 31, 2022, the Company was in default under its finance lease obligation, therefore, the aggregate future minimum lease payments and accrued interest under this finance lease in the amount of $0.2 million are deemed to be immediately due. |
(2) | Expenses are included in general and administrative expenses in the unaudited condensed consolidated statements of operations. |
Aggregate future minimum lease payments under right-of-use operating and finance leases are as follows:
Schedule of Future Minimum Rentals Under Right-of-use Operating and Finance Leases
Right-of-Use Operating Leases | Finance Lease | |||||||
Twelve months ending June 30: | ||||||||
2024 | $ | 216,239 | $ | 224,252 | ||||
2025 | 222,712 | - | ||||||
2026 | 74,598 | - | ||||||
2027 | - | - | ||||||
2028 | - | - | ||||||
Thereafter | - | - | ||||||
Total | 513,549 | 224,252 | ||||||
Less interest | (73,239 | ) | (3,791 | ) | ||||
Present value of minimum lease payments | 440,310 | 220,461 | ||||||
Less current portion of lease obligations | (168,761 | ) | (220,461 | ) | ||||
Lease obligations, net of current portion | $ | 271,549 | $ | - |
Note 9 – Fair Value, Derivative Financial Instruments and Deemed Dividends
Fair Value Measurements
The estimated fair value of financial instruments was determined by the Company using available market information and valuation methodologies considered to be appropriate. The fair value measurements accounting guidance is more fully discussed in Note 1. At June 30, 2023 and December 31, 2022, the carrying value of the Company’s accounts receivable, note receivable / receivable from related party, accounts payable and accrued expenses approximated their fair values due to their short-term nature.
21 |
The following table sets forth the financial assets and liabilities carried at fair value measured on a recurring basis as of June 30, 2023 (unaudited) and December 31, 2022:
Schedule of Fair Value of Assets and Liabilities Measured on Recurring Basis
Level 1 | Level 2 | Level 3 | Total | |||||||||||||
As of June 30, 2023: | ||||||||||||||||
Asset - InnovaQor Series B-1 Preferred Stock | $ | - | $ | - | $ | 9,016,072 | $ | 9,016,072 | ||||||||
Liability - Embedded conversion option of debenture | - | - | 455,336 | 455,336 | ||||||||||||
As of December 31, 2022: | ||||||||||||||||
Asset - InnovaQor Series B-1 Preferred Stock | $ | - | $ | - | $ | 9,016,072 | $ | 9,016,072 | ||||||||
Liability - Embedded conversion option of debenture | - | - | 455,336 | 455,336 |
InnovaQor Series B-1 Preferred Stock
During 2021, the Company sold several subsidiaries to InnovaQor. As consideration for the sale, the Company received 100 shares were used in 2021 to settle an outstanding liability leaving a balance of shares at June 30, 2023 and December 31, 2022. The fair value of the Company’s InnovaQor Series B-1 Preferred Stock investment was determined based on the Option Price Method (the “2017 Diamantis Note”“OPM”). The OPM treats common and preferred interests as call options on the equity value of the subject company, with exercise prices based on the liquidation preference of the preferred interests and participation thresholds for subordinated classes. The Black Scholes model was used to price the call options. The assumptions used were: risk free rate of 0.84%; volatility of 250.0%; and exit period of 5 years. Lastly, a discount rate of 35% was applied due to the lack of marketability of the InnovaQor Series B-1 Preferred Stock and the underlying liquidity of InnovaQor’s common stock. shares of InnovaQor’s Series B-1 Preferred Stock of which
In reviewing the fair value of the InnovaQor Series B-1 Preferred Stock, the Company believes that the value recorded at June 30, 2023 and December 31, 2022 of $9.0 million represents its fair value. In determining fair value, consideration was given to: (i) the variable rate conversion feature of the InnovaQor Series B-1 Preferred Stock in that changes in the price of the common stock do not affect conversion value; (ii) recent sales and offering prices by InnovaQor of shares of its common stock; (iii) that InnovaQor is actively seeking additional capital; and (iv) other considerations that we believe will bolster the underlying liquidity of InnovaQor’s common stock.
Embedded Conversion Option
The Company utilized the following method to value its derivative liability as of June 30, 2023 and December 31, 2022 for an embedded conversion option related to an outstanding convertible debenture valued at $455,336. The Company determined the fair value by comparing the conversion price per share, which based on the conversion terms is 85% of the market price of the Company’s common stock, multiplied by the number of shares issuable at the balance sheet dates to the actual price per share of the Company’s common stock multiplied by the number of shares issuable at that date with the difference in value recorded as a liability. There was no change in the value of the embedded conversion option in the three and six months ended June 30, 2023 and 2022 and the year ended December 31, 2022 as there was no change in the conversion price terms during the periods.
Deemed Dividends
During the three and six months ended June 30, 2023, there were no triggers of down round provisions of outstanding warrants and, therefore, no associated deemed dividends were recorded in the periods. During the three and six months ended June 30, 2022, the conversions of preferred stock triggered a reduction in the exercise prices of warrants containing down round provisions. In accordance with U.S. GAAP, the incremental fair value of the warrants, as a result of the decreases in the exercise prices, was measured using Black Scholes. The following assumptions were utilized in the Black Scholes valuation models for the three months ended June 30, 2022: risk free rates ranging from 194.7 million and $330.5 million were recorded as deemed dividends during the three and six months ended June 30, 2022, respectively. % to %, volatility ranging from % to % and terms ranging from to years. The following assumptions were utilized in the Black Scholes valuation models for the six months ended June 30, 2022: risk free rates ranging from % to %, volatility ranging from % to % and terms ranging from to years. The incremental value of modifications to warrants as a result of the down round provisions of $
In addition, deemed dividends of $0.2 million and $0.3 million were recorded in the three and six months ended June 30, 2022, respectively, as a result of the issuances of shares of our Series P Preferred Stock, as more fully discussed in Note 10. Deemed dividends are also discussed in Notes 1 and 3.
22 |
Note 10 – Stockholders’ Deficit
Authorized Capital
The Company has authorized shares of Common Stock at a par value of $ per share and authorized shares of Preferred Stock at a par value of $ per share.
Preferred Stock
As of June 30, 2023, the Company had outstanding shares of preferred stock consisting of these advances receivedthe issuances of the stock and no gains, losses or derivative liabilities have been recorded in 2017, plus accrued and unpaid interest of $0.5 million. In conjunctionconnection with the issuancepreferred stock. shares of its Series H Convertible Preferred Stock (the “Series H Preferred Stock”), shares of its Series L Convertible Preferred Stock (the “Series L Preferred Stock”), shares of its Series M Convertible Redeemable Preferred Stock (the “Series M Preferred Stock”), shares of its Series N Convertible Redeemable Preferred Stock (the “Series N Preferred Stock”), shares of its Series O Convertible Redeemable Preferred Stock (the “Series O Preferred Stock”) and shares of its Series P Preferred Stock. The Company’s outstanding shares of preferred stock do not contain mandatory redemption or other features that would require them to be presented on the balance sheet outside of equity and, therefore, they qualify for equity accounting treatment. As a result of the equity accounting treatment, fair value accounting is not required in connection with
Series H Preferred Stock
Each of the 2017 Diamantis Note, shares of the Company also issued to Mr. Diamantis warrants to purchase 27,667Series H Preferred Stock has a stated value of $ per share and is convertible into shares of the Company’s common stock exercisable at $15.00. The 2017 Diamantis Note was repaid on March 21, 2017 with the proceeds received from the issuancea conversion price of 85% of the Convertible Debentures (see Note 6). In May and June of 2017, the Company received advances from Mr. Diamantis, net of repayments totaling $0.2 million, at a 10% annum interest rate, which amount was paid in full on July 18, 2017.
Alcimede billed the Company $0.4 million and $0.3 million for consulting fees pursuant to a consulting agreement for eachvolume weighted average price of the nine months ended September 30, 2017 and 2016, respectively.Company’s common stock at the time of conversion.
Monarch Capital, LLC (“Monarch”) billed the Company for consulting fees pursuant to a consulting agreement in the amount of $0.1 million for the nine months ended September 30, 2017 and 2016, respectively. The agreement expired on August 31, 2017. Michael Goldberg, a director of the Company up until his resignation effective April 24, 2017, is the Managing Director of Monarch.
Note 8 – Capital Lease Obligations
The Company leases various assets under capital leases expiring through 2020 as follows. At September 30, 2017 (unaudited) and December 31, 2016, capital lease obligations consisted of the following:
September 30, 2017 | December 31, 2016 | |||||||
Medical equipment | $ | 4,497,025 | $ | 4,497,025 | ||||
Less accumulated depreciation | (3,582,631 | ) | (2,809,511 | ) | ||||
Net | $ | 914,394 | $ | 1,687,514 |
RENNOVA HEALTH, INC.
Notes to Condensed Consolidated Financial Statements
(unaudited)
Aggregate future minimum rentals under capital leases are as follows:
Year ended December 31, | ||||
2017 (October through December) | $ | 493,282 | ||
2018 | 1,427,375 | |||
2019 | 377,919 | |||
2020 | 32,611 | |||
Total | 2,331,187 | |||
Less interest | 103,983 | |||
Present value of minimum lease payments | 2,227,204 | |||
Less current portion of capital lease obligations | 1,491,666 | |||
Capital lease obligations, net of current portion | $ | 735,538 |
Note 9 – Stockholders’ Equity
Series L Preferred Stock
The Company has 5,000,000 shares, par value $0.01, of preferred stock authorized. As of September 30, 2017, the Company had outstanding 1,750,275 shares of preferred stock consisting of 215 shares of its Series GL Preferred Stock 60 shares of its Series H Preferred Stockis held by Alcimede LLC and 1,750,000 shares of its Series F Convertible Preferred Stock (the “Series F Preferred Stock”).
During the nine months ended September 30, 2017, 7,785 shares of Series H Preferred Stock were converted into 370,446 shares of common stock in accordance with the terms of the Series H Preferred Stock. Also during the nine months ended September 30, 2017, 2,174 shares of Series H Preferred Stock withhas a stated value of $2.2 million were exchanged for Exchange Debentures with an aggregate principal amount$ per share. Mr. Lagan is the sole manager of $2.7 million and warrants (see Note 6).
In connection with the acquisition of Genomas, Inc., on September 27, 2017, which is more fully discussed in Note 14, the Company issued 1,750,000 shares of itsAlcimede LLC. The Series FL Preferred Stock valued at $174,097. The following is a summary of certain terms and provisions of the Company’s Series F Preferred Stock:
Rank. The Series F Preferred Stock ranks on paritynot entitled to our common stock.
Conversion.receive any dividends. Each share of the Series FL Preferred Stock is convertible into shares of ourthe Company’s common stock (subject to adjustment as provided in the related certificate of designation of preferences, rights and limitations) at any time after the first anniversary of the issuance date at the option of the holder at a conversion price equal to the greater of $29.25 or the average closing price of the Company’s common stock foron the 10ten trading days immediately precedingprior to the conversion. conversion date. On June 30, 2023, the Series L Preferred Stock was convertible into approximately billion shares of the Company’s common stock at a conversion price of $0.00009 per share.
Series M Preferred Stock
On June 30, 2020, the Company and Mr. Diamantis entered into an exchange agreement wherein Mr. Diamantis agreed to the extinguishment of the Company’s indebtedness to him totaling $18.8 million, including accrued interest, on that date in exchange for shares of the Company’s Series M Preferred Stock with a par value of $ per share and a stated value of $ per share. See Note 6 for a discussion of the Company’s indebtedness to Mr. Diamantis as of June 30, 2023 and December 31, 2022.
The maximumterms of the Series M Preferred Stock include: (i) each share of the Series M Preferred Stock is convertible into shares of the Company’s common stock at a conversion price equal to 90% of the average closing price of the Company’s common stock on the ten trading days immediately prior to the conversion date but in any event not less than the par value of the Company’s common stock; (ii) dividends at the rate per annum of 10% of the stated value per share shall accrue on each outstanding share of Series M Preferred Stock from and after the date of the original issuance of such share of Series M Preferred Stock (subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization). The dividends shall accrue from day to day, whether or not declared, and shall be cumulative and non-compounding; provided, however, that such dividend shall be payable only when, as, and if declared by the Board of Directors and the Company shall be under no obligation to pay such dividends. No cash dividends shall be paid on the Company’s common stock unless the dividends are paid on the Series M Preferred Stock; and (iii) each holder of the Series M Preferred Stock shall be entitled to vote on all matters submitted to a vote of the holders of the Company’s common stock. Regardless of the number of shares of Series M Preferred Stock outstanding and so long as at least one share of Series M Preferred Stock is outstanding, the outstanding shares of Series M Preferred Stock shall have the number of votes, in the aggregate, equal to 51% of all votes entitled to be voted at any meeting of stockholders or action by written consent. Each outstanding share of the Series M Preferred Stock shall represent its proportionate share of the 51% allocated to the outstanding shares of Series M Preferred Stock in the aggregate. The Series M Preferred Stock shall vote with the common stock and any other voting securities as if they were a single class of securities. On August 13, 2020, Mr. Diamantis entered into the Voting Agreement with Mr. Lagan and Alcimede LLC (of which Mr. Lagan is the sole manager) pursuant to which Mr. Diamantis granted an irrevocable proxy to Mr. Lagan to vote the Series M Preferred Stock held by Mr. Diamantis. Mr. Diamantis has retained all other rights under the Series M Preferred Stock.
23 |
During the year ended December 31, 2021, Mr. Diamantis converted a total of 0.6 million into shares of the Company’s common stock. On August 27, 2021, the Company entered into an exchange agreement with Mr. Diamantis. Pursuant to the exchange agreement, Mr. Diamantis exchanged shares of his Series M Preferred Stock with a stated value of approximately $0.6 million for shares of the Company’s common stock and warrants to purchase 4,750 shares of the Company’s common stock at an exercise price of $70.00 per share. The warrants have a three-year term and, as of June 30, 2023, are exercisable into 3.7 billion shares of the Company’s common stock at an exercise price of $0.00009 per share as a result of down-round provision features. On June 30, 2023, shares of Series M Preferred Stock remained outstanding and were convertible into billion shares of the Company’s common stock. shares of his Series M Preferred Stock with a stated value of $
Series N Preferred Stock
The Company’s Board of Directors has designated shares of the shares of authorized preferred stock as the Series N Preferred Stock. Each share of Series N Preferred Stock has a stated value of $ . On August 31, 2020, the Company and its debenture holders exchanged, under the terms of Exchange, Redemption and Forbearance Agreements, certain outstanding debentures and all of the then outstanding shares of the Company’s Series I-1 Convertible Preferred Stock and Series I-2 Convertible Preferred Stock for shares of the Company’s Series N Preferred Stock.
The terms of the Series N Preferred Stock include: (i) each share of the Series N Preferred Stock is convertible into shares of the Company’s common stock, at any time and from time to time, at the option of the holder, into that number of shares of common stock issuable upondetermined by dividing the stated value of such share of Series N Preferred Stock, plus any accrued declared and unpaid dividends, by the conversion of the Series F Preferred Stock is 59,829. Any shares of Series F Preferred Stock outstanding on the fifth anniversary of the issuance date will be mandatorily converted into common stock at the applicable conversion price on such date.
Liquidation Preference. In the event of our liquidation, dissolution or winding-up, holders of Series F Preferred Stock will be entitled to receive the same amount that a holder of common stock would receive if the Series F Preferred Stock were fully converted into shares of our common stock atprice; (ii) the conversion price (assuming for such purposes thatis equal to 90% of the lowest VWAP during the 10 trading days immediately prior to the conversion date; (iii) dividends at the rate per annum of 10% of the stated value per share shall accrue on each outstanding share of Series FN Preferred Stock is then convertible) which amountsfrom and after the date of the original issuance of such share of Series N Preferred Stock (the “Series N Preferred Accruing Dividends”). The Series N Preferred Accruing Dividends shall accrue from day to day, whether or not declared, and shall be cumulative and non-compounding; provided, however, that such Series N Preferred Accruing Dividends shall be payable only when, as, and if declared by the Board of Directors. No cash dividends shall be paid pari passu with all holders ofon the common stock.
Voting Rights. Each share ofstock unless the Series FN Preferred Accruing Dividends are paid; and (iv) except as provided below or by law, the Series N Preferred Stock shall have one vote, and the holders of the Series F Preferred Stock shall vote together with the holders of our common stockno voting rights. However, as a single class.
Dividends. The holders of the Series F Preferred Stock will participate, on an as-if-converted-to-common stock basis, in any cash dividends to the holders of common stock.
Redemption. At any time, from time to time after the first anniversary of the issuance date, we have the right to redeem all or any portion of the outstanding Series F Preferred Stock at a price per share equal to $1.95 plus any accrued but unpaid dividends.
Negative Covenants. As long as any shares of Series FN Preferred Stock are outstanding, the Company mayshall not, amend,without the affirmative vote of the holders of a majority of the then outstanding shares of the Series N Preferred Stock, (a) alter or repeal any provision of our certificate of incorporation, the certificate of designation or our bylaws in a manner that materiallychange adversely affects the powers, preferences or rights given to the Series N Preferred Stock or alter or amend the Certificate of Designation, (b) amend its certificate of incorporation or other charter documents in any manner that adversely affects any rights of the holders, (c) increase the number of authorized shares of the Series F Preferred Stock.
RENNOVA HEALTH, INC.
Notes to Condensed Consolidated Financial Statements
(unaudited)
N Preferred Stock, Issued Subsequentor (d) enter into any agreement with respect to any of the foregoing.
During the six months ended June 30, 2023 and 2022, the holders converted 36,000 and $1.8 million, respectively, into million and billion shares, respectively, of the Company’s common stock. On June 30, 2023, shares of Series N Preferred Stock remained outstanding and were convertible into billion shares of the Company’s common stock. shares and shares, respectively, of their Series N Preferred Stock with a stated value of $
Series O Preferred Stock
On May 10, 2021, the Company closed an offering of shares of its newly-authorized Series O Preferred Stock. The offering was pursuant to the terms of the securities purchase agreement dated as of May 10, 2021. On September 30, 2017
In7, 2021, the Company entered into a second securities purchase agreement and on October 2017,28, 2021, the Company entered into a third securities purchase agreement. These agreements were between the Company and certain existing institutional investors of the Company. Under these agreements, the Company issued shares of its Series I-1 ConvertibleO Preferred Stock and it received $9.0 million in connection with a financing as more fully discussed in Note 15.aggregate proceeds.
CommonThe terms of the Series O Preferred Stock
The Company had 1,354,171 include: (i) each share of the Series O Preferred Stock is convertible into shares of the Company’s common stock, at any time and 186,692from time to time, at the option of the holder, into that number of shares of common stock determined by dividing the stated value of such share of Series O Preferred Stock, plus any accrued declared and unpaid dividends, by the conversion price; (ii) the conversion price is equal to 90% of the lowest VWAP during the 10 trading days immediately prior to the conversion date; (iii) dividends at the rate per annum of 10% of the stated value per share shall accrue on each outstanding share of Series O Preferred Stock from and after the date of the original issuance of such share of Series O Preferred Stock (the “Series O Preferred Accruing Dividends”). The Series O Preferred Accruing Dividends shall accrue from day to day, whether or not declared, and shall be cumulative and non-compounding; provided, however, that such Series O Preferred Accruing Dividends shall be payable only when, as, and if declared by the Board of Directors. No cash dividends shall be paid on the common stock unless the Series O Preferred Accruing Dividends are paid; and (iv) except as provided below or by law, the Series O Preferred Stock shall have no voting rights. However, as long as any shares of Series O Preferred Stock are outstanding, the Company shall not, without the affirmative vote of the holders of a majority of the then outstanding shares of the Series O Preferred Stock, (a) alter or change adversely the powers, preferences or rights given to the Series O Preferred Stock or alter or amend the Certificate of Designation, (b) amend its certificate of incorporation or other charter documents in any manner that adversely affects any rights of the holders, (c) increase the number of authorized shares of the Series O Preferred Stock, or (d) enter into any agreement with respect to any of the foregoing.
24 |
During the six months ended June 30, 2023, the holders converted 40,500 into million shares of the Company’s common stock. During the six months ended June 30, 2022, the holders converted shares of their Series O Preferred Stock with a stated value of $0.2 million into billion shares of the Company’s common stock. On June 30, 2023, shares of Series O Preferred Stock remained outstanding and were convertible into billion shares of the Company’s common stock. shares of their Series O Preferred Stock with a stated value of $
Series P Preferred Stock
On November 7, 2021, the Company entered into Exchange and Amendment Agreements (the “November 2021 Exchange Agreements”) with certain institutional investors in the Company wherein the investors agreed to reduce their holdings of $1.1 million principal value of then outstanding warrant promissory notes payable and $4.5 million of then outstanding non-convertible debentures, plus accrued interest thereon of $1.5 million, by exchanging the indebtedness and accrued interest for shares of the Company’s Series P Preferred Stock. Each share of the Series P Preferred Stock has a stated value of $ . In addition, pursuant to the November 2021 Exchange Agreements, the expiration dates of the March Warrants that were issued by the Company to the debenture holders in March 2017 were extended from March 21, 2022 to March 21, 2024.
On March 11, 2022, under the terms of a securities purchase agreement dated January 31, 2022, the Company issued to the institutional investors an additional 1.0 million. On April 1, 2022, the Company issued an additional shares of its Series P Preferred Stock and received proceeds of $0.5 million. During the three and six months ended June 30, 2022, the Company recorded $0.1 million and $0.3 million of deemed dividends, respectively, as a result of the issuances of shares of its Series P Preferred Stock during the periods. The deemed dividends resulted from the difference between the stated value of the shares issued and the proceeds received, as well as the 10% conversion price discount. shares of its Series P Preferred Stock for aggregate proceeds of $
The terms of the Series P Preferred Stock include: (i) each share of the Series P Preferred Stock is convertible into shares of the Company’s common stock, at Septemberany time and from time to time, at the option of the holder, into that number of shares of common stock determined by dividing the stated value of such share of Series P Preferred Stock, plus any accrued declared and unpaid dividends, by the conversion price; (ii) the conversion price is equal to 90% of the lowest VWAP during the 10 trading days immediately prior to the conversion date; (iii) dividends at the rate per annum of 10% of the stated value per share shall accrue on each outstanding share of Series P Preferred Stock from and after the date of the original issuance of such share of Series P Preferred Stock (the “Series P Preferred Accruing Dividends”). The Series P Preferred Accruing Dividends shall accrue from day to day, whether or not declared, and shall be cumulative and non-compounding; provided, however, that such Series P Preferred Accruing Dividends shall be payable only when, as, and if declared by the Board of Directors. No cash dividends shall be paid on the common stock unless the Series P Preferred Accruing Dividends are paid; and (iv) except as provided below or by law, the Series P Preferred Stock shall have no voting rights. However, as long as any shares of Series P Preferred Stock are outstanding, the Company shall not, without the affirmative vote of the holders of a majority of the then outstanding shares of the Series P Preferred Stock, (a) alter or change adversely the powers, preferences or rights given to the Series P Preferred Stock or alter or amend the Certificate of Designation, (b) amend its certificate of incorporation or other charter documents in any manner that adversely affects any rights of the holders, (c) increase the number of authorized shares of the Series P Preferred Stock, or (d) enter into any agreement with respect to any of the foregoing.
On June 30, 20172023, shares of the Company’s Series P Preferred Stock were outstanding and December 31, 2016, respectively. were convertible into billion shares of the Company’s common stock.
Common Stock
The Company issued 1,167,479had billion and billion shares of its common stock duringissued and outstanding at June 30, 2023 and December 31, 2022, respectively. During the ninesix months ended SeptemberJune 30, 2017 as follows:
The February 22, 2017 reverse stock split, which is more fully described in Note 1, resulted in the issuance of 526 shares of common stock due to the rounding up of fractional shares.
On March 13, 2017,2023, the Company issued 26,667 million shares of its common stock in settlementupon the conversion of $0.4 million of outstanding notes and warrants (see Note 5).
On March 15, 2017, the Company agreed to issue 2,056 shares of common stock to the holders of a like number of warrants to purchase the Company’s common stock in exchange for the warrants valued at $57,868.
During the nine months ended September 30, 2017, the Company issued 548,932its Series N Preferred Stock and million shares of its common stock upon conversion of $4.1 million shares of its Series O Preferred Stock. During the principal amount of the March Debentures (See Note 6).
On July 25, 2017,six months ended June 30, 2022, the Company issued 8,333 billion shares of its common stock valued at $42,510 for severance owed to a former employee underupon the termsconversions of the Company’s equity plan. The equity plan is more fully described below.
On August 14, 2017, the Company issued 181,933 shares of restricted stock to employeesits Series N Preferred Stock and directors, and later returned 4,933 shares of this stock to treasury, as more fully discussed under the headingRestricted Stock below.
On August 23, 2017, the Company issued 33,334 billion shares of its common stock upon the conversions of shares of its Series O Preferred Stock.
25 |
The Company has outstanding options, warrants, convertible preferred stock and convertible debentures. Exercise of the outstanding options and warrants, and conversions of the convertible preferred stock and debentures could result in paymentsubstantial dilution of professional service fees valuedthe Company’s common stock and a decline in the market price of the common stock. In addition, the terms of certain of the warrants, convertible preferred stock and convertible debentures issued by the Company provide for reductions in the per share exercise prices of the warrants and the per share conversion prices of the debentures and preferred stock (if applicable and subject to a floor in certain cases), in the event that the Company issues common stock or common stock equivalents (as that term is defined in the agreements) at $118,493.an effective exercise/conversion price that is less than the then exercise/conversion prices of the outstanding warrants, preferred stock or debentures, as the case may be. These provisions, as well as the issuances of debentures and preferred stock with conversion prices that vary based upon the price of our common stock on the date of conversion, have resulted in significant dilution of the Company’s common stock and have given rise to reverse splits of its common stock, including the Reverse Stock Split, which is more fully discussed in Note 1.
Restricted Stock
On August 14, 2017,13, 2020, Mr. Diamantis entered into the Board of Directors, based onVoting Agreement with the recommendationCompany, Mr. Lagan and Alcimede LLC (of which Mr. Lagan is the sole manager) pursuant to which Mr. Diamantis granted an irrevocable proxy to Mr. Lagan to vote the Series M Preferred Stock held by Mr. Diamantis. Mr. Diamantis has retained all other rights under the Series M Preferred Stock. Regardless of the Compensation Committeenumber of shares of Series M Preferred Stock outstanding and so long as at least one share of Series M Preferred Stock is outstanding, the outstanding shares of Series M Preferred Stock shall have the number of votes, in the aggregate, equal to 51% of all votes entitled to be voted at any meeting of stockholders or action by written consent. This means that the holders of Series M Preferred Stock have sufficient votes, by themselves, to approve or defeat any proposal voted on by the Company’s stockholders, unless there is a supermajority required under applicable law or by agreement.
As a result of the BoardVoting Agreement discussed above and in accordance with the provisionsNovember 5, 2021 Amendment to the Company’s Certificate of Incorporation, as amended, to provide that the number of authorized shares of the 2007 Equity Plan, approved grants to employees and directorsCompany’s common stock or preferred stock may be increased or decreased (but not below the number of shares then outstanding) by the affirmative vote of the holders of a majority in voting power of the stock of the Company, of an aggregate of 181,933 shares of restricted common stock of the Company. The grantswhich is more fully vest on the first anniversarydiscussed in Note 1, as of the date of grant, subjectfiling this report, the Company believes that it has the ability to the grantee’s continued status as an employeeensure that it has and or director, as the case may be, on the vesting date. During the nine months ended September 30, 2017, 4,933can obtain sufficient authorized shares of the restrictedits common stock were forfeited by their terms and returned to treasury and cancelled.cover all outstanding rights to acquire potentially dilutive common shares.
During the nine months ended September 30, 2017, the Company recognized stock-based compensation in the amount of $82,974 for the grant of the restricted stock based on a valuation of $3.75 per share. At September 30, 2017, the Company had approximately $580,750 of unrecognized compensation cost related to the restricted stock.
Stock Options
The Company maintained and sponsored the Tegal Corporation 2007 Incentive Award Equity Plan (the “2007 Equity Plan”). Tegal Corporation is the predecessor entity toprior name of the Company. The 2007 Equity Plan, as amended, provided for the issuance of stock options and other equity awards to the Company’s officers, directors, employees and consultants. During the nine months ended September 30, 2017 and 2016, the Company recognized stock-based compensation in the amount of $34,081 and $0.7 million, respectively, for the vesting of outstanding stock options. The 2007 Equity Plan terminated pursuant to its terms in September 2017. The following table summarizes the Company’s stock option activity for the nine months ended September 30, 2017:
RENNOVA HEALTH, INC.
Notes to Condensed Consolidated Financial Statements
(unaudited)
Number of options | Weighted- average exercise price | Weighted- average contractual term (Yrs.) | ||||||||||
Outstanding at December 31, 2016 | 47,268 | $ | 1,941.45 | 8.93 | ||||||||
Granted | - | - | ||||||||||
Expired | - | - | ||||||||||
Forfeit | (8,790 | ) | - | |||||||||
Exercised | - | - | ||||||||||
Outstanding at September 30, 2017 | 38,478 | $ | 2,072.75 | 8.68 | ||||||||
Exercisable at September 30, 2017 | 31,811 | $ | 2,445.84 |
As of SeptemberJune 30, 2017,2023 and December 31, 2022, the Company had approximately $155,582 of unrecognized compensation cost related to stock options granted underoutstanding and exercisable with a weighted average exercise price of $ million per share. At June 30, 2023, the Company’s 2007 Equity Plan, which is expected to be recognized over a weighted-average periodweighted average remaining contractual life was years for options outstanding and exercisable. The intrinsic value of 1.03 years.options exercisable at June 30, 2023 and December 31, 2022 was $ . As of June 30, 2023 and 2022, there was no remaining compensation expense associated with stock options as all of the outstanding options had fully vested as of December 31, 2019.
Warrants
The Company, as part of various debt and equity financing transactions, has issued warrants to purchase shares of the Company’s common stock. stock exercisable into a total of billion shares at June 30, 2023.
The following summarizes the information related to warrants issued and thewarrant activity during the ninesix months ended SeptemberJune 30, 2017:2023:
Number of warrants | Weighted average exercise price | |||||||
Balance at December 31, 2016 | 93,843 | $ | 175.50 | |||||
Warrants issued during the period | 17,900,999 | $ | 4.58 | |||||
Warrants exchanged/exercised during period | (6,500 | ) | ||||||
Warrants expired during the period | - | |||||||
Balance at September 30, 2017 | 17,988,342 | $ | 5.40 |
DuringSchedule of Warrants Activity
Number of Shares of Common Stock Issuable for Warrants | Weighted average exercise price | |||||||
Balance at December 31, 2022 | 511,333,351,090 | $ | 0.00009 | |||||
Issuance of warrants | - | - | ||||||
Expiration of warrants | (1 | ) | (794,998.13 | ) | ||||
Balance at June 30, 2023 | 511,333,351,089 | $ | 0.00009 |
26 |
Included in the nine-months ended September 31,warrants outstanding at June 30, 2023 were the March Warrants issued in March 2017 the Company issued 16,350,132 warrants with a weighted average exercise price of $5.03 per share in connection with the issuances of debentures asMarch 2017 Debenture. (The March 2017 Debenture is more fully discussed in Note 6.
Basic) The Company issued these warrants to purchase shares of the Company’s common stock to several accredited investors. On June 30, 2023, the March Warrants were exercisable into an aggregate of approximately billion shares of the Company’s common stock. The March Warrants were issued to the investors in three tranches, Series A Warrants, Series B Warrants and Diluted Loss per Share
Basic lossSeries C Warrants. At June 30, 2023, the Series A Warrants were exercisable for 190.0 billion shares of the Company’s common stock. They were exercisable upon issuance in March 2017 and had an initial term of exercise equal to five years. On June 30, 2023, the Series B Warrants were exercisable for 127.6 billion shares of the Company’s common stock. They were exercisable upon issuance in March 2017, and had an initial term of exercise of eighteen months, which was extended until March 21, 2022. On June 30, 2023, the Series C Warrants were exercisable for 190.0 billion shares of the Company’s common stock and had an initial term of five years provided such warrants shall only vest if, when and to the extent that the holders exercise the Series B Warrants. On November 7, 2021, the expiration dates of the March Warrants were extended to March 21, 2024. On June 30, 2023, the Series A, Series B and Series C Warrants each have an exercise price of $0.00009 per share, excludes dilutionwhich reflects down round provision adjustments pursuant to their terms. The March Warrants are subject to “full ratchet” and is computed by dividing loss attributable to common stockholders by the weighted-averageother customary anti-dilution protections.
The number of common shares outstanding during the period. Diluted loss per share reflects the potential dilution that could occur if securities or other contracts to issueof common stock were exercised or converted intoissuable under outstanding warrants and the exercise prices of the warrants as reflected in the table above have been adjusted to reflect the full ratchet and other dilutive and down round provisions pursuant to the warrant agreements. As a result of the down round provisions of the outstanding warrants, subsequent issuances of the Company’s common stock or common stock equivalents at prices below the then current exercise prices of the warrants have resulted in increases in the issuancenumber of shares issuable pursuant to the warrants and decreases in the exercise prices of the warrants. See, also, Notes 1 and 3 for a discussion of the dilutive effect on the Company’s common stock that then shared in the incomeas a result of the Company. Foroutstanding warrants.
Deemed Dividends
During the three and ninesix months ended SeptemberJune 30, 20172022, reductions in the exercise prices of the warrants gave rise to deemed dividends. See Note 9 for the assumptions used in the calculations of deemed dividends. Deemed dividends are also discussed under the heading “Preferred Stock” above and 2016, basic loss per share is the same as diluted loss per share.in Notes 1 and 3.
Diluted loss per share excludes all dilutive potential shares if their effect is anti-dilutive. As of September 30, 2017 and 2016, the following potential common stock equivalents were excluded from the calculation of diluted loss per share as their effect was anti-dilutive:
As of September 30, | ||||||||
2017 | 2016 | |||||||
Warrants | 17,988,342 | 78,102 | ||||||
Convertible preferred stock | 71,147 | 47,463 | ||||||
Convertible debt | 4,353,898 | 3,911 | ||||||
Stock options | 38,478 | 49,331 | ||||||
22,451,865 | 178,807 |
RENNOVA HEALTH, INC.
Notes to Condensed Consolidated Financial Statements
(unaudited)
Note 1011 – Supplemental Disclosure of Cash Flow Information
The supplemental cash flow information for the nine months ended September 30, 2017 and 2016 (unaudited) is as follows:Schedule of Supplemental Cash Flow Information
2023 | 2022 | |||||||
Six Months Ended June 30, | ||||||||
2023 | 2022 | |||||||
(unaudited) | (unaudited) | |||||||
Cash paid for interest | $ | 411,791 | $ | 944,082 | ||||
Cash paid for income taxes | $ | - | $ | - | ||||
Non-cash investing and financing activities: | ||||||||
Stated value of Series N Preferred Stock converted into common stock | $ | 36,000 | $ | 1,833,712 | ||||
Stated value of Series O Preferred Stock converted into common stock | 40,500 | 179,460 | ||||||
Deemed dividends from issuances of Series P Preferred Stock | - | 333,333 | ||||||
Deemed dividends from triggers of down round provisions of warrants | - | 330,543,036 |
Nine Months Ended September 30, | ||||||||
2017 | 2016 | |||||||
Cash paid for interest | $ | 1,106,835 | $ | 1,237,622 | ||||
Cash paid for income taxes | $ | 506,313 | $ | - | ||||
Non-cash investing and financing activities: | ||||||||
Services and severance settled through issuance of common stock | $ | 161,003 | $ | 2,131,829 | ||||
Exchange of convertible debentures for convertible debentures and warrants | $ | 10,734,336 | $ | - | ||||
Series F Preferred Stock issued for business acquisition | $ | 174,097 | $ | - | ||||
Note payable and warrants settled through issuance of common stock | $ | 440,000 | $ | - | ||||
Convertible debenture issued in exchange of Series H Preferred Stock | $ | 2,695,760 | $ | - | ||||
Debentures converted into common stock | $ | 4,064,162 | $ | - | ||||
Deemed dividend for trigger of down round provision feature | $ | 53,341,619 | $ | - |
Note 1112 – Commitments and Contingencies
Concentration of Credit Risk
Credit risk with respect to accounts receivable is generally diversified due to the large number of patients at its facilities. The Company does have significant receivable balances with government and other payers. Generally, the Company does not require collateral or other security to support accounts receivables. However, the Company continually monitors and evaluates its client acceptance and collection procedures to minimize potential credit risks associated with its accounts receivable and establishes an allowance for uncollectible accounts and as a consequence, believes that its accounts receivable credit risk exposure beyond such allowance is not material to the financial statements.
The Company maintains its cash balances in high credit quality financial institutions. The Company’s cash balances may, at times, exceed the deposit insurance limits provided by the Federal Deposit Insurance Corp.
Legal Matters
From time to time, the Company may be involved in a variety of claims, lawsuits, investigations and proceedings related to contractual disputes, employment matters, regulatory and compliance matters, intellectual property rights and other litigation arising in the ordinary course of business. The Company operates in a highly regulated industry which may inherently lend itself to legal matters. Management is aware that litigation has associated costs and that results of adverse litigation verdicts could have a material effect on the Company’s financial position or results of operations. The Company’s policy is to expense legal fees and expenses incurred in connection with the legal proceedings in the period in which the expense is incurred. Management, in consultation with legal counsel, has addressed known assertions and predicted unasserted claims below.
27 |
Biohealth Medical Laboratory, Inc,Inc. and PB Laboratories, LLC (the “Companies”) filed suit against CIGNA Health in 2015 alleging that CIGNA failed to pay claims for laboratory services the Companies provided to patients pursuant to CIGNA - issued and CIGNA - administered plans. In 2016, the U.S. District Court dismissed part of the Companies’ claims for lack of standing. The Companies appealed that decision to the Eleventh Circuit Court of Appeals, which recentlyin late 2017 reversed the District Court’s decision and found that the Companies have standing to raise claims arising out of traditional insurance plans, as well as self-funded plans.
In July 2019, the Companies and EPIC filed suit against CIGNA Health for failure to pay claims for laboratory services provided. Cigna Health, in turn, sued for alleged improper billing practices. The Company’s Epinex Diagnostics Laboratories, Inc. subsidiary was sued in a California state court by two former employees who alleged that they were wrongfully terminated, as well as for a variety of unpaid wage claims. The parties entered into a settlement agreement of this matter on July 29, 2016 for approximately $0.2 million, and the settlement was consummated on August 25, 2016. In October of 2016, the plaintiffs in this matter filed a motion with the court seeking payment for attorneys’ fees in the approximate amount of $0.7 million. On March 24, 2017, the court granted plaintiffs’ motion for payment of attorneys’ fees in the amount of $0.3 million, andsuit remains ongoing but because the Company has accrued this amount in its condensed consolidateddid not have the financial statements. Additionally,resources to see the Company is seeking indemnification for these amounts from Epinex Diagnostics, Inc. (“EDI”),legal action to conclusion it assigned the seller of Epinex Diagnostic Laboratories, Inc. (“EDL”), pursuant to a Stock Purchase Agreement entered into by and among the parties.
In February 2016, the Company received notice that the Internal Revenue Service (the “IRS”) placed a lien against Medytox Solutions, Inc. and its subsidiaries relating to unpaid 2014 taxes due, plus penalties and interest, in the amount of $5.0 million. The Company paid $0.1 million toward its 2014 tax liability on March 2016. The Company filed its 2015 Federal tax return on March 15, 2016 and the accompanying election to carryback the reported net operating losses was filed in April 2016. On August 24, 2016, the lien was released, and on September of 2016 the Company received a refundbenefit, if any, from the IRS in the amount of $1.9 million. In November of 2016, the IRS commenced an audit of the Company’s 2015 Federal tax return. The Company is currently unablesuit to predict the outcome of the audit or any liabilityMr. Diamantis for his financial support to the Company that may result fromand assumption of all costs to carry the audit.case to conclusion.
On September 27, 2016, a tax warrant was issued against the Company by the Florida Department of Revenue (the “DOR”) for unpaid 2014 state income taxes in the approximate amount of $0.9$0.9 million, including penalties and interest. On January 25, 2017, the Company paid the DOR $250,000 as partial payment on this liability, and in February 2017 theThe Company entered into a Stipulation Agreement with the DOR which will allowallowing the Company to make monthly installment payments of $35,000installments until February 2018 and negotiate a new payment agreement then, if the balance of $0.3 million cannot be satisfied in a lump sum. If at any time during the Stipulation period the Company fails to timely file any required tax returns with the DOR or does not meet the payment obligations under the Stipulation Agreement, the entire amount due will be accelerated. The Company is current with the agreed payment plan.
RENNOVA HEALTH, INC.
Notes to Condensed Consolidated Financial Statements
(unaudited)
In December of 2016, TCS-Florida, L.P. (“Tetra”), filed suit against the Company for failure to make the required payments under an equipment leasing contract that the Company had with Tetra (see Note 8). On January 3, 2017, Tetra received a Default Judgment against the Company in the amount of $2.6 million, representing the balance owed on the leases, as well as additional interest, penalties and fees.July 2019. The Company has recognized this amount in its consolidated financial statements as of December 31, 2016. In January and February of 2017, the Company made payments to Tetra in connection with this judgment aggregatingreduce the amount owed. The balance accrued of approximately $0.4 million remained outstanding to $0.7 million, and on February 15, 2017 the Company entered into a forbearance agreement with Tetra whereby the remaining $1.9 million due will be paid in 24 equal monthly installments. Payments commenced on May 1, 2017. The Company is current with its payments.DOR at June 30, 2023.
In December of 2016, DeLage Landen Financial Services, Inc. (“DeLage”), filed suit against the Company for failure to make the required payments under an equipment leasing contract that the Company had with DeLage (see Note 8). On January 24, 2017, DeLage received a default judgment against the Company in the approximate amount of $1.0 million, representing the balance owed on the lease, as well as additional interest, penalties and fees. The Company has recognized this amount in its consolidated financial statements as of December 31, 2016. On February 8, 2017, a Stay of Execution was filed and under its terms the balance due will be paid in variable monthly installments through January of 2019, with an implicit interest rate of 4.97%. The Company is current in its payments.
On December 7, 2016, the holders of the Tegal Notes (see Note 5) filed suit against the Company seeking payment for the amounts due under the notes in the aggregate of $0.4 million, includingand accrued interest. A request for entry of default judgment was filed on January 24, 2017. A Case Management Conference is scheduled for December 5, 2017. The Company has submitted a settlement agreement proposal toOn April 23, 2018, the holders of the Tegal Notes received a judgment against the Company in the amount of $384,384 plus post-judgment interest. On June 1, 2023, the Company and is awaitingthe holders of the Tegal Notes agreed to settle all amounts owed pursuant to the judgment for a response.
Note 12 – Segment Information
Operating segments are defined under U.S. GAAP as componentstotal of $462,500 comprised of an enterpriseinitial payment of $200,000 followed by six monthly payments of $43,750. The Company has made all required payments to date.
In February 2020, Anthony O’Killough sued the Company and Mr. Diamantis, as guarantor, in New York State Supreme Court for which discrete financial information is available and are evaluated regularlythe County of New York, for approximately $2.0 million relating to the promissory note issued by the enterprise’s chief operating decision makerCompany in determining how to allocate resourcesSeptember 2019. In May 2020, the Company, Mr. Diamantis, as guarantor, and assess performance.Mr. O’Killough entered into a Stipulation providing for a payment of a total of $2.2 million (which included accrued “penalty” interest as of that date) in installments through November 1, 2020. The Company operatesmade payments totaling $450,000 in four reportable business segments:2020. On January 18, 2022, Mr. Diamantis paid $750,000 and the remaining balance was due 120 days thereafter. Mr. O’Killough agreed to forebear from any further enforcement action until then. On various dates during the remainder of 2022, Mr. Diamantis made additional payments to Mr. O’Killough totaling $300,000 and the Company gave Mr. Diamantis $350,000 for further payment to Mr. O’Killough. The Company is obligated to repay Mr. Diamantis for the payments, plus interest, that he made to Mr. O’Killough. As a result of these payments, the past due balance owed to Mr. O’Killough was $1.1 million on December 31, 2022. During the six months ended June 30, 2023, the parties entered into a final settlement wherein the Company and Mr. Diamantis settled the obligation in full for $580,000. The promissory note, forbearance agreement and final settlement are also discussed in Note 6.
In July 2019, CHSPSC, the former owners of Jamestown Regional Medical Center, obtained judgments against the Company totaling of $1.3 million. The Company has recorded these judgments as liabilities as of June 30, 2023. However, management believes that a number of insurance payments were made to CHSPSC for services provided after the change of ownership and believes that these payments will offset portions of the judgments.
On June 30, 2021, the Company entered into a settlement agreement with the Tennessee Bureau of Workers’ Compensation. Per the terms of the settlement agreement, the Company is obligated to pay a total of $109,739, payable in a lump sum payment of $32,922 on or before August 15, 2021 and in 24 consecutive monthly payments of $3,201 each on or before the 15th day of each month beginning September 15, 2021. The Company made the required payments due to date and has recorded the remaining amounts owed as a liability as of June 30, 2023.
A sealed qui tam lawsuit in the US District Court for the Southern District of Florida against the Company was filed in July 2021. This lawsuit was unsealed in November 2022 and Clifford Barron disclosed as the Plaintiff-Relator asserted violations of the False Claims Act. Clifford Barron was an employee of CollabRx, Inc. (a San Francisco based, wholly owned subsidiary of the Company) until early 2018. Following his resignation on January 17, 2018, Clifford Barron sought and received a judgment against the Company for approximately $253,000 he claimed was owed to him by the CollabRx subsidiary for severance and payment of COBRA. On receiving the judgment, he collected all monies owed to him under this judgment, including from the Company’s rural healthcare operations in Tennessee with which he was not involved. Payments included approximately $164,000 secured from hospital operating and other bank accounts by garnishments initiated by Jonathan Swann Taylor of Taylor & Knight, GP, Knoxville Tennessee, on behalf of Clifford Barron in May 2022. Clifford Barron has not been an employee of any subsidiary of the Company since January 2018, is not involved with the Company and has no knowledge of the Company’s operations, financial status, or controls. On November 21, 2022, the Company was advised that the U.S. Department of Justice was intervening in the action filed by the Plaintiff-Relator, Clifford Barron and has requested repayment of HHS Provider Relief Funds that certain subsidiaries of the Company obtained and other relief. The Company has retained the services of a specialist third-party accounting firm to complete a forensic review of the expenditure of all monies expended since the receipt of HHS Provider Relief Funds. It has been discovered that certain filing requirements of the Company’s operating subsidiaries were incomplete or contained errors that did not accurately reflect the expenditure of HHS Provider Relief Funds received. The Company disputes the allegations made in the False Claims Act complaint and believes that the forensic review of funds expended will address the lawsuit and demonstrate adherence with the applicable rules for use of HHS Provider Relief Funds. Accordingly, no amount has been accrued for this potential liability at June 30, 2023 and December 31, 2022. There is no assurance that the Company will be able to retain all HHS Provider Relief Funds it has received nor avoid payment of other relief sought by the Department of Justice. Any requirement to repay a significant amount of HHS Provider Relief Funds could have a material adverse effect on the Company.
28 |
The Company’s Decision SupportNote 13 – Discontinued Operations
EPIC Reference Labs, Inc. and Informatics segment is nowOther Non-Operating Subsidiaries
During the third quarter of 2020, the Company made a decision to sell EPIC and it made a decision to discontinue other non-operating subsidiaries, and as a result, EPIC’s operations and the other non-operating subsidiaries’ liabilities have been included in discontinued operations asfor all periods presented. The Company was unable to find a buyer for EPIC and, therefore, it has been classified as held for sale as of September 30, 2017. The accounting policies of the reportable segments are the same as those described in Note 2, Summary of Significant Accounting Policies, of the Company’s audited consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2016ceased all efforts to sell EPIC and in Note 1 for the adoption to ASU 2017-11. Selected financial information for the Company’s operating segments is as follows:closed down its operations.
RENNOVA HEALTH, INC.
Notes to Condensed Consolidated Financial Statements
(unaudited)
Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
2017 | 2016 | 2017 | 2016 | |||||||||||||
Net revenues - External | ||||||||||||||||
Clinical Laboratory Operations | $ | 586,663 | $ | (9,085 | ) | $ | 1,994,639 | $ | 3,461,987 | |||||||
Supportive Software Solutions | 208,070 | 50,447 | 698,359 | 605,575 | ||||||||||||
Hospital Operations | 619,478 | - | 619,478 | - | ||||||||||||
$ | 1,414,211 | $ | 41,362 | $ | 3,312,476 | $ | 4,067,562 | |||||||||
Net revenues - Intersegment (***) | ||||||||||||||||
Supportive Software Solutions | 217,431 | 502,055 | 501,924 | 1,036,396 | ||||||||||||
$ | 217,431 | $ | 502,055 | $ | 501,924 | $ | 1,036,396 | |||||||||
(Loss) income from operations | ||||||||||||||||
Clinical Laboratory Operations | $ | (1,039,118 | ) | $ | (7,364,096 | ) | $ | (3,809,146 | ) | $ | (10,590,435 | ) | ||||
Supportive Software Solutions | (660,800 | ) | (1,253,386 | ) | (1,721,694 | ) | (3,800,893 | ) | ||||||||
Hospital Operations | (2,093,805 | ) | - | (3,114,473 | ) | - | ||||||||||
Corporate | (1,369,765 | ) | (2,940,956 | ) | (5,058,565 | ) | (7,059,644 | ) | ||||||||
Eliminations | - | 33,663 | 8,181 | 100,987 | ||||||||||||
$ | (5,163,488 | ) | $ | (11,524,775 | ) | $ | (13,695,697 | ) | $ | (21,349,985 | ) | |||||
Depreciation and amortization | ||||||||||||||||
Clinical Laboratory Operations | $ | 410,801 | $ | 549,748 | $ | 1,265,174 | $ | 1,646,167 | ||||||||
Supportive Software Solutions | 25,015 | 163,749 | 227,999 | 490,236 | ||||||||||||
Hospital Operations | 15,436 | - | 22,045 | - | ||||||||||||
Corporate | 345 | 745 | 1,005 | 2,494 | ||||||||||||
Eliminations | - | (33,663 | ) | (8,181 | ) | (100,987 | ) | |||||||||
$ | 451,597 | $ | 680,579 | $ | 1,508,042 | $ | 2,037,910 | |||||||||
Capital expenditures | ||||||||||||||||
Clinical Laboratory Operations | $ | - | $ | - | $ | - | $ | 6,000 | ||||||||
Supportive Software Solutions | - | - | - | 9,998 | ||||||||||||
Hospital Operations | 160,413 | - | 1,554,499 | - | ||||||||||||
$ | 160,413 | $ | - | $ | 1,554,499 | $ | 15,998 |
***`Intersegment revenues are eliminated in consolidation.
September 30, 2017 | December 31, 2016 | |||||||
Total assets | ||||||||
Clinical Laboratory Operations | $ | 1,686,167 | $ | 3,986,126 | ||||
Supportive Software Solutions | 1,767,251 | 2,602,428 | ||||||
Decision Support and Informatics | - | 60,000 | ||||||
Hospital Operations | 1,748,986 | - | ||||||
Corporate | 3,037,112 | 2,130,191 | ||||||
Assets of AMSG classified as held for sale | 997,497 | 414,662 | ||||||
Eliminations | (2,871,080 | ) | (2,711,014 | ) | ||||
$ | 6,365,933 | $ | 6,482,393 |
RENNOVA HEALTH, INC.
Notes to Condensed Consolidated Financial Statements
(unaudited)
Note 13 – Recently Issued Accounting Standards
The following table provides a brief description of recently issued accounting standards:
Note 14 – Discontinued Operations
On July 12, 2017, the Company announced plans to spin off AMSG as an independent publicly traded company by way of a tax-free distribution to the Company’s stockholders. Completion of the spinoff is expected to occur in the first quarter of 2018 and is subject to numerous conditions, including effectiveness of a Registration Statement on Form 10 to be filed with the Securities and Exchange Commission, and consents, including under various funding agreements previously entered into by the Company. A record date to determine those stockholders entitled to receive shares in the spin off should be approximately 30 to 60 days prior to the date of the spinoff. The strategic goal of the spinoff is to create two public companies, each of which can focus on its own strengths and operational plans. In addition, after the spinoff, each company will provide a distinct and targeted investment opportunity.
In accordance with ASC 205-20 and having met the criteria for “held for sale”, as the Company reached this decision prior to September 30, 2017, the Company has reflected amounts relating to AMSG as a disposal group classified as held for sale and included as part of discontinued operations. AMSG had been included in the Decision Support and Informatics segment, except for the Company’s subsidiary, Alethea Laboratories, Inc., which had been included in the Clinical Laboratory Operations segment. Segment disclosures in Note 12 no longer include amounts relating to AMSG following the reclassification to discontinued operations.
Carrying amounts of major classes of assetsliabilities of EPIC and liabilities classified as held for sale andthe other non-operating subsidiaries included as part of discontinued operations in the unaudited condensed consolidated balance sheets as of June 30, 2023 (unaudited) and December 31, 2022 consisted of the following:
Schedule of Discontinued Operation of Unaudited Balance Sheet and Operation Statement
June 30, 2023 | December 31, 2022 | |||||||
Accounts payable | $ | 1,115,066 | $ | 1,115,066 | ||||
Accrued expenses | 349,143 | 341,046 | ||||||
Current liabilities of discontinued operations | $ | 1,464,209 | $ | 1,456,112 |
Consolidated Loss from Discontinued Operations:
RENNOVA HEALTH, INC.
Notes
Three Months Ended June 30, 2023 (unaudited) | Three Months Ended June 30, 2022 (unaudited) | Six Months Ended June 30, 2023 (unaudited) | Six Months Ended June 30, 2022 (unaudited) | |||||||||||||
General and administrative expenses | $ | - | $ | 2,811 | $ | - | $ | 4,245 | ||||||||
Other expense | (8,097 | ) | (1,134 | ) | (8,097 | ) | (1,134 | ) | ||||||||
Provision for income taxes | - | - | - | - | ||||||||||||
Loss from discontinued operations | $ | (8,097 | ) | $ | (3,945 | ) | $ | (8,097 | ) | $ | (5,379 | ) |
Note 14 – Recent Accounting Pronouncements
In August 2020, the FASB issued ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40). The new guidance provides accounting for convertible instruments and contracts in an entity’s own equity. The FASB issued this Update to Condensed Consolidated Financial Statements
(unaudited)
September 30, 2017 | December 31, 2016 | |||||||
(unaudited) | (unaudited) | |||||||
Cash | $ | 8,690 | $ | 2,962 | ||||
Accounts receivable, net | 6,503 | 267,681 | ||||||
Prepaid expenses and other current assets | 53,582 | 67,257 | ||||||
Current assets classified as held for sale | $ | 68,775 | $ | 337,900 | ||||
Property and equipment, net | $ | - | $ | 53,012 | ||||
Goodwill | 914,972 | - | ||||||
Deposits | 13,750 | 23,750 | ||||||
Non-current assets classified as held for sale | $ | 928,722 | $ | 76,762 | ||||
Accounts payable (includes related parties) | $ | 837,989 | $ | 422,864 | ||||
Accrued expenses | 253,991 | 1,253,117 | ||||||
Current portion of notes payable | 276,632 | - | ||||||
Current liabilities classified as held for sale | $ | 1,368,612 | $ | 1,675,981 | ||||
Non-current liabilities classified as held for sale | $ | - | $ | 26,598 |
Major line items constituting loss from discontinued operations in the consolidated statements of operations for the nine months ended September 30, 2017 and 2016 consisted of the following:
September 30, 2017 | September 30, 2016 | |||||||
(unaudited) | (unaudited) | |||||||
Revenue from services | $ | 224,224 | $ | 1,154,967 | ||||
Cost of services | 9,282 | 162,266 | ||||||
Gross profit | 214,942 | 992,701 | ||||||
Operating expenses | 1,225,638 | 4,073,873 | ||||||
Other income (expenses) | 42,775 | (253,142 | ) | |||||
Loss from discontinued operations | $ | (1,053,471 | ) | $ | (2,828,030 | ) |
Acquisition of Genomas, Inc. on September 27, 2017
On September 29, 2016, the Company announced that it had entered into a Stock Purchase Agreement (the “Purchase Agreement”) to acquire the remaining outstanding equity securities of Genomas, Inc. (“Genomas”) that the Company did not already own, representing approximately 85% of the outstanding equity interests in Genomas, for 1,750,000 shares of the Company’s newly - designated Series F Preferred Stock. (The Series F Preferred Stock is more fully described in Note 9 and below.) Genomas is a biomedical company that develops PhyzioType Systems for DNA-guided management and prescription of drugs used to treat mental illness, pain, heart disease, and diabetes. The Company had previously announced that on July 19, 2016 it acquired approximately 15% of the outstanding equity of Genomas from Hartford Healthcare Corporation (“Hartford”), along with approximately $1.5 million of notes payable to Hartford and certain rights to and license participation in technology that is used by Genomas, for $250,000 in cash. Under the terms of the Purchase Agreement, the Company also agreed to assume approximately $0.8 million of indebtedness and other obligations of Genomas. The closing of this acquisition, which was subject to, among other things, receipt of regulatory and licensure approvalsaddress issues identified as well as other customary closing conditions, did not occur until September 27, 2017. As a result of delaysthe complexity associated with applying U.S. GAAP for certain financial instruments with characteristics of liabilities and equity. The Board focused on amending the guidance on convertible instruments and the guidance on the derivatives scope exception for contracts in an entity’s own equity. This standard will be effective for us for annual periods beginning on January 1, 2024, including interim periods within those fiscal years. Early adoption of this standard is not permitted for us because we have already adopted ASU 2017-11 “Earnings Per Share (Topic 260) Distinguishing Liabilities from Equity (Topic 480) Derivatives and Hedging (Topic 815).” We have not yet determined the closingimpact of adopting this new accounting guidance on our consolidated financial statements.
In June 2022, the FASB issued ASU 2022-03, Fair Value Measurement (Topic 820), Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions. The FASB issued this ASU to: (1) clarify the guidance in Topic 820, Fair Value Measurement, when measuring the fair value of an equity security subject to contractual restrictions that prohibit the sale of an equity security, (2) amend a related illustrative example, and (3) introduce new disclosure requirements for equity securities subject to contractual sale restrictions that are measured at fair value in accordance with Topic 820. The amendments in this ASU do not change the principles of fair value measurement. For public business entities, the amendments are effective for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. Early adoption is permitted for both interim and annual financial statements that have not yet been issued or made available for issuance. The Company should apply the amendments prospectively with any adjustments from the adoption of the transaction, the Company expensed all amounts previously paid for the company during the fourth quarter of 2016, including outstanding advances to Genomasamendments recognized in the amount of $0.4 million. Genomas will be spun-off as part of AMSG, so it is presented here in discontinued operations.
RENNOVA HEALTH, INC.
Notes to Condensed Consolidated Financial Statements
(unaudited)
The Series F Preferred Stock issued effective September 27, 2017 has an aggregate stated value of $1,750,000,earnings and is convertible into shares of the Company’s common stock at any time after the one-year anniversary of the closing date at a conversion price per common share equal to the greater of $29.25 or the average closing sales price of the Company’s common stock for the 10 trading days immediately preceding the conversion. The maximum number of common shares issuable upon the conversion of the Series F Preferred Stock is 59,829. The Company valued the Series F Preferred Stock based on the value of the common stock issuable upon conversiondisclosed on the date of adoption. We have not yet determined the acquisition, which was $174,097.
The following table summarizes the (preliminary) fair valuesimpact of assets acquired and liabilities assumed at the acquisition date of Genomas. The Fair Market Value appears to equal cost. The Company has one year to revalue goodwill and other intangible assets in accordance with GAAP per ASC 850-10-25-14.
Cash | $ | 7,990 | ||
Accounts receivable, net | 6,503 | |||
Accounts payable and accrued expenses | (458,736 | ) | ||
Deferred revenue | (20,000 | ) | ||
Loans payable short-term | (142,514 | ) | ||
Note payable long-term | (134,118 | ) | ||
Total identifiable net liabilities | (740,875 | ) | ||
Goodwill | 914,972 | |||
Total consideration | $ | 174,097 |
The acquisition of Genomas was accounted for under the purchase method ofadopting this new accounting and, accordingly, the unaudited condensedguidance on our consolidated financial statements reflectstatements.
29 |
Other recent accounting standards issued by the resultsFASB, including its Emerging Issues Task Force, the American Institute of operations of Genomas from the date of acquisition. Unaudited pro forma results of operations for the three-months ended September 30, 2017 and 2016Certified Public Accountants, and the nine-months ended September 30, 2017 and 2016 are included below. Such pro forma information assumes that the Genomas acquisition had occurred as of January 1, 2017 and 2016, respectively, and revenue is presented in accordance with our accounting policies. These unaudited pro forma statements have been prepared for comparative purposes only andSEC did not or are not intendedbelieved by management to be indicative of what our results would have been hada material impact on the acquisition occurred at the beginning of the periods presentedCompany’s present or the results which may occur in the future.future consolidated financial statements.
Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
(unaudited) | (unaudited) | |||||||||||||||
2017 | 2016 | 2017 | 2016 | |||||||||||||
Net Revenue | $ | 1,439,151 | $ | 122,432 | $ | 3,460,125 | $ | 4,251,890 | ||||||||
Loss from discontinued operations | (475,065 | ) | 452,083 | (1,070,620 | ) | (1,871,057 | ) | |||||||||
Net loss | (10,930,151 | ) | (10,770,201 | ) | (31,189,252 | ) | (21,158,568 | ) | ||||||||
Deemed dividend from triggher of down | ||||||||||||||||
round provision feature | (2,280,280 | ) | - | (53,341,619 | ) | - | ||||||||||
Net loss to common shareholders | $ | (13,210,431 | ) | $ | (10,770,201 | ) | $ | (84,530,871 | ) | $ | (21,158,568 | ) | ||||
Loss per share basic and diluted: | ||||||||||||||||
Loss per share – discontinued operations | $ | (0.40 | ) | $ | (4.92 | ) | $ | (1.57 | ) | $ | (35.71 | ) | ||||
Net loss per common share | $ | (10.99 | ) | $ | (117.32 | ) | $ | (123.69 | ) | $ | (403.88 | ) |
Note 15 – Subsequent Events
Common Stock ListingMyrtle Commencement of Operations
As previously announced, on April 18, 2017, the Company was notified by Nasdaq that the stockholders’ equity balance reported onOn August 10, 2023, Myrtle received its state license to operate an alcohol and drug treatment facility at the Company’s Form 10-K for the year ended December 31, 2016 fell below the $2.5 million minimum requirement for continued listing under the Nasdaq Capital Market’s Listing Rule 5550(b)(1) (the “Rule”). As of September 30, 2017, the Company reported a stockholders’ deficit of $18.8 million.
In accordance with the Rule, the Company submitted a plan to Nasdaq outlining how it intended to regain compliance. OnBig South Fork Medical Center campus and, accordingly, commenced operations on August 17, 2017, Nasdaq notified the Company that its plan to correct the stockholders’ equity deficiency did not contain sufficient evidence to support a correction being achieved in the required time frame. The Company appealed this decision to a Hearing Panel which, on October 23, 2017, maintained this position and denied the Company a continued listing. Effective October 25, 2017, the Company’s common stock (RNVA) and warrants to purchase common stock (RNVAW) were no longer listed on the Nasdaq Stock Market but began trading on the OTCQB instead.
Subsequent to September 30, 2017, the Company has issued an aggregate of 4.3 million shares of common stock upon the conversion of debentures and exercise of warrants.
RENNOVA HEALTH, INC.
Notes to Condensed Consolidated Financial Statements
(unaudited)
Series I-1 Convertible Preferred Stock
On October 30, 2017, the Company closed an offering of $4,960,000 stated value of its newly-authorized Series I-1 Convertible Preferred Stock (the “Series I-1 Preferred Stock”). The offering was pursuant to the terms of the Securities Purchase Agreement, dated as of October 30, 2017 (the “Purchase Agreement”), between the Company and certain existing institutional investors of the Company. The Company received proceeds of $4,000,000 from the offering.
The Purchase Agreement gives the investors the right to participate in up to 50% of any offering of common stock or common stock equivalents by the Company. In the event of any such offering, the investors may also exchange all or some of their Series I-1 Preferred Stock for such new securities on an $0.80 stated value of Series I-1 Preferred Stock for $1.00 of new subscription amount basis.
The following14, 2023. Myrtle is a summary of certain terms and provisions of the Series I-1 Preferred Stock:
General.The Company’s board of directors has designated up to 4,960 shares of the 5,000,000 authorized shares of preferred stock as the Series I-1 Preferred Stock. Each share of Series I-1 Preferred Stock has a stated value of $1,000.
Rank.The Series I-1 Preferred Stock is senior in right of payment, including dividend rights and liquidation preference, to the Company’s Series G Preferred Stock and Series H Preferred Stock.
Conversion.Each share of Series I-1 Preferred Stock is convertible into shares of the Company’s common stock at any time at the option of the holder at a conversion price equal to the lesser of (i) $1.00, subject to adjustment, and (ii) 85% of the lesser of the volume weighted average market price of the common stock on the day prior to conversion or on the day of conversion. The conversion price is subject to “full ratchet” and other customary anti-dilution protections as more fully described in the Certificate of Designation of the Series I-1 Preferred Stock.
Liquidation Preference.Upon any liquidation, dissolution or winding-up of the Company, the holders of Series I-1 Preferred Stock shall be entitled to receive an amount equal to the stated value of the Series I-1 Preferred Stock, plus any accrued and unpaid dividends thereon and any other fees or liquidated damages then due and owing for each share of Series I-1 Preferred Stock, before any distribution or payment shall be made on any junior securities.
Voting Rights.Shares of Series I-1 Preferred Stock generally have no voting rights, except as required by law and except that the affirmative vote of the holders of a majority of the then outstanding shares of Series I-1 Preferred Stock is required to (a) alter or change adversely the powers, preferences or rights given to the Series I-1 Preferred Stock or alter or amend the Certificate of Designation of the Series I-1 Preferred Stock, (b) authorize or create any class of stock ranking as to dividends, redemption or distribution of assets upon liquidation senior to, or otherwise pari passu with, the Series I-1 Preferred Stock, (c) amend the Company’s certificate of incorporation or other charter documents in any manner that adversely affects any rights of the holders, (d) increase the number of authorized shares of Series I-1 Preferred Stock, or (e) enter into any agreement with respect to any of the foregoing.
Dividends.Holders of Series I-1 Preferred Stock shall be entitled to receive dividends on shares of Series I-1 Preferred Stock equal (on an as-converted to common stock basis) to and in the same form as dividends actually paid on shares of common stock when, as and if dividends are paid on shares of common stock. No other dividends shall be paid on shares of Series I-1 Preferred Stock.
Redemption.Upon the occurrence of certain Triggering Events (as defined in the Certificate of Designation of the Series I-1 Preferred Stock), the holder shall, in addition to any other right it may have, have the right, at its option, to require the Company to either redeem the Series I-1 Preferred Stock in cash or in certain circumstance in shares of common stock at the redemption prices set forth in the Certificate of Designation.
Negative Covenants.As long as at least a specified number of shares of Series I-1 Preferred Stock are outstanding, unless the holders of 67% of the then outstanding shares of Series I-1 Preferred Stock shall have given prior written consent, the Company and its subsidiaries are, with certain exceptions, limited from (a) incurring indebtedness, (b) creating liens, (c) amending its charter documents, (d) repurchasing or acquiring shares of common stock or common stock equivalents, (e) paying cash dividends on junior securities, (f) entering into transactions with affiliates, or (g) entering into any agreement with respect to the foregoing.
RENNOVA HEALTH, INC.
Notes to Condensed Consolidated Financial Statements
(unaudited)
Series I-2 Convertible Preferred Stock
On October 30, 2017, the Company entered into exchange agreements with the holders of the September Debentures to provide that the holders may, from time to time, exchange their September Debentures for shares of a newly-authorized Series I-2 Convertible Preferred Stock of the Company (the “Series I-2 Preferred Stock”). The exchange agreements permit the holders of the September Debentures to exchange specified principal amounts of the September Debentures on various closing dates from December 2, 2017 through March 1, 2018. Any exchange is at the option of the holders. Each holder may reduce the principal amount of September Debentures exchanged on any particular closing date, or elect not to exchange any September Debentures at all on a closing date. If a holder does choose to exchange less principal amount of September Debentures, or no September Debentures at all, it can carry forward such lesser amount to a future closing date and then exchange more than the originally specified principal amount for that later closing date. For each $0.80 of principal amount of September Debenture surrendered to the Company at any closing date, the Company will issue the holder a share of Series I-2 Preferred Stock with a stated value of $1.00. Each share of Series I-2 Preferred Stock is convertible into shares of the Company’s common stock at any time at the option of the holder at a conversion price equal to the lesser of (i) $1.00, subject to adjustment, and (ii) 85% of the lesser of the volume weighted average market price of the common stock on the day prior to conversion or on the day of conversion. The conversion price is subject to “full ratchet” and other customary anti-dilution protections as more fully described in the Certificate of Designation of the Series I-2 Preferred Stock.
The following is a summary of certain terms and provisions of the Series I-2 Preferred Stock.
General.The Company’s board of directors has designated up to 12,000 shares of the 5,000,000 authorized shares of preferred stock as the Series I-2 Preferred Stock. Each share of Series I-2 Preferred Stock has a stated value of $1,000.
Rank.The Series I-2 Preferred Stock is senior in right of payment, including dividend rights and liquidation preference, to the Company’s Series G Preferred Stock and Series H Preferred Stock.
Liquidation Preference. Upon any liquidation, dissolution or winding-up of the Company, the holders of Series I-2 Preferred Stock shall be entitled to receive an amount equal to the stated value of the Series I-2 Preferred Stock, plus any accrued and unpaid dividends thereon and any other fees or liquidated damages then due and owing for each share of Series I-2 Preferred Stock, before any distribution or payment shall be made on any junior securities.
Voting Rights. Shares of Series I-2 Preferred Stock generally have no voting rights, except as required by law and except that the affirmative vote of the holders of a majority of the then outstanding shares of Series I-2 Preferred Stock is required to (a) alter or change adversely the powers, preferences or rights given to the Series I-2 Preferred Stock or alter or amend the Certificate of Designation of the Series I-2 Preferred Stock, (b) authorize or create any class of stock ranking as to dividends, redemption or distribution of assets upon liquidation senior to, or otherwise pari passu with, the Series I-2 Preferred Stock, (c) amend the Company’s certificate of incorporation or other charter documents in any manner that adversely affects any rights of the holders, (d) increase the number of authorized shares of Series I-2 Preferred Stock, or (e) enter into any agreement with respect to any of the foregoing.
Dividends. Holders of Series I-2 Preferred Stock shall be entitled to receive dividends on shares of Series I-2 Preferred Stock equal (on an as-converted to common stock basis) to and in the same form as dividends actually paid on shares of common stock when, as and if dividends are paid on shares of common stock. No other dividends shall be paid on shares of Series I-2 Preferred Stock.
Redemption.Upon the occurrence of certain Triggering Events (as defined in the Certificate of Designation of the Series I-2 Preferred Stock), the holder shall, in addition to any other right it may have, have the right, at its option, to require the Company to either redeem the Series I-2 Preferred Stock in cash or in certain circumstance in shares of common stock at the redemption prices set forth in the Certificate of Designation.
Negative Covenants.As long as at least a specified number of shares of Series I-2 Preferred Stock are outstanding, unless the holders of 67% of the then outstanding shares of Series I-2 Preferred Stock shall have given prior written consent, the Company and its subsidiaries are, with certain exceptions, limited from (a) incurring indebtedness, (b) creating liens, (c) amending its charter documents, (d) repurchasing or acquiring shares of common stock or common stock equivalents, (e) paying cash dividends on junior securities, (f) entering into transactions with affiliates, or (g) entering into any agreement with respect to the foregoing.
Modification of Anti-Dilution Provisions of the March Debentures and March Warrants
On October 30, 2017, the Company agreed to amend the March Debentures and March Warrants, which are more fully discussed in Note 6,1.
InnovaQor Note Receivable Modifications
On August 9, 2023, the Company and InnovaQor mutually agreed to removemodify the floorpromissory note receivable to extend the maturity date from June 30, 2023 to December 31, 2023 and to provide for additional interest in the anti-dilution provisions therein.
Conversionsform of March Debentures and Exercises5% of Warrants
During the month of October 2017, $2,185,464.02 aggregate principal amount of March Debentures were exercised for 1,924,037 shares of common stock andto be added to the Company received $633,000 uponamount payable under the exercise of Class B Warrants issuednote. The promissory note receivable is more fully discussed in March 2017 for the issuance of 600,000 shares of common stock.Note 7.
RENNOVA HEALTH, INC.
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.
SPECIAL NOTE CONCERNING FORWARD-LOOKING STATEMENTS
Certain statements made in this Form 10-Q are “forward-looking statements” (within the meaning of the Private Securities Litigation Reform Act of 1995) regarding the plans and objectives of management for future operations. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. The forward-looking statements included herein are based on current expectations that involve numerous risks and uncertainties. The Company’s plans and objectives are based, in part, on assumptions involving its continued business operations. Assumptions related to the foregoing involve judgments with respect to, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the control of the Company. Although the Company believes its assumptions underlying the forward-looking statements are reasonable, any of the assumptions could prove to be inaccurate and, therefore, there can be no assurance the forward-looking statements included in this report will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the inclusion of such information should not be regarded as a representation by the Company or any other person that the objectives and plans of the Company will be achieved.
The forward-looking statements included in this Form 10-Q and referred to elsewhere are related to future events or our strategies or future financial performance. In some cases, you can identify forward-looking statements by terminology such as “may,” “should,” “believe,” “anticipate,” “future,” “potential,” “estimate,” “expect,” “intend,” “plan,” or the negative of such terms or comparable terminology. All forward-looking statements included in this Form 10-Q are based on information available to us as of the filing date of this report, and the Company assumes no obligation to update any such forward-looking statements, except as required by law. Our actual results could differ materially from the forward-looking statements.
Important factors that might cause our actual results to differ materially from the results contemplated by the forward-looking statements are contained in the “Risk Factors” section of our Annual Report on Form 10-K for the fiscal year ended December 31, 20162022 (the “2016“2022 Form 10-K”) and in our subsequent filings with the Securities and Exchange Commission. The following discussion of our results of operations should be read in conjunction with the audited financial statements contained within the 20162022 Form 10-K and with our unaudited condensed consolidated financial statements and related notes thereto included elsewhere in this report.
COMPANY OVERVIEW
Our Services
We are a healthcare enterprise that delivers products andprovider of health care services to healthcare providers, their patients and individuals.for our patients. We currently operate in three synergistic divisions: 1) Clinical diagnostics through our clinical laboratories; 2) supportive software solutions to healthcare providers including Electronic Health Records (“EHR”), Laboratory Information Systems and Medical Billing services; and 3) the recent addition of a rural critical accessown one operating hospital in Tennessee. We aspireOneida, Tennessee, a hospital located in Jamestown, Tennessee that we plan to createreopen, and operate and an operating rural clinic in Kentucky. In addition, the Company owns a more sustainable relationship with our customers by offering neededsubsidiary pursuing opportunities in the behavioral health sector and, interoperable solutions to capture multiple revenue streams from medical providers.
Our Services
Our principal lineon August 14, 2023, commenced operations of business to date is laboratory bloodan alcohol and urine testing services performed by our Clinical Laboratory Operations business segment, with a particular emphasisdrug treatment facility on the provisioncampus of urine drug toxicology testing to physicians, clinics and rehabilitation facilitiesits hospital in the United States. Testing services to rehabilitation facilities represented approximately 60% and 85%Oneida, Tennessee. The Company’s operations consist of our revenues for the nine months ended September 30, 2017 and 2016, respectively.only one segment.
31 |
Our Supportive Software Solutions segment provides Scott County Community Hospital (d/b/a customizable EHR and revenue cycle management services providing a full suite of billing services to substance abuse and behavioral health providers, as well as a dictation-based ambulatory EHR for physician practices and advanced transcription services.Big South Fork Medical Center)
On January 13, 2017, we closed on an asset purchase agreement to acquireacquired certain assets related to Scott County Community Hospital, based in Oneida, Tennessee (the “Hospital“Oneida Assets”). The HospitalOneida Assets include a 52,000 square52,000-square foot hospital building and 6,300 square6,300-square foot professional building on approximately 4.3 acres. Scott County Community Hospital is classified as a Critical Access Hospital (rural) withhas 25 beds, a 24/7 emergency department operating rooms and a laboratory that provides a range of diagnostic services. Scott County Community Hospital closed in July 2016 in connection with the bankruptcy filing of its parent company, Pioneer Health Services, Inc. We acquired the HospitalOneida Assets out of bankruptcy for a purchase price of $1.0 million. The hospital, which has since been renamed Big South Fork Medical Center, became operational on August 8, 2017. The hospital became certified as a Critical Access Hospital (rural) hospital in December 2021, retroactive to June 30, 2021.
CarePlus Rural Health Clinic
On March 5, 2019, we acquired certain assets related to an outpatient clinic located in Williamsburg, Kentucky known as CarePlus Clinic. The clinic, which was acquired from CarePlus Rural Health Clinic, LLC, offers compassionate care in a modern, patient-friendly facility. The CarePlus Clinic is located 32 miles northeast of our Big South Fork Medical Center.
Myrtle Recovery Centers, Inc.
In the second quarter of 2022, we formed a subsidiary, Myrtle Recovery Centers, Inc. (“Myrtle”), to pursue opportunities in the behavioral health sector, initially in our core, rural markets. We believe thatintend to focus on leveraging our existing physical locations and corporate and regional infrastructure to offer behavioral health services, including substance abuse treatment. Services will be provided on either an inpatient, residential basis or an outpatient basis.
On August 10, 2023, Myrtle was granted a license under the rules of the Department of Mental Health and Substance Abuse Services of Tennessee to operate an alcohol and drug treatment facility in Oneida Tennessee. The facility, which is located at Rennova’s Big South Fork Medical Center campus, commenced operations and began accepting patients on August 14, 2023. The facility offers alcohol and drug residential detoxification and residential rehabilitation treatment services for up to 30 patients. Myrtle intends to offer outpatient opioid treatment services at its Oneida facility in the future.
On April 11, 2023, Myrtle sold shares of its common stock equivalent to a 1.961% ownership stake in the subsidiary for de minimis value to an unaffiliated individual licensed as a physician in Tennessee. The shares have certain transfer restrictions, including the right of the subsidiary to transfer the shares to another physician licensed in Tennessee for de minimis value. The shares were sold to the individual for Tennessee healthcare regulatory reasons.
Jamestown Regional Medical Center
On June 1, 2018, we acquired from Community Health Systems, Inc. certain assets related to an acute care hospital located in Jamestown, Tennessee, referred to as Jamestown Regional Medical Center, for a purchase price of $0.7 million. The hospital is an 85-bed facility of approximately 90,000-square feet on over eight acres of land, which offered a 24-hour emergency department with two trauma bays and seven private exam rooms, inpatient and outpatient medical services and a progressive care unit which provided telemetry services. The acquisition also included a separate physician practice known as Mountain View Physician Practice, Inc.
The Company suspended operations at the hospital will provide us with a stable revenue base, as well as the potential for significant synergistic opportunities with our Clinical Laboratory Operations business segment. The Company is also actively seeking opportunities regarding other similar rural hospitals.
RENNOVA HEALTH, INC.
Our Decision Support and Informatics business segment develops and markets medical information and clinical decision support products and services intended to set a standard for the clinical interpretation of genomics-based, precision medicine. CollabRx offers interpretation and decision support solutions that enhance cancer diagnoses and treatment through actionable data analytics and reporting for oncologists and their patients. This segment is now considered part of our discontinued operations.
RESULTS OF OPERATIONS
Critical Accounting Policies and Estimates
Our discussion and analysis of financial condition and results of operations are based on our condensed consolidated financial statements, which have been preparedphysician practice in accordance with U.S. generally accepted accounting principles (“GAAP”). The preparation of these financial statements requires us to make a number of estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements. Such estimates and assumptions affect the reported amounts of revenues and expenses during the reporting period. We base our estimates on historical experiences and on various other assumptions that we believe to be reasonable under the circumstances. Actual results may differ materially from these estimates under different assumptions and conditions. We continue to monitor significant estimates made during the preparation of our financial statements. On an ongoing basis, we evaluate estimates and assumptions based upon historical experience and various other factors and circumstances. We believe our estimates and assumptions are reasonable in the circumstances; however, actual results may differ from these estimates under different future conditions.
We have identified the policies and significant estimation processes discussed below as critical to our business and to the understanding of our results of operations. For a detailed application of these and other accounting policies, see Note 2 to the audited consolidated financial statements as of and for the year ended December 31, 2016 included in the 2016 Form 10-K.
Revenue Recognition
Service revenues are principally generated from laboratory testing services, including chemical diagnostic tests such as blood analysis and urine analysis. Laboratory service revenues are recognized at the time the testing services are performed and billed and are reported at their estimated net realizable amounts.
Net service revenues are determined utilizing gross service revenues net of contractual adjustments and discounts. Even though it is the responsibility of the patient to pay for laboratory service bills, most individuals in the United States have an agreement with a third-party payer such as a commercial insurance provider, Medicaid or Medicare to pay all or a portion of their healthcare expenses; the majority of services provided by us are to patients covered under a third-party payer contract. In most cases, the Company is provided the third-party billing information and seeks payment from the third party in accordance with the terms and conditions of the third party payer for health service providers like us. Each of these third-party payers may differ not only in terms of rates, but also with respect to terms and conditions of payment and providing coverage (reimbursement) for specific tests. Estimated revenues are established based on a series of procedures and judgments that require industry specific healthcare experience and an understanding of payer methods and trends. Despite follow up billing efforts, the Company does not currently anticipate collection of a significant portion of self-pay billings, including the patient responsibility portion of the billing for patients covered by third party payers. The Company currently does not have any capitated agreements.
We review our calculations for the realizability of gross service revenues on a monthly basis in order to make certain that we are properly allowing for the uncollectable portion of our gross billings and that our estimates remain sensitive to variances and changes within our payer groups. The contractual allowance calculation is made on the basis of historical allowance rates for the various specific payer groups on a monthly basis with a greater weight being given to the most recent trends; this process is adjusted based on recent changes in underlying contract provisions and shifts in the testing being performed. This calculation is routinely analyzed by us on the basis of actual allowances issued by payers and the actual payments made to determine what adjustments, if any, are needed. Based on the calculations at September 30, 2017 and 2016, we determined that the collectible portion of our gross billings that should be reflected in net revenues was approximately 13% and 15%, respectively, of the outgoing gross billings.
Contractual Allowances and Doubtful Accounts
Accounts receivable are reported at realizable value, net of allowances for credits and doubtful accounts, which are estimated and recorded in the period the related revenue is recorded. The Company has a standardized approach to estimating and reviewing the collectability of its receivables based on a number of factors, including the period they have been outstanding. Historical collection and payer reimbursement experience is an integral part of the estimation process related to allowances for contractual credits and doubtful accounts. In addition, the Company regularly assesses the state of its billing operations in order to identify issues which may impact the collectability of these receivables or reserve estimates. Receivables deemed to be uncollectible are charged against the allowance for doubtful accounts at the time such receivables are written-off. Recoveries of receivables previously written-off are recorded as credits to the allowance for doubtful accounts. Revisions to the allowances for doubtful accounts estimates are recorded as an adjustment to provision for bad debts.
RENNOVA HEALTH, INC.
Impairment or Disposal of Long-Lived Assets
The Company accounts for the impairment or disposal of long-lived assets according to the Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification (“ASC”) Topic 360,Property, Plant and Equipment(“ASC 360”). ASC 360 clarifies the accounting for the impairment of long-lived assets and for long-lived assets to be disposed of, including the disposal of business segments and major lines of business. Long-lived assets are reviewed when facts and circumstances indicate that the carrying value of the asset may not be recoverable. When necessary, impaired assets are written down to estimated fair value based on the best information available. Estimated fair value is generally based on either appraised value or measured by discounting estimated future cash flows. Considerable management judgment is necessary to estimate discounted future cash flows. Accordingly, actual results could vary significantly from such estimates. We did not record any impairment charges during the nine months ended September 30, 2017 and 2016.
Derivative Financial Instruments and Fair Value
We account for warrants issued in conjunction with the issuance of common stock and certain convertible debt instruments in accordance with the guidance contained in ASC Topic 815,Derivatives and Hedging (“ASC 815”) and ASC Topic 480,Distinguishing Liabilities from Equity (“ASC 480”). For warrant instruments and conversion options embedded in promissory notes that are not deemed to be indexed to the Company’s own stock, we classified such instruments as liabilities at their fair values at the time of issuance and adjusted the instruments to fair value at each reporting period. These liabilities were subject to re-measurement at each balance sheet date until extinguished either through conversion or exercise, and any change in fair value was recognized in our statement of operations. The fair values of these derivative and other financial instruments had been estimated using a Black-Scholes model and other valuation techniques.
In July 2017, the FASB issued ASU 2017-11“Earnings Per Share (Topic 260) Distinguishing Liabilities from Equity (Topic 480) Derivatives and Hedging (Topic 815).” The amendments in Part I of this Update change the classification analysis of certain equity-linked financial instruments (or embedded features) with down round features. When determining whether certain financial instruments should be classified as liabilities or equity instruments, a down round feature no longer precludes equity classification when assessing whether the instrument is indexed to an entity’s own stock. The amendments also clarify existing disclosure requirements for equity-classified instruments. As a result, a freestanding equity-linked financial instrument (or embedded conversion option) no longer would be accounted for as a derivative liability at fair valueJune 2019, as a result of the existence of a down round feature. For freestanding equity classified financial instruments, the amendments require entities that present earnings per share (EPS) in accordance with Topic 260 to recognize the effecttermination of the down round feature when ithospital’s Medicare agreement and other factors. The Company is triggered. That effectevaluating whether to reopen the facility as an acute care hospital or as another type of healthcare facility. Jamestown is treated aslocated 38 miles west of Big South Fork Medical Center.
Outlook
We currently operate one hospital, a dividendrural health clinic and asan alcohol and drug treatment facility. We also own another hospital at which operations are currently suspended. Owning a reductionnumber of income availablefacilities in the same geographic location will create numerous efficiencies in management, purchasing and staffing and will enable the provision of additional, specialized and more valuable services that are needed by rural communities but cannot be sustained by a standalone facility. We remain confident that this is a sustainable model we can continue to common shareholders in basic EPS. Convertible instruments with embedded conversion options that have down round features are now subjectgrow through acquisition and development.
32 |
Three Months Ended June 30, 2023 Compared to the specialized guidance for contingent beneficial conversion features (in Subtopic 470-20, Debt—Debt with Conversion and Other Options), including related EPS guidance (in Topic 260). The amendments in Part II of this Update recharacterize the indefinite deferral of certain provisions of Topic 480 that now are presented as pending content in the Codification, to a scope exception. Those amendments do not have an accounting effect.Three Months Ended June 30, 2022
Under current GAAP, an equity-linked financial instrument with a down round feature that otherwise is not required to be classified as a liability under the guidance in Topic 480 is evaluated under the guidance in Topic 815, Derivatives and Hedging, to determine whether it meets the definition of a derivative. If it meets that definition, the instrument (or embedded feature) is evaluated to determine whether it is indexed to an entity’s own stock as part of the analysis of whether it qualifies for a scope exception from derivative accounting. Generally, for warrants and conversion options embedded in financial instruments that are deemed to have a debt host (assuming the underlying shares are readily convertible to cash or the contract provides for net settlement such that the embedded conversion option meets the definition of a derivative), the existence of a down round feature results in an instrument not being considered indexed to an entity’s own stock. This results in a reporting entity being required to classify the freestanding financial instrument or the bifurcated conversion option as a liability, which the entity must measure at fair value initially and at each subsequent reporting date.
The amendments in this Update revise the guidance for instruments with down round features in Subtopic 815-40, Derivatives and Hedging—Contracts in Entity’s Own Equity, which is considered in determining whether an equity-linked financial instrument qualifies for a scope exception from derivative accounting. An entity still is required to determine whether instruments would be classified in equity under the guidance in Subtopic 815-40 in determining whether they qualify for that scope exception. If they do qualify, freestanding instruments with down round features are no longer classified as liabilities and embedded conversion options with down round features are no longer bifurcated.
RENNOVA HEALTH, INC.
For entities that present EPS in accordance with Topic 260, and when the down round feature is included in an equity-classified freestanding financial instrument, the value of the effect of the down round feature is treated as a dividend when it is triggered and as a numerator adjustment in the basic EPS calculation. This reflects the occurrence of an economic transfer of value to the holder of the instrument, while alleviating the complexity and income statement volatility associated with fair value measurement on an ongoing basis. Convertible instruments are unaffected by the Topic 260 amendments in this Update.
The amendments in Part 1 of this Update are a cost savings relative to current GAAP. This is because, assuming the required criteria for equity classification in Subtopic 815-40 are met, an entity that issued such an instrument no longer measures the instrument at fair value at each reporting period (in the case of warrants) or separately accounts for a bifurcated derivative (in the case of convertible instruments) on the basis of the existence of a down round feature. For convertible instruments with embedded conversion options that have down round features, applying specialized guidance such as the model for contingent beneficial conversion features rather than bifurcating an embedded derivative also reduces cost and complexity. Under that specialized guidance, the issuer recognizes the intrinsic value of the feature only when the feature becomes beneficial instead of bifurcating the conversion option and measuring it at fair value each reporting period.
The amendments in Part II of this Update replace the indefinite deferral of certain guidance in Topic 480 with a scope exception. This has the benefit of improving the readability of the Codification and reducing the complexity associated with navigating the guidance in Topic 480.
We have early adopted this amendment as it has a material impact on our condensed consolidated financial statements.
Stock Based Compensation
We account for Stock-Based Compensation under ASC 718 “Compensation – Stock Compensation”, which addresses the accounting for transactions in which an entity exchanges its equity instruments for goods or services, with a primary focus on transactions in which an entity obtains employee services in share-based payment transactions. ASC 718 requires measurement of the cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award. Incremental compensation costs arising from subsequent modifications of awards after the grant date must be recognized.
The Company accounts for stock-based compensation awards to non-employees in accordance with ASC 505-50, Equity-Based Payments to Non-Employees. Under ASC 505-50, the Company determines the fair value of the options, warrants or stock-based compensation awards granted as either the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable. Any stock options or warrants issued to non-employees are recorded in expense and additional paid-in capital in stockholders’ equity (deficit) over the applicable service periods using variable accounting through the vesting dates based on the fair value of the options or warrants at the end of each period.
Three months ended September 30, 2017 compared to three months ended September 30, 2016
The following table summarizes the results of our consolidated continuing operations for the three months ended SeptemberJune 30, 20172023 and 2016 (unaudited):2022:
Three Months Ended September 30, | ||||||||||||||||
2017 | 2016 | |||||||||||||||
$ | % | $ | % | |||||||||||||
Net revenues | $ | 1,414,211 | 100.0 | % | $ | 41,362 | 100.0 | % | ||||||||
Operating expenses: | ||||||||||||||||
Direct costs of revenue | 309,347 | 21.9 | % | 305,157 | 737.8 | % | ||||||||||
General and administrative expenses | 5,169,478 | 365.5 | % | 6,497,718 | 15709.4 | % | ||||||||||
Sales and marketing expenses | 170,028 | 12.0 | % | 415,976 | 1005.7 | % | ||||||||||
Bad debt expense | 477,249 | 33.7 | % | 3,666,707 | 8864.9 | % | ||||||||||
Depreciation and amortization | 451,597 | 31.9 | % | 680,579 | 1645.4 | % | ||||||||||
Loss from operations | (5,163,488 | ) | -365.1 | % | (11,524,775 | ) | -27863.2 | % | ||||||||
Interest expense | (5,331,681 | ) | -377.0 | % | (1,651,629 | ) | -3993.1 | % | ||||||||
Other income, net | 40,455 | 2.9 | % | 127,008 | 307.1 | % | ||||||||||
Change in fair value of derivative instruments | - | 0.0 | % | 1,827,112 | 4417.4 | % | ||||||||||
Gain on extinguishment of debt | - | 0.0 | % | - | 0.0 | % | ||||||||||
Net loss | $ | (10,454,714 | ) | -739.3 | % | $ | (11,222,284 | ) | -27131.9 | % |
Three Months Ended June 30, | ||||||||||||||||
2023 | 2022 | |||||||||||||||
% | % | |||||||||||||||
Net Revenues | $ | 6,389,219 | 100.0 | % | $ | 3,606,236 | 100.0 | % | ||||||||
Operating expenses: | ||||||||||||||||
Direct costs of revenues | 1,834,107 | 28.7 | % | 1,571,673 | 43.6 | % | ||||||||||
General and administrative expenses | 2,358,758 | 36.9 | % | 1,880,167 | 52.1 | % | ||||||||||
Depreciation and amortization | 99,357 | 1.6 | % | 117,216 | 3.3 | % | ||||||||||
Income from continuing operations before other income (expense), income taxes and net loss attributable to noncontrolling interest | 2,096,997 | 32.8 | % | 37,180 | 1.0 | % | ||||||||||
Other income (expense), net | 212,368 | 3.3 | % | (316,369 | ) | -8.8 | % | |||||||||
Gain from forgiveness of debt | 200,000 | 3.1 | % | 334,819 | 9.3 | % | ||||||||||
Loss from legal settlements, net | (276,313 | ) | -4.3 | % | (76,218 | ) | -2.1 | % | ||||||||
Interest expense | (431,484 | ) | -6.8 | % | (479,253 | ) | -13.3 | % | ||||||||
Provision for income taxes | (517,000 | ) | -8.1 | % | - | 0.0 | % | |||||||||
Net loss attributable to noncontrolling interest | 1,362 | 0.0 | % | - | 0.0 | % | ||||||||||
Net income (loss) from continuing operations | $ | 1,285,930 | 20.1 | % | $ | (499,841 | ) | -13.9 | % |
RENNOVA HEALTH, INC.
Net Revenues
Consolidated netNet revenues were $1.4$6.4 million for the three months ended SeptemberJune 30, 2017,2023, as compared to $41 thousand for the three months ended September 30, 2016, an increase of $1.4 million. The increase is mainly the result of two factors; (1) the opening of the Hospital which resulted in net revenues of $0.6$3.6 million for the three months ended SeptemberJune 30, 2017 and (2)2022, an increase of $2.8 million. We attribute the increase in the Clinical Laboratory Operations business segment revenuenet revenues to greater inpatient admissions, increased outpatient services, higher reimbursement rates and certain collections from prior periods related to Critical Access Hospital designation at our Big South Fork Medical Center.
Direct Cost of $0.6Revenues
Direct costs of revenues increased by $0.3 million compared to last year, even though there was a 75% decline in insured test volumes. The net revenue decline for the three months ended SeptemberJune 30, 2016 was2023 compared to the three months ended June 30, 2022. We attribute the increase primarily to higher salaries and wages and professional fees. Salaries and wages increased primarily due to greater inpatient admissions and increased non-clinical staffing, partially offset by reduced contract labor. Professional fees increased as a result of the determination thatrestructuring of our relationships with certain professional service firms.
General and Administrative Expenses
General and administrative expenses increased by $0.5 million in the collectible portion of gross billings should be reflected at 15%, asthree months ended June 30, 2023 compared to 20%the three months ended June 30, 2022. Our hospital operations general and administrative expenses contributed approximately $0.5 million of the increase due primarily to increased salaries and wages, professional fees and an increase in property taxes. In addition, we incurred approximately $0.1 million of startup expenses associated with Myrtle, partially offset by a reduction of approximately $0.1 million of corporate related expenses.
Depreciation and Amortization
Depreciation and amortization expense remained relatively constant at approximately $0.1 million and $0.1 million in the three months ended June 30, 2023 and 2022, respectively.
Income from earlier in 2016. This change in estimate resulted in a reductionContinuing Operations Before Other Income (Expense), Income Taxes and Net Loss Attributable to Noncontrolling Interest
Income from continuing operations before other income (expense), income taxes and net loss attributable to noncontrolling interest for the three months ended June 30, 2023 was $2.1 million compared to income of $37,180 for the three months ended June 30, 2022. We attribute the increase to the $2.8 million increase in net revenues in the amountthree months ended June 30, 2023 compared to the comparable 2022 period, partially offset by the increases in direct costs of $1.7 million.net revenues and general and administrative expenses in the three months ended June 30, 2023 versus the 2022 period.
Other Income (Expense), Net revenues in our Supportive Software Solutions increased by
Other income, net of $0.2 million for the three months ended SeptemberJune 30, 2017 compared to the same period a year ago.
Direct Cost2023 consisted primarily of Revenue
Direct costsvarious miscellaneous income items, partially offset by $0.1 million of revenue is essentially unchanged in the three months ended September 30, 2017, as compared to the three months ended September 30, 2016.
Generalpenalties and Administrative Expenses
General and administrative expenses decreased by $1.3 million, or 20%, in the third quarterinterest from non-payment of 2017 as compared to the same period a year ago. The decrease is mainly the resultpayroll taxes. Other expense, net of a $1.1 million reduction in employee compensation and related costs, as we significantly reduced our headcount throughout the latter half of 2016 and 2017 in response to the decline in revenues, and a $0.2 million reduction in maintenance costs for our laboratory equipment.
Sales and Marketing Expenses
The decline in sales and marketing expenses of $0.2 million, or 59%, for the three months ended September 30, 2017 as compared to the three months ended September 30, 2016 was primarily due to a reduction in sales employee and contractor compensation expenses in the amount of $0.2 million, as well as reduced travel, advertising and commissionable collections related to the decline in net revenues.
Bad Debt Expense
Bad debt expense for the three months ended September 30, 2017 was $0.5 million, as compared to $3.7$0.3 million for the three months ended SeptemberJune 30, 2016.2022 consisted primarily of penalties and interest from non-payment of payroll taxes.
33 |
DuringGain from Forgiveness of Debt
Gain from forgiveness of debt of $0.2 million for the three months ended SeptemberJune 30, 2016, we recorded a charge of $3.5 million related to receivables in our Clinical Laboratory Operations segment that were deemed uncollectible. The primary factors in rendering these receivables uncollectible were our failure to obtain preauthorization2023 resulted from the third party prior to rendering services and the lackforgiveness of an existing preferred provider contract with the third-party payer. We also increased the allowancea portion of outstanding notes payable. Gain from forgiveness of debt for doubtful accounts for our Supportive Software Solutions segment by $0.2 million.
During the three months ended SeptemberJune 30, 2017,2022 resulted from the Hospital business segment deemed uncollectibleforgiveness of Paycheck Protection Program loans (“PPP Notes”).
Loss from Legal Settlements, Net
The loss from legal settlements, net was $0.3 million and $0.1 million for the three months ended June 30, 2023 and 2022, respectively. The loss from legal settlements, net for the three months ended June 30, 2023 resulted primarily from the adjustment of reserves related to judgments with the former owners of Jamestown Regional Medical Center.
Interest Expense
Interest expense was $0.4 million related to the August and September receivables since their Medicare & Medicaid certification was not approved until October 11, 2017. The Company will submit all claims for services rendered for payment since the opening of the hospital. We also increased the allowance for doubtful accounts for our Supportive Software Solutions segment by $0.1 million.
Depreciation and Amortization Expenses
Depreciation and amortization expense was $0.5 million for the three months ended SeptemberJune 30, 2017 as compared to $0.7 million for the same period a year ago, as some of our property2023 and equipment became fully depreciated during 2016 and our capital expenditures have been minimal due to the reduced sample volume at our laboratories.
Loss from Operations
Our operating loss decreased by $6.4 million, to $5.2 million for the three months ended September 30, 2017, as compared to $11.5 million for the three months ended September 30, 2016. The decrease is due to the $5.0 million decrease in total operating expenses and the $1.4 million increase in net revenues.
Interest Expense
2022, respectively. Interest expense for the three months ended SeptemberJune 30, 2017 was $5.3 million, as compared to $1.7 million2023 and 2022 consisted of interest expense on debentures and notes payable.
Provision for Income Taxes
The provision for income taxes of $517,000 for the three months ended SeptemberJune 30, 2016. Interest expense in2023 compared to no provision for the three months ended SeptemberJune 30, 2017 includes a $4.8 million non-cash interest charge related2022 was due to the issuance of convertible debentures and warrants during the period. Interest expensetaxable income in the three months ended September 30, 2016 mainly consists of an interest charge of $0.5 million related to2023 period versus a loss for the $5 million prepaid forward purchase contract and $0.4 million of non-cash interest expense related to the accretion of debt discounts.2022 period.
RENNOVA HEALTH, INC.Net Income (Loss) from Continuing Operations
OtherNet income (expense)
Other income decreased by $1.9 million for three months ended September 30, 2017 as compared to same period a year ago. The decrease consists primarily of $2.1 million in non-cash gains on the change in fair value of derivative financial instruments related to convertible notes and warrants recorded in 2016.
Net Loss
Our net loss from continuing operations for the three months ended SeptemberJune 30, 20172023 was $10.5$1.3 million, as compared to $11.2a net loss from continuing operations of $0.5 million for the samethree months ended June 30, 2022. The improvement in the 2023 period as compared to the 2022 period was primarily due to $2.1 million of a year ago,income from continuing operations before other income (expense), income taxes and net loss attributable to noncontrolling interest in the three months ended June 30, 2023 compared to income of $37,180 for the comparable 2022 period and $0.2 million of other income, net in the 2023 period compared to $0.3 million of other expense, net in the 2022 period, partially offset by an increase of $0.2 million from loss from legal settlements, net in the 2023 period, a decrease of $0.8 million. The change is primarily due$0.1 million from the forgiveness of debt in the 2023 period and $0.5 million of income taxes in the 2023 period.
Six months ended June 30, 2023 compared to the decrease in operating expenses of $5.0 million, an increase of $3.6 million in interest expense, and a decrease of $2.0 million in other income (expense), offset by the increase in revenue of $1.4 million.
The following table presents key financial and operating metrics for our Clinical Laboratory Operations segment:
Three Months Ended September 30, | ||||||||||||||||
Clinical Laboratory Operations | 2017 | 2016 | Change | % | ||||||||||||
Net revenues | $ | 586,663 | $ | (9,085 | ) | $ | 595,748 | 6557.5 | % | |||||||
Operating expenses: | ||||||||||||||||
Direct costs of revenue | 191,537 | 224,285 | (32,748 | ) | -14.6 | % | ||||||||||
Bad debt expense | (43,887 | ) | 3,475,252 | (3,519,139 | ) | -101.3 | % | |||||||||
General and administrative expenses | 897,038 | 2,691,078 | (1,794,040 | ) | -66.7 | % | ||||||||||
Sales and marketing expenses | 170,292 | 414,648 | (244,356 | ) | -58.9 | % | ||||||||||
Depreciation and amortization | 410,801 | 549,748 | (138,947 | ) | -25.3 | % | ||||||||||
Loss from operations | $ | (1,039,118 | ) | $ | (7,364,096 | ) | $ | 6,324,978 | -85.9 | % | ||||||
Key Operating Measures - Revenues: | ||||||||||||||||
Insured tests performed | 15,415 | 61,106 | (45,691 | ) | -74.8 | % | ||||||||||
Net revenue per insured test | $ | 38.06 | $ | (0.15 | ) | $ | 38.21 | 25697.9 | % | |||||||
Revenue recognition percent of gross billings | 13.0 | % | 15.0 | % | -2.0 | % | ||||||||||
Key Operating Measures - Direct Costs: | ||||||||||||||||
Total samples processed | 5,320 | 7,850 | (2,530 | ) | -32.2 | % | ||||||||||
Direct costs per sample | $ | 36.00 | $ | 28.57 | $ | 7.43 | 26.0 | % |
The following table presents key financial metrics for our Supportive Software Solutions segment:
Three Months Ended September 30, | ||||||||||||||||
Supportive Software Solutions | 2017 | 2016 | Change | % | ||||||||||||
Net revenues | $ | 208,070 | $ | 50,447 | $ | 157,623 | 312.5 | % | ||||||||
Operating expenses: | ||||||||||||||||
Direct costs of revenue | 47,347 | 80,872 | (33,525 | ) | -41.5 | % | ||||||||||
General and administrative expenses | 722,790 | 865,143 | (142,353 | ) | -16.5 | % | ||||||||||
Sales and marketing expenses | 491 | 1,329 | (838 | ) | -63.1 | % | ||||||||||
Bad debt expense | 73,227 | 192,740 | (119,513 | ) | -62.0 | % | ||||||||||
Depreciation and amortization | 25,015 | 163,749 | (138,734 | ) | -84.7 | % | ||||||||||
Loss from operations | $ | (660,800 | ) | $ | (1,253,386 | ) | $ | 592,586 | -47.3 | % |
RENNOVA HEALTH, INC.
The following table presents key financial metrics for our Hospital segment:
Three Months Ended September 30, | ||||||||||||||||
Hospital | 2017 | 2016 | Change | % | ||||||||||||
Net revenues | $ | 619,478 | $ | - | $ | 619,478 | - | |||||||||
Operating expenses: | ||||||||||||||||
Direct costs of revenue | 69,145 | - | 69,145 | - | ||||||||||||
General and administrative expenses | 2,180,793 | - | 2,180,793 | - | ||||||||||||
Bad debt expense | 447,909 | - | 447,909 | - | ||||||||||||
Depreciation and amortization | 15,436 | - | 15,436 | - | ||||||||||||
Loss from operations | $ | (2,093,805 | ) | $ | - | $ | (2,093,805 | ) | - |
The following table presents key financial metrics for our Corporate group:
Three Months Ended September 30, | ||||||||||||||||
Corporate | 2017 | 2016 | Change | % | ||||||||||||
Operating expenses: | ||||||||||||||||
General and administrative expenses | $ | 1,364,927 | $ | 2,940,211 | $ | (1,575,284 | ) | -53.6 | % | |||||||
Direct costs of revenue | 1,319 | - | 1,319 | - | ||||||||||||
Sales and marketing expenses | 3,174 | - | 3,174 | - | ||||||||||||
Depreciation and amortization | 345 | 745 | (400 | ) | -53.7 | % | ||||||||||
Loss from operations | $ | (1,369,765 | ) | $ | (2,940,956 | ) | $ | 1,571,191 | -53.4 | % |
RENNOVA HEALTH, INC.
Ninesix months ended SeptemberJune 30, 2017 compared to Nine months ended September 30, 20162022
The following table summarizes the results of our consolidated continuing operations for the ninesix months ended SeptemberJune 30, 20172023 and 2016:2022:
Nine Months Ended September 30, | ||||||||||||||||
2017 | 2016 | |||||||||||||||
$ | % | $ | % | |||||||||||||
Net revenues | $ | 3,312,476 | 100.0 | % | $ | 4,067,562 | 100.0 | % | ||||||||
Operating expenses: | ||||||||||||||||
Direct costs of revenue | 849,632 | 25.6 | % | 1,128,060 | 27.7 | % | ||||||||||
General and administrative expenses | 12,978,349 | 391.8 | % | 17,142,263 | 421.4 | % | ||||||||||
Sales and marketing expenses | 620,560 | 18.7 | % | 1,441,322 | 35.4 | % | ||||||||||
Bad debt expense | 1,051,590 | 31.7 | % | 3,667,992 | 90.2 | % | ||||||||||
Depreciation and amortization | 1,508,042 | 45.5 | % | 2,037,910 | 50.1 | % | ||||||||||
Loss from operations | (13,695,697 | ) | -413.5 | % | (21,349,985 | ) | -524.9 | % | ||||||||
Interest expense | (16,510,525 | ) | -498.4 | % | (4,700,664 | ) | -115.6 | % | ||||||||
Other income, net | 91,212 | 2.8 | % | 6,763,138 | 166.3 | % | ||||||||||
Change in fair value of derivative instruments | (42,702,815 | ) | -1289.2 | % | - | 0.0 | % | |||||||||
Gain on extinguishment of debt | 42,702,815 | 1289.2 | % | - | 0.0 | % | ||||||||||
Income tax expense | 3,622 | 0.1 | % | - | 0.0 | % | ||||||||||
Net loss | $ | (30,118,632 | ) | -909.2 | % | $ | (19,287,511 | ) | -474.2 | % |
Six Months Ended June 30, | ||||||||||||||||
2023 | 2022 | |||||||||||||||
% | % | |||||||||||||||
Net Revenues | $ | 11,305,115 | 100.0 | % | $ | 4,750,756 | 100.0 | % | ||||||||
Operating expenses: | ||||||||||||||||
Direct costs of revenues | 3,687,153 | 32.6 | % | 2,946,316 | 62.0 | % | ||||||||||
General and administrative expenses | 4,575,428 | 40.5 | % | 3,452,503 | 72.7 | % | ||||||||||
Depreciation and amortization | 193,492 | 1.7 | % | 234,040 | 4.9 | % | ||||||||||
Income (loss) from continuing operations before other income (expense), income taxes and net loss attributable to noncontrolling interest | 2,849,042 | 25.2 | % | (1,882,103 | ) | -39.6 | % | |||||||||
Other income (expense), net | 255,114 | 2.3 | % | (42,281 | ) | -0.9 | % | |||||||||
Gain from forgiveness of debt | 200,000 | 1.8 | % | 334,819 | 7.0 | % | ||||||||||
Gain (loss) from legal settlements, net | 286,719 | 2.5 | % | (76,218 | ) | -1.6 | % | |||||||||
Interest expense | (983,747 | ) | -8.7 | % | (1,100,190 | ) | -23.2 | % | ||||||||
Provision for income taxes | (517,000 | ) | -4.6 | % | - | 0.0 | % | |||||||||
Net loss attributable to noncontrolling interest | 1,362 | 0.0 | % | - | 0.0 | % | ||||||||||
Net income (loss) from continuing operations | $ | 2,091,490 | 18.5 | % | $ | (2,765,973 | ) | -58.2 | % |
34 |
Net Revenues
Consolidated netNet revenues were $3.3$11.3 million for the ninesix months ended SeptemberJune 30, 2017,2023, as compared to $4.1$4.8 million for the ninesix months ended SeptemberJune 30, 2016,2022, an increase of $6.5 million. We attribute the increase in net revenues to greater inpatient admissions, increased outpatient services, higher reimbursement rates and certain collections from prior periods related to Critical Access Hospital designation at our Big South Fork Medical Center. We began billing as a decrease of $0.8 million, or 19%. The decrease is mainly the result of a 72% decline in insured test volumes in our Clinical Laboratory Operations business segment, offset by the net revenue of theCritical Access Hospital in the amount of $0.6 million. Net revenues in our Supportive Software Solutions increased by $0.1 million or 15% for the ninethree months ended SeptemberJune 30, 2017 as compared2022 retroactive to the same period a year ago.June 30, 2021.
Direct CostCosts of RevenueRevenues
Direct costs of revenue decreasedincreased by 25%, from$0.7 million for the six months ended June 30, 2023 compared to the six months ended June 30, 2022. We attribute the increase primarily to higher salaries and wages and professional fees. Salaries and wages increased primarily due to greater inpatient admissions and increased non-clinical staffing, partially offset by reduced contract labor. Professional fees increased as a result of the restructuring of our relationships with certain professional service firms.
General and Administrative Expenses
General and administrative expenses increased by $1.1 million in the ninesix months ended SeptemberJune 30, 2016 to $0.8 million in the nine months ended September 30, 2017. The decrease is a result of reduced expenses for transcription, data storage and software license related to our Supportive Software Solutions segment as well as a decrease in reagents and supplies at our laboratories offset by an increase of $0.1 million related2023 compared to the Hospital.
General and Administrative Expenses
General2022 period. Our hospital operations general and administrative expenses decreasedincreased by $4.2approximately $0.9 million or 24%, for the nine months ended September 30, 2017, compared to the same period a year ago. The decrease is mainly the result of a $3.0 million reduction in employee compensation and related costs, net of Hospital employee compensation of $1.6 million, as we significantly reduced our headcount throughout the latter half of 2016 and 2017 in response to the decline in revenues in our Clinical and Supportive Software, and a $0.2 million reduction in maintenance costs for our laboratory equipment and a $0.8 million decrease in stock compensation expense.
Sales and Marketing Expenses
The decline in sales and marketing expenses of $0.8 million, or 57%, for the nine months ended September 30, 2017 as compared to the nine months ended September 30, 2016 was primarily due to increased salaries and wages, professional and purchased services and property taxes. In addition, we incurred $146,000 of startup expenses associated with Myrtle and a reduction$54,000 increase in sales employee and contractor compensation expenses in the amount of $0.8 million, as well as reduced travel, advertising and commissionable collectionscorporate related to the decline in net revenues.expenses.
Bad Debt Expense
Bad debt expense for the nine months ended September 30, 2017 was $1.1 million, as compared to $3.7 million for the same period of a year ago. The decrease is mainly due to the $3.5 million bad debt charge in 2016 related to receivables in our Clinical Laboratory Operations segment.
RENNOVA HEALTH, INC.
Depreciation and Amortization ExpensesExpense
Depreciation and amortization expense remained relatively constant at approximately $0.2 million and $0.2 million in the six months ended June 30, 2023 and 2022, respectively.
Income (Loss) from Continuing Operations Before Other Income (Expense), Income Taxes and Net Loss Attributable to Noncontrolling Interest
Our income from continuing operations before other income (expense), income taxes and net loss attributable to noncontrolling interest for the six months ended June 30, 2023 was $1.5$2.8 million compared to a loss of $1.9 million for the ninesix months ended SeptemberJune 30, 2017 as2022. We attribute the $4.7 million improvement in the six months ended June 30, 2023 to the $6.5 million increase in net revenues in the six months ended June 30, 2023 compared to $2.0the comparable 2022 period, partially offset by higher direct costs of net revenues and general and administrative expenses in the six months ended June 30, 2023 versus the 2022 period.
Other Income (Expense), net
Other income, net for the six months ended June 30, 2023 of $0.3 million consisted primarily of various other miscellaneous income items, partially offset by $0.2 million of penalties and interest associated with past due payroll taxes. Other expense, net for the six months ended June 30, 2022 of $42,281 consisted primarily of $0.4 million of penalties and interest associated with past due payroll taxes, partially offset by approximately $0.4 million of various other miscellaneous income items.
Gain from Forgiveness of Debt
Gain from forgiveness of debt of $0.2 million for the same periodsix months ended June 30, 2023 resulted from the forgiveness of a year ago, as someportion of our property and equipment became fully depreciated during 2016 and our capital expenditures have been minimal due to the reduced sample volume at our laboratories. Mostoutstanding notes payable. Gain from forgiveness of the capital expendituresdebt for the Hospital insix months ended June 30, 2022 resulted from the amountforgiveness of $1.5PPP Notes.
Gain (Loss) from Legal Settlements, net
The gain from legal settlements, net was $0.3 million started depreciating at the time the Hospital was opened in August 2017.
Loss from Operations
Our operating loss decreased by $7.7 million, to $13.7and $0.1 million for the ninesix months ended SeptemberJune 30, 2017, as compared to $21.32023 and 2022, respectively. The gain from legal settlements, net in the 2023 period resulted primarily from a gain of $0.6 million forfrom the nine months ended September 30, 2016. The decrease is due to the $8.4 million decrease in total operating expensessettlement of an obligation under a note payable, partially offset by $0.3 million associated with the $0.8 million decrease in net revenues.adjustment of reserves related to judgments with the former owners of Jamestown Regional Medical Center.
Interest Expense
Interest expense for the ninesix months ended SeptemberJune 30, 20172023 was $16.5$1.0 million as compared to $4.7$1.1 million for the ninesix months ended SeptemberJune 30, 2016.2022. Interest expense for the six months ended June 30, 2023 included $0.9 million for interest on debentures and notes payable and $58,000 for interest on loans from Mr. Diamantis, a former member of our Board of Directors. Interest expense for the six months ended June 30, 2022 included $1.0 million for interest on debentures and notes payable and $0.1 million for interest on loans from Mr. Diamantis.
35 |
Provision for Income Taxes
The provision for income taxes of $517,000 for the six months ended June 30, 2023 compared to no provision for the three months ended June 30, 2022 was due to the taxable income in the nine2023 period versus a loss for the 2022 period.
Net Income (Loss) from Continuing Operations
Net income from continuing operations for the six months ended SeptemberJune 30, 2017 includes a $8.52023 was $2.1 million non-cash interest charge related to the issuance of convertible debentures and warrants during the period, and $6.2 million for amortization of debt discount.
Other income (expense)
Other income (expense) decreased by $6.8 million for nine months ended September 30, 2017 as compared to the same period a year ago. The decrease consists of the $6.8 million in non-cash gains on the change in fair value of derivative financial instruments related to convertible notes and warrants recorded in 2016.
Net Loss
Our net loss from continuing operations of $2.8 million for the ninesix months ended SeptemberJune 30, 2017 was $30.1 million,2022. The improvement in the results from continuing operations in the 2023 period as compared to $19.3the 2022 period of approximately $4.9 million for the same period a year ago, an increase of $10.8 million. The change iswas primarily due to the increaseincome from continuing operations before other income (expense), income taxes and net loss attributable to noncontrolling interest of $12.2$2.8 million in non-cashthe 2023 period versus a loss of $1.9 in the comparable 2022 period, a gain from legal settlements, net of $0.3 million in the 2023 period compared to a loss from legal settlements, net of $0.1 million in the 2022 period and a reduction in interest and amortizationexpense of debt discount charge, and$0.1 million in the 2023 period compared to the 2022 period. Partially offsetting the improvement was a decrease of $6.8$0.1 million in other income (expense), offset by a decreasethe gain from forgiveness of debt in loss from operations of $7.7 million.
The following table presents key financial and operating metrics for our Clinical Laboratory Operations segment:
Nine Months Ended September 30, | ||||||||||||||||
Clinical Laboratory Operations | 2017 | 2016 | Change | % | ||||||||||||
Net revenues | $ | 1,994,639 | $ | 3,461,987 | $ | (1,467,348 | ) | -42.4 | % | |||||||
Operating expenses: | ||||||||||||||||
Direct costs of revenue | 605,593 | 898,444 | (292,851 | ) | -32.6 | % | ||||||||||
Bad debt expense | 526,934 | 3,475,252 | (2,948,318 | ) | -84.8 | % | ||||||||||
General and administrative expenses | 2,794,143 | 6,592,565 | (3,798,422 | ) | -57.6 | % | ||||||||||
Sales and marketing expenses | 611,941 | 1,439,994 | (828,053 | ) | -57.5 | % | ||||||||||
Depreciation and amortization | 1,265,174 | 1,646,167 | (380,993 | ) | -23.1 | % | ||||||||||
(Loss) income from operations | $ | (3,809,146 | ) | $ | (10,590,435 | ) | $ | 6,781,289 | -64.0 | % | ||||||
Key Operating Measures - Revenues: | ||||||||||||||||
Insured tests performed | 52,374 | 187,283 | (134,909 | ) | -72.0 | % | ||||||||||
Net revenue per insured test | $ | 38.08 | $ | 18.49 | $ | 19.60 | 106.0 | % | ||||||||
Revenue recognition percent of gross billings | 13.0 | % | 15.0 | % | -2.0 | % | ||||||||||
Key Operating Measures - Direct Costs: | ||||||||||||||||
Total samples processed | 16,246 | 19,039 | (2,793 | ) | -14.7 | % | ||||||||||
Direct costs per sample | $ | 37.28 | $ | 47.19 | $ | (9.91 | ) | -21.0 | % |
RENNOVA HEALTH, INC.
The following table presents key financial metrics for our Supportive Software Solutions segment:
Nine Months Ended September 30, | ||||||||||||||||
Supportive Software Solutions | 2017 | 2016 | Change | % | ||||||||||||
Net revenues | $ | 698,359 | $ | 605,575 | $ | 92,784 | 15.3 | % | ||||||||
Operating expenses: | ||||||||||||||||
Direct costs of revenue | 122,728 | 229,616 | (106,888 | ) | -46.6 | % | ||||||||||
General and administrative expenses | 1,992,088 | 3,492,547 | (1,500,459 | ) | -43.0 | % | ||||||||||
Sales and marketing expenses | 491 | 1,329 | (838 | ) | -63.1 | % | ||||||||||
Bad debt expense | 76,747 | 192,740 | (115,993 | ) | -60.2 | % | ||||||||||
Depreciation and amortization | 227,999 | 490,236 | (262,237 | ) | -53.5 | % | ||||||||||
Loss from operations | $ | (1,721,694 | ) | $ | (3,800,893 | ) | $ | 2,079,199 | -54.7 | % |
The decrease in general and administrative expenses relates primarily to the reduction in employee compensation and related costs, as we significantly reduced our headcount.
The following table presents key financial metrics for our Hospital segment:
Nine Months Ended September 30, | ||||||||||||||||
Hospital | 2017 | 2016 | Change | % | ||||||||||||
Net revenues | $ | 619,478 | $ | - | $ | 619,478 | - | |||||||||
Operating expenses: | ||||||||||||||||
Direct costs of revenue | 78,815 | - | 78,815 | - | ||||||||||||
General and administrative expenses | 3,185,182 | - | 3,185,182 | - | ||||||||||||
Bad debt expense | 447,909 | - | 447,909 | - | ||||||||||||
Depreciation and amortization | 22,045 | - | 22,045 | - | ||||||||||||
Loss from operations | $ | (3,114,473 | ) | $ | - | $ | (3,114,473 | ) | - |
The following table presents key financial metrics for our Corporate group:
Nine Months Ended September 30, | ||||||||||||||||
Corporate | 2017 | 2016 | Change | % | ||||||||||||
Operating expenses: | ||||||||||||||||
General and administrative expenses | $ | 5,006,936 | $ | 7,057,150 | $ | (2,050,214 | ) | -29.1 | % | |||||||
Direct costs of revenue | 42,496 | - | 42,496 | - | ||||||||||||
Sales and marketing expenses | 8,128 | - | 8,128 | - | ||||||||||||
Depreciation and amortization | 1,005 | 2,494 | (1,489 | ) | -59.7 | % | ||||||||||
Loss from operations | $ | (5,058,565 | ) | $ | (7,059,644 | ) | $ | 2,001,079 | -28.3 | % |
The decrease in general and administrative expenses is mainly due to reductions in stock-based compensation in 2017 as2023 period compared to the prior year2022 period and $0.5 million of income tax expense in the amount of $0.8 million, $0.7 million of interest2023 period.
Liquidity and penalties that were recognized in 2016 in connection with unpaid taxes, and a $0.3 million decrease in salaries due to headcount reduction.Capital Resources
RENNOVA HEALTH, INC.Overview
LIQUIDITY AND CAPITAL RESOURCES
For the yearsix months ended December 31, 2016 and through SeptemberJune 30, 2017,2023, we have financed our operations primarilywith the $3.3 million of cash that we generated from the saleoperations and $0.6 million of loans from Mr. Diamantis, a former member of our equity securities, short-term advancesBoard of Directors. During the six months ended June 30, 2022, we financed our operations with $1.5 million from related parties,issuances of our Series P Convertible Redeemable Preferred Stock and $0.8 million of loans from Mr. Diamantis. Also, during the issuance of debentures and the proceedssix months ended June 30, 2022, we received $0.3 million from pledging certainHHS Provider Relief Funds. During the six months ended June 30, 2023, the Company repaid $1.3 million of loans from Mr. Diamantis and $0.4 million of debentures. During the six months ended June 30, 2023 and 2022, we repaid $0.8 million and $1.2 million of notes payable, respectively. Each of these financing transactions is more fully discussed in Notes 6 and 10 to our accounts receivable as discussed below. accompanying unaudited condensed consolidated financial statements.
Future cash needs for working capital, capital expenditures, pursuit of opportunities in the behavioral health sector, debt service obligations and potential acquisitions will require management to seek additional equity or obtain additional credit facilities.capital. The salesale/issuance of additional equity will result in additional dilution to our stockholders. A portion
Going Concern and Liquidity
Under Accounting Standards Codification (“ASC”), Presentation of our cash may be usedFinancial Statements—Going Concern (Subtopic 205-40) (“ASC 205-40”), the Company has the responsibility to acquire evaluate whether conditions and/or investevents raise substantial doubt about its ability to meet its future financial obligations as they become due within one year after the date that the financial statements are issued. As required by ASC 205-40, this evaluation shall initially not take into consideration the potential mitigating effects of plans that have not been fully implemented as of the date the financial statements are issued. Management has assessed the Company’s ability to continue as a going concern in complementary businesses or products or to obtainaccordance with the right to use complementary technologies. From time to time, inrequirement of ASC 205-40.
At June 30, 2023, the ordinary course of business, we evaluate potential acquisitions of such businesses, products or technologies.
At September 30, 2017, weCompany had cash on hand from continuing operations of approximately $41,019, a working capital deficit of $18.0 million and a stockholders’ deficit of $18.8 million. In addition, we$40.9 million and $27.0 million, respectively. While the Company incurred a loss from continuing operationsnet income of $30.1$2.1 million for the ninesix months ended SeptemberJune 30, 2017. As2023, it incurred a net loss of $3.3 million for the year ended December 31, 2022 and as of the date of this report, ourits cash position is critically deficient and payments critical to our ability to operatefor its operations in the ordinary course are not being made in the ordinary course. Our fixed operating expenses, including payroll, rent, capital lease paymentsmade. The prior year loss and other fixed expenses,related factors, including past due accounts payable and payroll taxes, as well as payment defaults under the costs required to operate Big South Fork Medical Center, are approximately $1.5-$2.0 million per month.
On October 30, 2017, we raised $4.0 million from the issuanceterms of our Series I-1 Convertible Preferred Stock (the “Series I-1 Preferred Stock”)certain outstanding notes payable and debentures, as more fully discussed below. However, our failurein Notes 5 and 6 to raise additional capital in the coming months will have a material adverse effect on our ability to operate our business. In addition, we will be required toaccompanying unaudited condensed consolidated financial statements, raise additional capital in order to fund our operations for the next twelve months. There can be no assurances that we will be able to raise the necessary capital on terms that are acceptable to us, or at all. If we are unable to secure the necessary funding as and when required, it will have a material adverse effect on our business and we may be required to downsize, further reduce our workforce, sell some of our assets or possibly curtail or even cease operations, raising substantial doubt about ourthe Company’s ability to continue as a going concern.concern for 12 months from the filing date of this report.
On July 12, 2017 we announced that we plan to spin offThe Company’s accompanying unaudited condensed consolidated financial statements are prepared assuming the Advanced Molecular Services Group (“AMSG”)Company can continue as an independent publicly traded company by waya going concern, which contemplates continuity of a tax-free distribution to our shareholders. Completionoperations through realization of assets, and the spinoff is expected to occur during the first quartersettling of 2018, and is subject to numerous conditions, including effectiveness of a Registration Statement on Form 10 to be filed with the Securities and Exchange Commission and consents, including under various funding agreements previously entered into by the Company. The intent of the spinoff is to create two public companies, each of which can focus on its own strengths and operational plans. We also announced on July 24, 2017 that the Big South Fork Medical Center received CMS regional office licensure approval. The hospital opened in August 2017. We expect that the hospital will provide us additional revenue and cash flow sources.
During 2017, we entered into financings as follows:
In 2017, we received short-term advances from Christopher Diamantis, a member of our Board of Directors,liabilities in the amountnormal course of $3.3 million. On March 7, 2017 we issued a promissory notebusiness. In 2021, the Company sold subsidiaries to Mr. Diamantis inInnovaQor Inc. and the amount of $3.8 million (the “2017 Diamantis Note”) in connection with the advances weCompany received in 2017, plus accrued and unpaid interest reflecting the advances we received in both fiscal 2016 and 2017, in the amount of $0.5 million.
On February 2, 2017, we issued $1.59 million of convertible debentures (the “February Debentures”) and warrants to purchase 6,66714,950 shares of our common stock and received cash proceeds of $1.5 million.
On March 21, 2017, we issued $10.85 million aggregate principal amount of Senior Secured Original Issue Discount Convertible Debentures due two years from the date of issuance (the “Convertible Debentures”) and three series of warrants to purchase shares of our common stock to several accredited investors. We received net proceeds from this transaction in the approximate amount of $8.4 million. We used $3.8 million of the net proceeds to repay the 2017 Diamantis Note and $0.75 million of the net proceeds to make a partial repayment on the TCA Debenture (as defined below). The remainder of the net proceeds were used for general corporate purposes. In conjunction with the issuance of the Convertible Debentures, the holder of the February Debentures exchanged these debentures for $2.7 million of new debentures (the “Exchange Debentures” and, collectively with the Convertible Debentures, the “March Debentures”) on the same terms as, and pari passu with, the Convertible Debentures and warrants. Additionally, the holders of an aggregate of $2.2 million stated value of ourInnovaQor, Inc.’s Series HB-1 Non-Voting Convertible Preferred Stock (the “Series H“InnovaQor Series B-I Preferred Stock”) exchanged such preferred stock into $2.5valued at $9.1 million principal amountas consideration for the sale. As of Exchange Debentures and warrants. All ofJune 30, 2023, the March Debentures contain a 24% original issue discount.
On June 2, 2017 and June 22, 2017, we issued $1.9 million aggregate principal amount of Original Issue Discount Debentures due three months from the date of issuance of these two issuances (collectively, the “June Debentures”) and warrants to purchase an aggregate of 100,000Company held 14,850 shares of common stock to accredited investors for a purchase price of $1.8InnovaQor’s Series B-1 Preferred Stock valued at $9.0 million and cash proceeds of $1.5 million.as an investment.
RENNOVA HEALTH, INC.The accompanying unaudited condensed consolidated financial statements do not include any adjustments that might be necessary if we are unable to continue as a going concern.
On July 17, 2017, we closed an offering of $4,136,862 aggregate principal amount of Original Issue Discount Debentures due October 17, 2017 and warrants to purchase an aggregate of 141,333 shares of common stock for consideration of $2,000,000 in cash and the exchange of the $1,902,700 aggregate principal amount of Original Issue Discount Debentures due September 22, 2017 issued by us on June 22, 2017.
On September 19, 2017, we closed an offering of $2,604,000 principal amount of Senior Secured Original Issue Discount Convertible Debentures due September 19, 2019 (the “New Debentures”) and three series of warrants to purchase shares of our common stock. The offering was pursuant to the terms of a Securities Purchase Agreement, dated as of August 31, 2017, between us and certain of our existing institutional investors. We received proceeds of $2,100,000 from the offering.
Also on September 19, 2017, we closed exchanges by which the holders of our July Debentures exchanged $4,136,862 principal amount of such debentures for $6,412,136 principal amount of new debentures and warrants on the same items as, and pari passu with, the New Debentures (the “September Exchange Debentures” and, together with the New Debentures, the “September Debentures”). All issuance amounts of the September Debentures reflect a 24% original issue discount.
On October 30, 2017, we closed an offering of $4,960,000 stated value of our newly-authorized Series I-1 Preferred Stock. The offering was pursuant to the terms of the Securities Purchase Agreement, dated as of October 30, 2017, between us and certain of our existing institutional investors. We received proceeds of $4,000,000 from the offering.
In September of 2016, we received $0.4 million from the sale of convertible notes and warrants with a maturity date of March 15, 2017. On March 13, 2017, these securities were exchanged for 26,666 shares of our common stock.
On March 31, 2016, we entered into an agreement to pledge certain of our accounts receivable as collateral against a prepaid forward purchase contract. The receivables had an estimated collectable value of $8.7 million which had been adjusted down to approximately $1.5 million and $0 on our balance sheet as of December 31, 2016 and September 30, 2017, respectively. The consideration received was $5.0 million. In exchange for the consideration received, the counterparty received the right to: (i) a 20% per annum investment return from us on the consideration, with a minimum repayment term of six months and minimum return of $0.5 million, (ii) all payments recovered from the accounts receivable up to $5.25 million, if paid in full within six months, or $5.5 million, if not paid in full within six months, and (iii) 20% of all payments of the accounts receivable in excess of amounts received in (i) and (ii). On March 31, 2017, to the extent that the counterparty has not been paid $6.0 million, we were required to pay the difference, plus 30% interest per annum on the total balance. As of SeptemberJune 30, 2017, and the date of this report, we had not collected any amounts due on these receivables, and $6.9 million, including accrued interest, is currently due to the counterparty. We currently do not have the financial resources to satisfy this obligation. Mr. Diamantis has guaranteed our payment obligation under this agreement.
On November 3, 2016, we received a Notice of Default from TCA Global Credit Master Fund, LP (“TCA”), the holder of a secured convertible debenture with an original outstanding principal amount of $3.0 million (the “TCA Debenture”), related to our failure to pay the monthly principal and interest payments required under the TCA Debenture. Prior to our issuance of the March Debentures on March 21, 2017, we had not made the last nine required payments under the TCA Debenture, other than a $0.4 million payment we made in February of 2017. In conjunction with the issuance of the March Debentures on March 21, 2017, we entered into a letter agreement with TCA, which (i) waived any non-payment default through March 21, 2017; (ii) provided for the $0.75 million payment discussed above; (iii) set forth a revised repayment schedule whereby the remaining principal plus interest aggregating to approximately $2.6 million was to be repaid in various monthly installments from April of 2017 through September of 2017; and (iv) provided for payment of an additional service fee in the amount of $150,000, which was due on June 27, 2017, the day after the effective date of the registration statement filed by us; which amount is reflected in accrued expenses in the accompanying consolidated balance sheet at September 30, 2017. In addition, TCA entered into an intercreditor agreement with the purchasers of the March Debentures which sets forth rights, preferences and priorities with respect to the security interests in our assets. On September 19, 2017, the Company entered into a new agreement with TCA, which extended the repayment schedule through to December 31, 2017. The Company is current with its payments.
As of September 30, 2017,2023, we were party to the following legal matters:
Biohealth Medical Laboratory, Inc, and PB Laboratories, LLC (the “Companies”) filed suit against CIGNA Healthproceedings, which are presented in 2015 alleging that CIGNA failed to pay claims for laboratory services the Companies provided to patients pursuant to CIGNA - issued and CIGNA - administered plans. In 2016, the U.S. District Court dismissed part of the Companies’ claims for lack of standing. The Companies appealed that decisionNote 12 to the Eleventh Circuit Court of Appeals, which recently reversed the District Court’s decision and found that the Companies have standing to raise claims arising out of traditional insurance plans as well as self-funded plans.
Our Epinex Diagnostics Laboratories, Inc. subsidiary had been sued in a California state court by two former employees who alleged that they were wrongfully terminated, as well as for a variety of unpaid wage claims. The parties entered into a settlement agreement of this matter on July 29, 2016 for approximately $0.2 million, and the settlement was consummated on August 25, 2016. In October of 2016, the plaintiffs in this matter filed a motion with the court seeking payment for attorneys’ fees in the approximate amount of $0.7 million. On March 24, 2017, the court granted plaintiffs’ motion for payment of attorneys’ fees in the amount of $0.3 million, and we have accrued this amount in itsaccompanying unaudited condensed consolidated financial statements. Additionally, we are seeking indemnification for these amounts from Epinex Diagnostics, Inc. (“EDI”), the seller of Epinex Diagnostic Laboratories, Inc. (“EDL”), pursuant to a Stock Purchase Agreement entered into by and among the parties.
RENNOVA HEALTH, INC.
InFebruary 2016, we received notice that the Internal Revenue Service (the “IRS”) had placed a lien against Medytox Solutions, Inc. and its subsidiaries relating to unpaid 2014 taxes due, plus penalties and interest, in the amount of $5.0 million. We paid $0.1 million toward the 2014 tax liability on March 2016. We filed our 2015 Federal tax return on March 15, 2016 and the accompanying election to carryback the reported net operating losses was filed in April 2016. On August 24, 2016, the lien was released, and in September of 2016, we received a refund from the IRS in the amount of $1.9 million. In November of 2016, the IRS commenced an audit of our 2015 Federal tax return. We are currently unable to predict the outcome of the audit or any liability to us that may result from the audit.
On September 27, 2016, a tax warrant was issued against us by the Florida Department of Revenue (the “DOR”) for unpaid 2014 state income taxes in the approximate amount of $0.9 million, including penalties and interest. On January 25, 2017, we paid the DOR $250,000 as partial payment on this liability, and in February 2017, we entered into a Stipulation Agreement with the DOR which will allow us to make monthly installment payments of $35,000 until February 2018 and negotiate a new payment agreement then, if the balance of $0.3 million cannot be satisfied in a lump sum. If at any time during the Stipulation period we fail to timely file any required tax returns with the DOR or do not meet the payment obligations under the Stipulation Agreement, the entire amount due will be accelerated. The Company is current with the agreed payment plan.
InDecember of 2016, TCS-Florida, L.P. (“Tetra”), filed suit against us for failure to make the required payments under an equipment leasing contract that we had with Tetra. On January 3, 2017, Tetra received a Default Judgment against us in the amount of $2.6 million, representing the balance owed on the leases, as well as additional interest, penalties and fees. We have recognized this amount in our consolidated financial statements as of December 31, 2016. In January and February of 2017, we made payments to Tetra in connection with this judgment aggregating to $0.7 million, and on February 15, 2017, we entered into a forbearance agreement with Tetra whereby the remaining $1.9 million due will be paid in 24 equal monthly installments. Payments commenced on May 1, 2017. The Company is current with its payments.
InDecember of 2016, DeLage Landen Financial Services, Inc. (“DeLage”), filed suit against us for failure to make the required payments under an equipment leasing contract that we had with DeLage. On January 24, 2017, DeLage received a default judgment against us in the approximate amount of $1.0 million, representing the balance owed on the lease, as well as additional interest, penalties and fees. We have recognized this amount in our consolidated financial statements as of December 31, 2016. On February 8, 2017, a Stay of Execution was filed and under its terms the balance due will be paid in variable monthly installments through January of 2019, with an implicit interest rate of 4.97%. The Company is current with its payments.
On December 7, 2016, the holders of the notes payable to CommerceNet and Jay Tannenbaum (the “Tegal Notes”) filed suit against us seeking payment for the amounts due under the notes in the aggregate of $0.4 million, including accrued interest. A request for entry of default judgment was filed on January 24, 2017. A Case Management Conference is scheduled for December 5, 2017.
The following table presents our capital resources as of SeptemberJune 30, 20172023 and December 31, 2016:2022:
September 30, 2017 | December 31, 2016 | Change | ||||||||||
Cash | $ | 41,019 | $ | 75,017 | $ | (33,998 | ) | |||||
Working capital | (17,990,110 | ) | (16,344,128 | ) | (1,645,982 | ) | ||||||
Total debt, excluding discounts and deferred financing fees | 28,484,822 | 9,339,747 | 19,145,075 | |||||||||
Capital lease obligations | 2,227,204 | 3,570,174 | (1,342,970 | ) | ||||||||
Stockholders’ deficit | $ | (18,788,423 | ) | $ | (14,885,896 | ) | $ | (3,902,527 | ) |
June 30, | December 31, | |||||||||||
2023 | 2022 | Change | ||||||||||
Cash | $ | 725,517 | $ | 499,470 | $ | 226,047 | ||||||
Working capital deficit | 40,899,034 | 42,944,995 | (2,045,961 | ) | ||||||||
Total debt | 11,793,555 | 14,534,630 | (2,741,075 | ) | ||||||||
Finance lease obligation | 220,461 | 220,461 | - | |||||||||
Stockholders’ deficit | 27,012,555 | 29,094,588 | (2,082,033 | ) |
RENNOVA HEALTH, INC.
The following table presents the major sources and uses of cash for the ninesix months ended SeptemberJune 30, 20172023 and 2016:2022:
Nine Months Ended September 30, | Six Months Ended June 30, | |||||||||||||||||||||||
2017 | 2016 | Change | 2023 | 2022 | Change | |||||||||||||||||||
Cash used in operations | $ | (11,783,441 | ) | $ | (17,040,274 | ) | $ | 5,256,833 | ||||||||||||||||
Cash provided by (used in) operations | $ | 3,346,897 | $ | (1,210,158 | ) | $ | 4,557,055 | |||||||||||||||||
Cash used in investing activities | (1,552,563 | ) | 63,273 | (1,615,836 | ) | (1,153,981 | ) | (462,883 | ) | (691,098 | ) | |||||||||||||
Cash provided by financing activities | 13,302,006 | 8,658,115 | 4,643,891 | |||||||||||||||||||||
Cash (used in) provided by financing activities | (1,966,869 | ) | 1,075,392 | (3,042,261 | ) | |||||||||||||||||||
Net change in cash | $ | (33,998 | ) | $ | (8,318,886 | ) | $ | 8,284,888 | 226,047 | (597,649 | ) | 823,696 | ||||||||||||
Cash and cash equivalents, beginning of the year | 499,470 | 724,524 | (225,054 | ) | ||||||||||||||||||||
Cash and cash equivalents, end of the period | $ | 725,517 | $ | 126,875 | $ | 598,642 |
The decrease incomponents of cash used inprovided by (used in) operations for the ninesix months ended SeptemberJune 30, 20172023 and 2016 is2022 are presented in the following table:
Nine Months Ended September 30, | ||||||||||||
2017 | 2016 | Change | ||||||||||
Net loss | $ | (30,118,632 | ) | $ | (19,287,511 | ) | $ | (10,831,121 | ) | |||
Non-cash adjustments to income | 17,475,571 | 2,320,100 | 15,155,471 | |||||||||
Accounts receivable | (252,717 | ) | 1,878,086 | (2,130,803 | ) | |||||||
Accounts payable and accrued expenses | 3,449,565 | (1,348,163 | ) | 4,797,728 | ||||||||
Loss from discontinued operations | (1,053,471 | ) | (2,828,030 | ) | 1,774,559 | |||||||
Other | (539,116 | ) | 2,441,858 | (2,980,974 | ) | |||||||
Net cash used in operating activities | (11,038,800 | ) | (16,823,660 | ) | 5,784,860 | |||||||
Cash used in discontinued operations | (744,641 | ) | (216,614 | ) | (528,027 | ) | ||||||
Cash used in operations | $ | (11,783,441 | ) | $ | (17,040,274 | ) | $ | 5,256,833 |
Six Months Ended June 30, | ||||||||||||
2023 | 2022 | Change | ||||||||||
Net income (loss) from continuing operations, including noncontrolling interest | $ | 2,090,128 | $ | (2,765,973 | ) | $ | 4,856,101 | |||||
Non-cash adjustments to net income (loss) (1) | (293,227 | ) | (23,703 | ) | (269,524 | ) | ||||||
Changes in operating assets and liabilities: | ||||||||||||
Accounts receivable | 229,819 | 186,131 | 43,688 | |||||||||
Inventory | 7,280 | 36,890 | (29,610 | ) | ||||||||
Accounts payable and accrued expenses | 962,939 | 1,352,286 | (389,347 | ) | ||||||||
Income taxes payable | 517,000 | - | 517,000 | |||||||||
Loss from discontinued operations | (8,097 | ) | (5,379 | ) | (2,718 | ) | ||||||
Other | (167,042 | ) | 11,304 | (178,346 | ) | |||||||
Net cash provided by (used in) operating activities of continuing operations | 3,338,800 | (1,208,444 | ) | 4,547,244 | ||||||||
Cash provided by (used in) operating activities of discontinued operations | 8,097 | (1,714 | ) | 9,811 | ||||||||
Cash provided by (used in) operations | $ | 3,346,897 | $ | (1,210,158 | ) | $ | 4,557,055 |
(1) | Non-cash adjustments to net income for the six months ended June 30, 2023 of $0.3 million included primarily $0.2 million of gain from forgiveness of debt and $0.3 million of gain from legal settlements, net, partially offset by $0.2 million of depreciation and amortization. Non-cash adjustments to net loss for the six months ended June 30, 2022 of $23,703 included primarily $0.3 million of gain from forgiveness of PPP Notes, partially offset by $0.2 million of depreciation and amortization and $0.1 million of loss from legal settlements, net. |
37 |
Common Stock and Common Stock Equivalents
The increaseCompany had 29,934,322,257 and 29,084,322,257 shares of its common stock issued and outstanding at June 30, 2023 and December 31, 2022, respectively. During the six months ended June 30, 2023, the Company issued an aggregate of 850,000,000 shares of its common stock upon conversions of 36 shares of its Series N Convertible Redeemable Preferred Stock (the “Series N Preferred Stock”) and 40.5 shares of its Series O Convertible Redeemable Preferred Stock (the “Series O Preferred Stock”). During the six months ended June 30, 2022, the Company issued 4.2 billion shares of its common stock upon conversions of 1,833.71 shares of its Series N Preferred Stock and 179.46 shares of its Series O Preferred Stock.
The terms of certain of the outstanding warrants, convertible preferred stock and convertible debentures issued by the Company provide for reductions in cash usedthe per share exercise prices of the warrants and the per share conversion prices of the debentures and preferred stock (if applicable and subject to a floor in investing activitiescertain cases), in the event that the Company issues common stock or common stock equivalents (as that term is defined in the agreements) at an effective exercise/conversion price that is less than the then exercise/conversion price of the outstanding warrants, preferred stock or debentures, as the case may be. In addition, the majority of these equity-based securities contain exercise/conversion prices that vary based upon the price of the Company’s common stock on the date of exercise/conversion (see Notes 6, 9 and 10 to the accompanying unaudited condensed consolidated financial statements). These provisions have resulted in significant dilution of the Company’s common stock and have given rise to reverse splits of the Company’s common stock, including a 1-for-10,000 reverse stock split effected on March 15, 2022. As a result of these down round provisions, the potential common stock equivalents, including outstanding common stock, totaled 1.0 trillion at June 30, 2023 and August 8, 2023.
On August 13, 2020, Mr. Diamantis entered into the Voting Agreement and Irrevocable Proxy (the “Voting Agreement”) with the Company, Mr. Seamus Lagan and Alcimede LLC (of which Mr. Lagan, the Company’s Chief Executive Officer, is the sole manager) pursuant to which Mr. Diamantis granted an irrevocable proxy to Mr. Lagan to vote the Series M Preferred Stock held by Mr. Diamantis. Mr. Diamantis has retained all other rights under the Series M Preferred Stock. Regardless of the number of shares of Series M Preferred Stock outstanding and so long as at least one share of Series M Preferred Stock is outstanding, the outstanding shares of Series M Preferred Stock shall have the number of votes, in the aggregate, equal to 51% of all votes entitled to be voted at any meeting of stockholders or action by written consent. This means that the holders of Series M Preferred Stock have sufficient votes, by themselves, to approve or defeat any proposal voted on by the Company’s stockholders, unless there is a supermajority required under applicable law or by agreement.
Also, on November 5, 2021, the Company amended its Certificate of Incorporation, as amended, to provide that the number of authorized shares of its common stock or preferred stock may be increased or decreased (but not below the number of shares then outstanding) by the affirmative vote of the holders of a majority in voting power of the stock of the Company entitled to vote generally in the election of directors, irrespective of the provisions of Section 242(b)(2) of the General Corporation Law of the State of Delaware (or any successor provision thereto), voting together as a single class, without a separate vote of the holders of the class or classes the number of authorized shares of which are being increased or decreased unless a vote by any holders of one or more series of preferred stock is required by the express terms of any series of preferred stock pursuant to the terms thereof.
As a result of the Voting Agreement and the November 5, 2021 amendment to the Company’s Certificate of Incorporation discussed above, as of the date of filing of this report, the Company believes that it has the ability to ensure that it has and or can obtain sufficient authorized shares of its common stock to cover all potentially dilutive shares of common stock outstanding.
OTHER MATTERS
Inflation and Supply Chain Issues
The healthcare industry is very labor intensive and salaries and benefits are subject to inflationary pressures, as are supply and other costs. The nationwide shortage of nurses and other clinical staff and support personnel has been a significant operating issue facing us and other healthcare providers. In particular, like others in the healthcare industry, we continue to experience a shortage of nurses and other clinical staff and support personnel. This staffing shortage may require us to further enhance wages and benefits to recruit and retain nurses and other clinical staff and support personnel or require us to hire expensive temporary personnel. Our ability to pass on increased costs associated with providing healthcare to Medicare and Medicaid patients is limited due to the acquisition of the Hospital Assetsvarious federal, state and local laws which have been enacted that, in January of 2017. Cash provided by investing activities for the nine months ended September 30, 2017 consists of $1.6 million.certain cases, limit our ability to increase prices.
38 |
Cash provided by financing activities for the nine months ended September 30, 2017 consists of the $15.7 million of net proceeds received in connection with the issuance of debentures and warrants and $1.1 million of related party payments net of advances, partially offset by payments on capital lease obligations in the amount of $1.3 million.
Cash provided by financing activities for the nine months ended September 30, 2016 consists of the $5.0 million received from the prepaid forward purchase contract and the $7.5 million in proceeds from a public offering, partially offset by the $3.4 million of related party payments, net of advances, and repayment of capital lease obligations in the amount of $0.8 million.
OTHER MATTERS
Inflation
We do not believe inflation has a significant effect on the Company’s operations at this time.
Off Balance Sheet Arrangements
Under SEC regulations, we are required to disclose the Company’s off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on the Company’s financial condition, results of operations, liquidity, capital expenditures or capital resources that are material to investors. Off-balance sheet arrangements consist of transactions, agreements or contractual arrangements to which any entity that is not consolidated with us is a party, under which we have:
● | Any obligation under certain guarantee contracts. | |
● | Any retained or contingent interest in assets transferred to an unconsolidated entity or similar arrangement that serves as credit, liquidity or market risk support to that entity for such assets. | |
● | Any obligation under a contract that would be accounted for as a derivative instrument, except that it is both indexed to the Company’s stock and classified in stockholder’s equity in the Company’s statement of financial position. | |
● | Any obligation arising out of a material variable interest held by us in an unconsolidated entity that provides financing, liquidity, market risk or credit risk support to us, or engages in leasing, hedging or research and development services with us. |
RENNOVA HEALTH, INC.
As of SeptemberJune 30, 2017,2023, the Company had no off-balance sheet arrangements that have, or are reasonably likely to have, a current or future effect on the Company’s financial condition, results of operations, liquidity, capital expenditures or capital resources that is material to investors.
Item 3. Quantitative and Qualitative Disclosures About Market Risk.
Not applicable
Item 4. Controls and Procedures.
(a) | Evaluation of Disclosure Controls and Procedures |
In connection with the preparation of this Quarterly Report on Form 10-Q, an evaluation was carried out by the Company’s management, with the participation of our chief executive officer and interim chief financial officer, of the effectiveness of the Company’sWe maintain disclosure controls and procedures (as definedthat are designed to ensure that material information required to be disclosed in Rules 13a-15(e) and 15d-15(e)our periodic reports filed under the Securities Exchange Act of 1934, (“Exchangeas amended (the “Exchange Act”)) as of September 30, 2017. Disclosure controls and procedures are designed to ensure that information required to be disclosed in reports filed or submitted under the Exchange Act, is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms and to ensure that such information is accumulated and communicated to our management, including the chief executive officer,our Chief Executive Officer and Interim Chief Financial Officer as appropriate, to allow timely decisions regarding required disclosures.
disclosure. Under the supervision and with the participation of our management, including our Chief Executive Officer, who also serves as our Interim Chief Financial Officer, we conducted an evaluation of our disclosure controls and procedures. Based on thatthe foregoing evaluation, our management concluded that, as of June 30, 2023, our disclosure controls and procedures were not effective to provide reasonable assurance that the end ofinformation required to be disclosed by us in reports that we file or submit under the period covered by this report,Exchange Act is recorded, processed, summarized, and reported within the time periods specified in SEC rules and forms, and is accumulated and communicated to our management, including our Chief Executive Officer and Interim Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. Our management, including our Chief Executive Officer (Principal Executive Officer), who also serves as our Interim Chief Financial Officer (Principal Financial Officer), does not expect that our disclosure controls and procedures (as defined in Rules 13a-15(e)will prevent all errors and 15d-15(e) under the Exchange Act) wereall fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not effective. In connection with such evaluation, management concludedabsolute, assurance that the material weaknessobjectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in internalall control over financial reporting identifiedsystems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within our Company have been detected. These inherent limitations include, but are not limited to, the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the control. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.
39 |
In our Annual Report on Form 10-K for the year ended December 31, 2016 continued to exist, and as such2022, we identified material weaknesses in our disclosure controls and procedures were not effective as of September 30, 2017.internal control over financial reporting. Insufficient staffing, accounting processes and procedures led to a lack of contemporaneous documentation supporting the accounting for certain transactions and the approval of certain cash disbursements. There are risks related to the timing and accuracy of the integration of information from various accounting systems whereby the Company has experienced delays in receiving information in a timely manner from its subsidiaries. Based on these material weaknesses in internal control over financial reporting, management concluded the Company did not maintain effective internal control over financial reporting as of December 31, 2022. As of June 30, 2023, we concluded that these material weaknesses continued to exist.
The Company expects improvements to be made on the integration of information issues during 2023 and 2024 as we plan to move towards securing a more timely and accurate reporting system. The Company is continuing to further remediate the material weaknesses identified above. The Company has taken or is in the process of taking the following steps to remediate these material weaknesses: (i) increasing the staffing of its internal accounting department, including the addition of a full time Chief Financial Officer;department; and (ii) beginning the process of converting to a new integrated accounting system to enhance controls and procedures for recording accounting transactions; and (iii) implementing enhanced documentation procedures to be followed by the internal accounting department, including independent review of material cash disbursements.department.
Notwithstanding such material weakness,weaknesses, management believes that the unaudited condensed consolidated financial statements included in this Form 10-Q fairly present in all material respects the Company’s financial condition, results of operations and cash flows for the periods and dates presented.
(b) | Changes in Internal Control over Financial Reporting |
During the ninethree months ended SeptemberJune 30, 2017,2023, there werehave been no changes in our internal control over financial reporting that have materially affected or are reasonably likely to materially affect our internal control over financial reporting.reporting except as disclosed above.
From time to time,time-to-time, the Company may be involved in a variety of claims, lawsuits, investigations and proceedings related to contractual disputes, employment matters, regulatory and compliance matters, intellectual property rights and other litigation arising in the ordinary course of business. The Company operates in a highly regulated industry which may inherently lend itself to legal matters. Management is aware that litigation has associated costs and that results of adverse litigation verdicts could have a material effect on the Company’s financial position or results of operations. Management, in consultation with legal counsel, has addressed known assertions and predicted unasserted claims, which are presented in Note 1112 to the accompanying unaudited condensed consolidated financial statements.
RENNOVA HEALTH, INC.
In addition to the other information set forth in this report, you should carefully consider the risk factors discussed in Part I, Item 1A of the 2016our 2022 Form 10-K, which could materially affect our business, financial condition, or future results. There have been no material changes to the risk factors previously disclosed in our 20162022 Form 10-K.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.
During the three-months ended September 30, 2017, the Company had the following issuance of unregistered sales of equity securities that was not previously disclosed on a Current Report on Form 8-K:None.
On August 15, 2017, the Company issued 33,334 shares of its common stock in payment of professional service fees valued at $118,493. These securities were issued without registration in reliance upon the exemption provided by Section 4(2) of the Securities Act of 1933, as amended, as a transaction by an issuer not involving a public offering.
Item 3. Defaults Upon Senior Securities.
None.
Item 4. Mine Safety Disclosures.
Not applicable.
None.
40 |
RENNOVA HEALTH, INC.
* | Filed herewith |
** | Furnished herewith |
*Furnished herewith
RENNOVA HEALTH, INC.SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
RENNOVA HEALTH, INC. | ||
Date: | By: | /s/ Seamus Lagan |
Seamus Lagan | ||
Chief Executive Officer, President and Interim Chief Financial Officer (Principal Executive Officer and |